Development and psychometric properties of a semi-structured clinical interview for psychosis sub-groups (SCIPS) by Kinoshita, Yoshihiro
University of Southampton Research Repository
ePrints Soton
Copyright © and Moral Rights for this thesis are retained by the author and/or other 
copyright owners. A copy can be downloaded for personal non-commercial 
research or study, without prior permission or charge. This thesis cannot be 
reproduced or quoted extensively from without first obtaining permission in writing 
from the copyright holder/s. The content must not be changed in any way or sold 
commercially in any format or medium without the formal permission of the 
copyright holders.
  
 When referring to this work, full bibliographic details including the author, title, 
awarding institution and date of the thesis must be given e.g.
AUTHOR (year of submission) "Full thesis title", University of Southampton, name 
of the University School or Department, PhD Thesis, pagination
http://eprints.soton.ac.uk
  
UNIVERSITY OF SOUTHAMPTON 
 
FACULTY OF MEDICINE, HEALTH AND BIOLOGICAL SCIENCES 
 
School of Medicine 
 
 
 
 
 
 
 
 
 
Development and Psychometric Properties of  
a Semi-structured Clinical Interview for  
Psychosis Sub-groups (SCIPS) 
 
by 
 
Yoshihiro Kinoshita 
 
 
 
 
 
 
 
 
Thesis for the degree of Doctor of Philosophy 
 
 
 
June 2009 
  1
UNIVERSITY OF SOUTHAMPTON 
ABSTRACT 
FACULTY OF MEDICINE, HEALTH AND BIOLOGICAL SCIENCES 
SCHOOL OF MEDICINE 
Doctor of Philosophy 
DEVELOPMENT AND PSYCHOMETRIC PROPERTIES OF  
A SEMI-STRUCTURED CLINICAL INTERVIEW FOR  
PSYCHOSIS SUB-GROUPS (SCIPS) 
By Yoshihiro Kinoshita 
 
Background: Schizophrenia has long been considered to be remarkably heterogeneous, 
and there have been a number of attempts to identify sub-groups of this disorder which 
are more homogeneous. Nevertheless, most of these have not been used in either research 
or clinical practice to any great extent, because diagnoses by way of these strategies 
would be unstable over time and impractical. In such circumstances, the vulnerability-
stress model has led to the development of a new concept of sub-grouping schizophrenia 
into 4 sub-types – drug related, traumatic, anxiety, and stress sensitivity. This 
conceptualisation is quite promising, not only because it may provide stable and practical 
diagnoses, but also because the terminology used therein is useful when it comes to 
destigmatising those who are currently diagnosed with schizophrenia.  
 
Methodology: In order to adapt this concept for practical use, this project set out to 
develop a semi-structured interview for making diagnoses according to it. Thereafter, 
psychometric properties of the interview were examined. This assessment tool was then 
used to confirm the longitudinal stability of the diagnosis. In order to establish the 
construct validity of this classification system, it was examined if the anxiety and stress 
sensitivity sub-groups in this system were different in terms of their external validators. 
Three psychopathological variables – evaluative belief, fear of negative evaluation from 
others, and depression – were assessed in a cross-sectional study during this process of 
validation. Three other clinical variables – two for the duration of hospitalization and one 
for the risk of self harming – were also used in a retrospective cohort study for the 
evaluation of the predictive value of the differentiation.  
 
Results and conclusion: Both the English and Japanese versions of the semi-structured 
clinical interview for psychosis sub-groups (SCIPS) were developed to sub-group 
patients into 4 categories, and their reliability and concurrent validity were established. 
The 6 month stability of SCIPS diagnoses of the drug related, anxiety and stress 
sensitivity sub-types was also indicated through a longitudinal study. A preliminary 
analysis provided little evidence of construct validity. The risk of self harming was, 
however, suggested as being associated with a distinction between the anxiety and stress 
sensitivity categories when the SCIPS was applied to a broader range of psychosis, 
including schizophrenia and schizoaffective disorder. 
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Chapter 1: Classification in Psychiatry 
 
1.1 Historical background 
From ancient times, people have long attempted to understand and classify mental illness 
adequately. Hippocrates, for instance, suggested that thoughts and feelings occur in the 
brain, while Plato believed that the soul struggles to find a balance between 2 conflicting 
impulses, one noble, the other driven by desire (Turner, 2007). By these attempts, a 
question of disease entities has both arisen and led to the development of a theory with 
which to form the basis of the main purposes of psychiatry: to identify natural disorders 
which are different to one another in principle, and to present the characteristic 
symptomatology, course, cause and physical findings thereof, in which there are no 
transitions (Jaspers, 1959).  
 
Although the formulation of classifications of psychopathology according to this theory 
attracted a great deal of interest during the nineteenth century, the identification of mental 
disorders in that period was crude by current standards (Blashfield, 1984). Some of the 
categories seen in the records of nineteenth century asylums were highly idiosyncratic 
and lacked general validity. Moreover, their meanings did not seem to be mutually 
exclusive. Hurd addressed both the variation in terminologies between the different 
institutions and the importance of adopting a uniform system (Hurd, 1881). During the 
1800s, the interest in psychiatric classifications, and the need for a more systematic 
approach, culminated with the work of German psychiatrist, Emil Kraepelin (1919). 
Kraepelin’s organization of mental disorders was proposed in his text books, and became 
the foundation of modern psychiatric classification systems.  
 
The Diagnostic and Statistical Manual of Mental Disorders (first edition-DSM-I) 
(American Psychiatric Association, 1952) was published by the American Psychiatric 
Association in 1952, with the aim of creating a classification which was a consensus of 
contemporary thinking. At about the same time, in 1951, the World Health Organization 
(WHO) proposed, for the first time, an international psychiatric classification scheme as 
part of the International Classification of Diseases (sixth edition-ICD-6) (World Health 
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Organization, 1948). Since that time, an international movement to develop a consensual 
classification system was accelerated. The result was the publication of the mental 
disorder section of the International Classification of Diseases (eighth edition-ICD-8) 
(World Health Organization, 1967), and the Diagnostic and Statistical Manual of Mental 
Disorders (second edition-DSM-II) (American Psychiatric Association, 1968). Although 
standardization was achieved with the earlier versions of the DSM and ICD, the 
reliability of clinical diagnoses was still poor. Accordingly, attempts were made to 
address this problem in the DSM-III (American Psychiatric Association, 1980) and the 
ICD-9 (World Health Organization, 1977). The former was then replaced by the DSM-
III-R in 1987, and the most recent version, DSM-IV, was published in 1994. Similarly, 
the current version of the ICD is in its tenth edition (ICD-10) (World Health Organization, 
1992). The next versions of both volumes (DSM-V and ICD-11) are now in the 
development stage, and are expected to be published in the near future. A release of a 
final, approved DSM-V is expected in May 2012, while the final ICD-11 is likely to be 
submitted to the World Health Assembly for approval by 2014.  
 
1.2 The purpose of classification 
As described above, classification has been a necessary and fundamental process in 
psychiatry. To understand why it is so important, it is helpful to consider the purposes 
behind a good classification scheme. The primary purpose of such a system is to provide 
nomenclature, which is essential for communication between those working in the field 
(Blashfield, 1984). A classification scheme can facilitate this by providing descriptive 
information about each entity included therein, and provides a basis upon which to make 
predictions. For instance, once a clinician is told that a patient’s diagnosis is a major 
depressive disorder, this will help him or her to attempt to discover information about 
probable symptoms, the likely course of the condition and the treatment plan. In addition 
to this primary purpose, a classification system can also be useful for theory formulation. 
For example, Linnaeus’s categorisation of living organisms in biology provided a firm 
foundation for Darwin’s theory of biological evolution (Blashfield, 1984).  
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1.3 Limitations of classification in psychiatry 
Although classification is thought to be an essential process in psychiatry, such systems 
are often criticised. There are 3 main complaints (Blashfield, 1984). Firstly, many of the 
schemes that have existed have been proved to have unacceptably low reliability values. 
This is something which should be taken seriously, because ‘there is no guarantee that a 
reliable system is valid, but assuredly an unreliable system must be invalid’ (Blashfield, 
1984). Secondly, there are concerns about validity. As referred to above, a reliable 
classification scheme is not necessarily valid. In fact, there is little empirical support for 
the clinical validity of most major mental disorders, although the introduction of the 
current diagnostic systems, the DSM and the ICD, has led to improvements in the 
reliability of diagnoses (Kendell, 1989). In other words, a question of whether psychiatric 
disorders represent discrete entities, or are simply situated on a continuum, cannot be 
answered. Thirdly, classification systems in psychiatry are often criticised from the 
perspective of labelling theory. This proposes that labels may become self-fulfilling, and 
can have a major effect on the individuals being identified thereby. For instance, it is 
often the case that patients diagnosed with schizophrenia are stigmatised, with the 
disorder recently being renamed as ‘disintegration syndrome’ in Japan (Kingdon et al., 
2007; Sato, 2006).  
 
Accordingly, whenever a new classification system for psychiatric disorders or their sub-
types is proposed, it should be designed to achieve acceptable levels of reliability and 
clinical validity. Moreover, it is essential that patients are comfortable with, and less 
stigmatised, by their diagnoses, or the sub-types thereof, in the scheme. 
 
1.4 Procedure for validating a classification system 
Six strategies for the evaluation of a syndrome’s clinical validity were outlined by 
Kendell (1989) (Table 1). In this approach, disorders are firstly identified and described 
by cluster analysis or ‘clinical intuition’. Next, the ‘boundaries’ between the syndromes 
or ‘points of rarity’ are identified using statistical forms of assessment, such as 
discriminant function and latent class analyses. The construct validity of the conditions is 
then established. To achieve this, many different predictions can be made, based upon the 
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theory or construct that is related to the conceptualisation of the disorders. In other words, 
follow-up studies can be conducted to prove a distinctive course or outcome, while a 
distinctive treatment response can be established by therapeutic trials. Distinctions in 
terms of aetiology (i.e., cause of the syndromes) and association with more fundamental 
abnormalities (e.g., histological, psychological, social, biochemical or molecular) is also 
important.  
 
Table 1: Validators of clinical syndromes (Kendell, 1989). 
1. Identification and description of the syndrome, either by ‘clinical intuition’ or by 
cluster analysis. 
 
2. Demonstration of boundaries or ‘points of rarity’ between related syndromes by 
discriminant function analysis, latent class analysis, etc. 
 
3. Follow-up studies establishing a distinctive course or outcome. 
 
4. Therapeutic trials establishing a distinctive treatment response. 
 
5. Family studies establishing that the syndrome ‘breeds true’. 
 
6. Association with some more fundamental abnormality, whether histological, 
psychological, biochemical or molecular. 
 
In fact, it has been indicated that diagnostic categories should only be deemed valid when 
they are shown to be different in terms of several key variables, such as clinical 
descriptions, genetic factors and prognoses (Kendell & Jablensky, 2003; Robins & Guze, 
1970). Possible diagnostic indicators were organised into 3 classes: antecedent (e.g., 
familial aggregation and pre-morbid personality), concurrent (e.g., psychological tests) 
and predictive validators (e.g., diagnostic stability and prognosis) (Kendler, 1980). In 
other words, a classification system can be validated and will be clinically relevant if the 
sub-types differ in the levels of the external validators, which are not included in the 
original diagnostic criteria. In addition, broad measures of clinical outcome can be 
introduced as such validators. 
 
1.5 Summary 
The history of classification in psychiatry can be traced back to, at least, the era of 
Hippocrates and Plato. Since the late nineteenth or early twentieth century, however, a 
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contemporary psychiatric classification system has been developed, to which Kraepelin 
made a significant contribution. Nowadays, 2 major schemes, the DSM and the ICD, are 
commonly employed for the categorisation of mental disorders. Although classification 
has been an essential and fundamental process in psychiatry, there have been many 
controversies relating to a number of both the previous and current systems, mainly 
because their levels of reliability and validity are unacceptable, and the labels employed 
tend to have self-fulfilling features which have a major effect on the individuals being 
identified thereby. In order to validate such a system, a procedure with 6 strategies was 
proposed, in which external validators can be employed to establish the construct validity 
of the classification.   
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Chapter 2: The Classification of Schizophrenia 
 
2.1 Overview 
Schizophrenia has a remarkably heterogeneous clinical presentation. In fact, there is 
general agreement that the patients who meet the criteria for the illness, according to the 
current versions of the DSM or ICD, are a very diverse group (Myin-Germeys, Delespaul, 
& van Os, 2005; van Os, 2009), which overlaps with bipolar disorder (Berrettini, 2000; 
Boks et al., 2007). Ever since the conceptualisation of schizophrenia by Kraepelin and 
Bleuler, it has been thought that there are sub-types thereof. Both the DSM-IV and ICD-
10 provide the concepts behind and the diagnostic criteria for these sub-types, which are 
derived from the original schemes proposed by Kraepelin and Bleuler. Furthermore, other 
concepts for classification, such as positive vs. negative and familial vs. non-familial 
schizophrenia, have also been provided with the aim of achieving greater stability and 
validity.  
 
2.2 Definition of psychosis and schizophrenia 
In Kaplan and Sadock’s Comprehensive Textbook of Psychiatry, psychosis is defined as 
‘a mental disorder in which the thoughts, affective response, ability to recognize reality, 
and ability to communicate and relate to others are sufficiently impaired to interfere 
grossly with the capacity to deal with reality; the classical characteristics of psychosis are 
impaired reality testing, hallucinations, delusions and illusions’ (Sadock & Sadock, 
2000a). Schizophrenia is described thus: ‘Schizophrenia is the paradigmatic illness of 
psychiatry. It is a clinical syndrome of variable but profoundly disruptive 
psychopathology, which involves thought, perception, emotion, movement, and 
behaviour. The expression of these symptoms varies across patients and over time, but 
the cumulative effect of the illness is always severe and usually long lasting’ (Sadock & 
Sadock, 2000b). In this thesis, I recognise that the conceptualisation of schizophrenia can 
be included in that of psychosis. In other words, the conceptualisation of the latter is 
broader and covers more than that of the former. 
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With regard to the diagnostic criteria for schizophrenia, those provided in the Diagnostic 
and Statistical Manual for Mental Disorders 4th edition (DSM-IV) (American Psychiatric 
Association, 2000) were used in this study. 
 
2.3 The evolution of schizophrenia classification 
Since Kraepelin (1919) first proposed the concept of dementia praecox, and, in his 
textbook (Bleuler, 1911), Bleuler broadened it, coining the term ‘the schizophrenias’ to 
refer to this conceptualisation, there have been a number of attempts to define the sub-
groups of this illness by consensus classification. In this section, a perspective on the 
concepts of these sub-types will be described.  
 
In his original thinking, dementia praecox, catatonia and dementia paranoides were 
proposed by Kraepelin as being 3 independent conditions (Kraepelin, 1919). In addition, 
he also listed 3 forms of dementia praecox: mild, severe and hebephrenia. Bleuler (1911), 
on the other hand, developed his conceptualisation of schizophrenia, including the 
dementia praecox, catatonia and dementia paranoides that were originally conceptualised 
by Kraepelin, by dividing the disorder into 4 sub-types: hebephrenic, catatonic, paranoid, 
and simple. This is the concept which was, essentially, adopted in the DSM-IV and the 
ICD-10 (see Table 2).  
 
2.4 Classification systems in the DSM-IV and ICD-10 
The schemes proposed by both the DSM and the ICD are widely used for classification 
purposes in schizophrenia research. The DSM-IV includes 4 main sub-types of the 
disorder: paranoid, disorganised, catatonic, and residual, as well as a further category, 
undifferentiated. Alternatively, the ICD-10 provides 5 main schizophrenia sub-groups: 
paranoid, hebephrenic, catatonic, residual and simple, as well as the additional categories 
of undifferentiated schizophrenia and post-schizophrenic depression. Table 2 presents the 
diagnostic criteria for these sub-types in the DSM-IV and the ICD-10. 
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Table 2: Diagnostic criteria for the sub-types of schizophrenia listed in the 
DSM-IV and the ICD-10 (American Psychiatric Association, 2000; World 
Health Organization, 1992). 
 
DSM-IV 
Paranoid Type 
A type of schizophrenia in which the following criteria are met: 
A. Preoccupation with one or more delusions or frequent auditory hallucinations. 
B. None of the following is prominent: disorganised speech, disorganised or catatonic 
behaviour, or flat or inappropriate affect. 
Disorganised Type 
A type of schizophrenia in which the following criteria are met: 
A. All of the following are prominent: 
(1) Disorganised speech 
(2) Disorganised behaviour 
(3) Flat or inappropriate affect 
B. The criteria are not met for catatonic type. 
Catatonic Type 
A type of schizophrenia in which the clinical picture is dominated by at least two of the 
following: 
(1) Motoric immobility as evidenced by catalepsy (including waxy flexibility) or stupor. 
(2) Excessive motor activity (that is apparently purposeless and not influenced by 
external stimuli). 
(3) Extreme negativism (an apparently motiveless resistance to all instructions or 
maintenance of a rigid posture against attempts to be moved) or mutism. 
(4) Peculiarities of voluntary movement as evidenced by posturing (voluntary assumption 
of inappropriate or bizarre postures), stereotyped movements, prominent mannerisms, 
or prominent grimacing. 
(5) Echolalia or echopraxia. 
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Table 2 continued. 
Undifferentiated Type 
A type of schizophrenia in which symptoms that meet Criterion A* are present, but the 
criteria are not met for the paranoid, disorganised, or catatonic type. 
Residual Type 
A type of schizophrenia in which the following criteria are met: 
A. Absence of prominent delusions, hallucinations, disorganised speech, and grossly 
disorganised or catatonic behaviour. 
B. There is continuing evidence of the disturbance, as indicated by the presence of 
negative symptoms or two or more symptoms listed in Criterion A for schizophrenia*, 
present in an attenuated form (e.g., odd beliefs, unusual perceptual experiences). 
*Criterion A for Schizophrenia 
A. Characteristic symptoms: Two (or more) of the following, each present for a 
significant portion of time during a 1-month period (or less if successfully treated): 
(1) Delusions 
(2) Hallucinations 
(3) Disorganised speech (e.g., frequent derailment or incoherence) 
(4) Grossly disorganised or catatonic behaviour 
(5) Negative symptoms, i.e., affective flattening, alogia, or avolition 
Note: Only one Criterion A symptom is required if delusions are bizarre or hallucinations 
consist of a voice keeping up a running commentary on the person’s behaviour or 
thoughts, or two or more voices conversing with each other. 
 
ICD-10 
Paranoid schizophrenia 
A. The general criteria for schizophrenia must be met. 
B. Delusions or hallucinations must be prominent (such as delusions of persecution, 
reference, exalted birth, special mission, bodily change, or jealousy; threatening or 
commanding voices, hallucinations of smell or taste. sexual or other bodily 
sensations). 
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Table 2 continued. 
C. Flattening or incongruity of affect, catatonic symptoms, or incoherent speech must 
not dominate the clinical picture, although they may be present to a mild degree. 
Hebephrenic schizophrenia 
A. The general criteria for schizophrenia must be met. 
B. Either of the following must be present: 
(1) Definite and sustained flattening or shallowness of affect; 
(2) Definite and sustained incongruity or inappropriateness of affect. 
C.  Either of the following must be present: 
(1) Behaviour that is aimless and disjointed rather than goal directed; 
(2) Definite thought disorder, manifesting as speech that is disjointed, rambling, or 
incoherent. 
D. Hallucinations or delusions must not dominate the clinical picture, although they may 
be present to a mild degree. 
Catatonic schizophrenia 
A. The general criteria for schizophrenia must eventually be met, although this may not 
be possible initially if the patient is uncommunicative. 
B. For a period of at least 2 weeks one or more of the following catatonic behaviours 
must be prominent: 
(1) Stupor (marked decrease in reactivity to the environment and reduction of 
spontaneous movements and activity) or mutism; 
(2) Excitement (apparently purposeless motor activity, not influenced by external 
stimuli); 
(3) Posturing (voluntary assumption and maintenance of inappropriate or bizarre 
postures); 
(4) Negativism (an apparently motiveless resistance to all instructions or attempts to 
be moved, or movement in the opposite direction); 
(5) Rigidity (maintenance of a rigid posture against efforts to be moved); 
(6) Waxy flexibility (maintenance of limbs and body in externally imposed 
positions); 
(7) Command automatism (automatic compliance with instructions). 
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Table 2 continued.  
Undifferentiated schizophrenia 
A. The general criteria for schizophrenia must be met. 
B. Either of the following must apply: 
(1) Insufficient symptoms to meet the criteria for any of the following: paranoid 
schizophrenia, hebephrenic schizophrenia, catatonic schizophrenia, post-
schizophrenic depression, or residual schizophrenia. 
(2) So many symptoms that the criteria for more than one of the sub-types listed in 
(1) above are met. 
Post-schizophrenic depression 
A. The general criteria for schizophrenia (F20.0-F20.3) must have been met within the 
past 12 months, but are not met at the present time. 
B. One of the conditions in criterion G1 (2) a, b, c, or d* for F20.0-F20.3 must still be 
present. 
C. The depressive symptoms must be sufficiently prolonged, severe, and extensive to 
meet criteria for at least a mild depressive episode. 
Residual schizophrenia 
A. The general criteria for schizophrenia must have been met at some time in the past, 
but are not met at the present time. 
B. At least four of the following ‘negative’ symptoms have been present throughout the 
previous 12 months: 
(1) psychomotor slowing or underactivity; 
(2) definite blunting of affect; 
(3) passivity and lack of initiative; 
(4) poverty of either the quantity or the content of speech; 
(5) poor non-verbal communication by facial expression, eye contact, voice 
modulation, or posture; 
(6) poor social performance or self-care. 
Simple schizophrenia 
A. There is slow but progressive development, over a period of at least 1 year, of all 
three of the following: 
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Table 2 continued. 
(1) a significant and consistent change in the overall quality of some aspects of 
personal behaviour, manifest as loss of drive and interests, aimlessness, idleness, a 
self-absorbed attitude, and social withdrawal; 
(2) gradual appearance and deepening of ‘negative’ symptoms such as marked apathy, 
paucity of speech, under-activity, blunting of affect, passivity and lack of 
initiative, and poor non-verbal communication (by facial expression, eye contact, 
voice modulation, and posture); 
(3) marked decline in social, scholastic, or occupational performance. 
B. At no time are there any of the symptoms referred to in criterion G1 for paranoid 
schizophrenia, hebephrenic schizophrenia, catatonic schizophrenia, and 
undifferentiated schizophrenia, nor are there hallucinations or well formed delusions 
of any kind, i.e., the individual must never have met the criteria for any other type of 
schizophrenia or for any other psychotic disorder. 
C. There is no evidence of dementia or any other organic mental disorder listed in F00-
F09. 
* Criterion G1 for F20.0-F20.3 
G1. Either at least one of the syndromes, symptoms, and signs listed under (1) below, or 
at least two of the symptoms and signs listed under (2) should be present for most of the 
time during an episode of psychotic illness lasting for at least 1 month (or at some time 
during most of the days). 
(1) At least one of the following must be present: 
(a) thought echo, thought insertion or withdrawal, or thought broadcasting; 
(b) delusions of control, influence, or passivity, clearly referred to body or limb 
movements or specific thoughts, actions, or sensations; delusional perception; 
(c) hallucinatory voices giving a running commentary on the patient’s behaviour, or 
discussing the patient among themselves, or other types of hallucinatory voices 
coming from some part of the body. 
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Table 2 continued. 
 
(d) persistent delusions of other kinds that are culturally inappropriate and completely 
impossible (e.g., being able to control the weather, or being in communication 
with aliens from another world).  
(2) or at least two of the following; 
(a) persistent hallucinations in any modality, when occurring every day for at least 1 
month, when accompanied by delusions (which may be fleeting or half-formed) 
without clear affective content, or when accompanied by persistent over-valued 
ideas; 
(b) neologisms, breaks, or interpolations in the train of thought, resulting in 
incoherence or irrelevant speech; 
(c) catatonic behaviour, such as excitement, posturing or waxy flexibility, negativism, 
mutism, and stupor; 
(d) ‘negative’ symptoms, such as marked apathy, paucity of speech, and blunting or 
incongruity of emotional responses (it must be clear that these are not due to 
depression or to neuroleptic medication).   
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2.5 Other proposed classification systems 
Although the diagnostic criteria for sub-types of schizophrenia are provided in both the 
DSM-IV and the ICD-10, there has been some criticism that these diagnoses are not 
stable over time (Kendler, Gruenberg, & Tsuang, 1985), and that their validity is not 
sufficiently high (Goldberg & Weinberger, 1995). Accordingly, other concepts for 
classification have been provided, so as to achieve greater stability and validity. Two 
main schemas, and some less significant others, have been adopted to provide such 
conceptualisation (Goldberg & Weinberger, 1995).  
 
2.5.1 Positive vs. negative schizophrenia 
Based upon the symptoms of schizophrenia, it was proposed that the illness could be 
divided into 2 main categories where there are positive and negative symptoms, and a 
remaining sub-type of ‘mixed schizophrenia’ for the patients who do not meet the 
aforementioned criteria, or meet the criteria for both (Andreasen & Olsen, 1982). In this 
concept, discrimination between positive and negative schizophrenia is based upon 
whether the symptoms of the disorder are predominantly positive (or florid), or 
predominantly negative (or deficit) (Table 3). Furthermore, an additional proposal was 
presented in which positive symptoms could be further divided into 2 classes, one of 
which is related to disorganised symptoms, while the other is associated with reality 
distortion, such as delusions and hallucinations (Liddle & Barnes, 1990). Alternatively, 
the concept of the deficit sub-type, developed by Carpenter and others, is almost the same 
as that behind negative schizophrenia, as proposed by Andreasen and her colleagues 
(Kirkpatrick et al., 1989). In this context, the deficit sub-type of schizophrenia is defined 
in terms of prominent, primary negative symptoms which endure for a long period of 
time (Kirkpatrick et al., 2001) (Table 4).  
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Table 3: Diagnostic criteria for positive and negative schizophrenia 
(Andreasen & Olsen, 1982). 
Positive schizophrenia 
1. At least one of the following is a prominent part of the illness. 
a. Severe hallucinations that dominate the clinical picture (auditory, haptic, or 
olfactory)(The judgement of severity should be based on various factors such as 
persistence, frequency, and effect on lifestyle.) 
b. Severe delusions (may be persecutory, jealous, somatic, religious, grandiose, or 
fantastic)(The judgement of frequency should be made as described for severity.) 
c. Marked positive formal thought disorder (manifested by marked incoherence, 
derailment, tangentiality, or illogicality) 
d. Repeated instances of bizarre or disorganised behaviour. 
2. None of the following is present to a marked degree. 
a. Alogia 
b. Affective flattening 
c. Avolition-apathy 
d. Anhedonia-asociality 
e. Attentional impairment 
Negative schizophrenia 
1. At least two of the following are present to a marked degree. 
a. Alogia (e.g., marked poverty of speech, poverty of content of speech) 
b. Affective flattening 
c. Anhedonia-associality (e.g., inability to experience pleasure or to feel intimacy, few 
social contacts) 
d. Avolition-apathy (e.g., anergia, impersistence at work or school) 
e. Attentional impairment 
2. None of the following dominates the clinical picture or is present to a marked 
degree.  
a. Hallucinations 
b. Delusions 
c. Positive formal thought disorder 
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Table 3 continued. 
d. Bizarre behaviour 
Mixed schizophrenia 
This category includes those patients that do not meet criteria for either positive or 
negative schizophrenia, or meet criteria for both. 
  31
Table 4: Diagnostic criteria for deficit schizophrenia (Kirkpatrick et al., 
2001). 
1. At least 2 of the following 6 features must be present and of clinically significant 
severity: 
Restricted affect 
Diminished emotional range 
Poverty of speech 
Curbing of interests 
Diminished sense of purpose 
Diminished social drive 
2. Two or more of these features must have been present for the preceding 12 months, 
and always have been present during periods of clinical stability (including chronic 
psychotic states). These symptoms may or may not be detectable during transient 
episodes of acute psychotic disorganisation or decompensation. 
3. Two or more of these enduring features are also idiopathic, i.e., not secondary to 
factors other than the disease process. Such factors include: 
Anxiety 
Drug effect 
Suspiciousness 
Formal thought disorder 
Hallucinations or delusions 
Mental retardation 
Depression 
4. The patient meets DSM criteria for schizophrenia. 
  32
2.5.2 Familial vs. non-familial schizophrenia 
Based upon the concept of heredity schizophrenia, there have been some attempts to 
classify the illness into familial and non-familial sub-types (Roy & Crowe, 1994). The 
former is defined by a family history of psychotic disorders, while ‘sporadic 
schizophrenia’ is defined by the absence of such a history (John et al., 2007).  
 
2.5.3 Other classification schemes 
In terms of neurophysiology and neuroanatomy, it was recognized that there is a group of 
schizophrenia patients who demonstrate either prefrontal cortical hypofunction 
(Weinberger & Berman, 1996) or small ventricular size (Crow, 1985). In addition, other 
researchers have attempted to identify specific groups by using other approaches (John et 
al., 2007; Magri et al., 2007). Indeed, John and his colleagues sub-group patients with 
schizophrenia according to neurometric analyses of quantitative electroenchephalography 
(John, Prichep, & Easton, 1994). On the other hand, Magri et al attempted to demonstrate 
the association between mitochondria DNA haplotypes and the onset of the disorder 
(Magri et al., 2007). 
 
2.6 Summary 
Schizophrenia has a remarkably heterogeneous clinical presentation. Indeed, since 
Kraepelin (1919) first proposed the concept of dementia praecox, and Bleuler (1911) 
extended it, coining the term schizophrenia when referring to this conceptualisation in his 
book , there have been several attempts to define categories of the illness by consensus 
classification. Both the DSM-IV and the ICD-10 provide the conceptualisation and 
diagnostic criteria for schizophrenia sub-types, which are derived from the original 
schemes proposed by Kraepelin and Bleuler. In addition, concepts for classification, such 
as positive vs. negative and familial vs. non-familial schizophrenia, have also been 
utilized to achieve greater stability and validity.  
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Chapter 3: Arguments on the Classification of Schizophrenia 
 
3.1 Overview 
As with classification systems in general, a number of difficulties in relation to the sub-
types of schizophrenia have been proposed. In fact, although quite a few concepts have 
been used to identify sub-groups of the illness, these categories have not been utilised in 
research or clinical practice to any great extent, mainly because these concepts for 
classification have not been properly validated. Accordingly, in this chapter, the validity 
of the current schemes for the categorisation of schizophrenia is discussed. The focus is 
on 2 of the major components thereof, namely the stability and prognostic value of 
classification, since their establishment is an essential process for confirming the value of 
such systems in research and clinical practice.  
 
3.2 Controversies about the DSM and ICD schemes for the classification of 
schizophrenia 
Two key problems, namely the instability of diagnoses and a lack of prognostic quality, 
are proposed as reducing the worth of these 2 major classification systems. Indeed, one 
study revealed that diagnoses obtained through these strategies were unstable over time 
and impractical (Kendler, Gruenberg, & Tsuang, 1985). In that research, the long term 
stability of the sub-types of schizophrenia, as defined by 4 diagnostic systems (DSM-III, 
Research Diagnostic Criteria, ICD-9, and the criteria proposed by Tsuang and Winokur), 
were examined, with the consequence being that their constancy was not satisfactorily 
established. For example, the corrected kappa values of all of the sub-groups diagnosed 
with the DSM-III and the ICD-9 were 0.19 (Standard error (SE) = 0.08) and 0.45 (SE = 
0.16) respectively. These results indicate that the diagnoses would not be useful for 
research or clinical practice purposes, because it is necessary to reconsider them over 
time as a consequence of changes that occur. The limited stability of the sub-types was 
also indicated in other work conducted by Deister and Marneros (1993). This study 
examined the long-term stability of the sub-groups of patients diagnosed with 
schizophrenia (n = 100) according to the DSM-III-R and the ICD-10. As summarized in 
Table 5, a category change was found in many cases, and particularly in some of the 
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specific sub-types (DSM-III-R: disorganized and catatonic; ICD-10: hebephrenic, 
catatonic and residual). In fact, no instances of a stable course were discovered at all, 
with the kappa values for the concordance of the sub-types between the first and second 
episodes, using the DSM-III-R and ICD-10 schemes, being 0.24 and 0.30 respectively.  
 
Table 5: Summary of the long-term stability of the sub-types as shown in 
Deister’s paper (n = 100) (Deister & Marneros, 1993). 
 
Initial sub-type Patients with  
stable course 
DSM-III-R 
Paranoid type (n = 31) 
Disorganised type (n = 7) 
Catatonic type (n = 6) 
Undifferentiated type (n = 33) 
Residual type (n = 23) 
 
14 (45.2%) 
0 (0.0%) 
0 (0.0%) 
3 (9.1%) 
4 (17.4%) 
ICD-10 
Paranoid (n = 48) 
Hebephrenic (n = 7) 
Catatonic (n = 6) 
Undifferentiated (n = 28) 
Residual (n = 11) 
 
18 (37.5%) 
0 (0.0%) 
0 (0.0%) 
7 (25.0%) 
0 (0.0%) 
 
In terms of the predictive value of the classification systems, 2 key studies have been 
conducted to demonstrate that these sub-types are predictors of important patient 
outcomes, such as prognoses and response to medication. Firstly, Kendler and his 
colleagues examined the short (2.5 years) and long term (24 years) outcomes in terms of 
social and clinical factors (i.e., residential, occupational and psychiatric status) (Kendler, 
Gruenberg, & Tsuang, 1984). However, no statistically significant differences were found 
in the short term outcomes of the sub-types diagnosed with the DSM-III or ICD-9. In 
terms of the long term outlook, although differences were revealed between the paranoid 
and the non-paranoid sub-groups (see Table 6), there was no distinction between the 
hebephrenic and undifferentiated categories.  
 
Although differences which implicate the predictive quality of the paranoid sub-type of 
schizophrenia were found, this study has 2 critical problems in terms of its design and the 
procedure used for statistical analysis. Firstly, all of the diagnoses were made by 
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retrospectively reviewing the index admission charts of the patients from the IOWA 500 
study, which had been conducted for other purposes. Indeed, the diagnoses of the sub-
types may well be biased by the information which was recorded in the charts, which 
gave each patient’s outcome. Secondly, type I errors, or false positives, caused by 
multiple comparisons, were not considered when the statistical analyses were carried out. 
This means that differences might be found where, in truth, there are none. 
 
Table 6: Summary of the differences in long-term outcome shown in 
Kendler’s paper (Kendler, Gruenberg, & Tsuang, 1984). 
Diagnostic 
system 
Comparison P v H Comparison P v U 
R O P R O P 
DSM-III  X   X X 
ICD-9 X X X N/A N/A N/A 
P: Paranoid sub-type; H: Hebephrenic sub-type; U: Undifferentiated sub-type. 
R: Residential outcome; O: Occupational outcome; P: Psychiatric outcome. 
Comparisons which showed significant differences (p < 0.05) were indicated with an ‘X’. 
N/A: Undifferentiated sub-type is not provided in the ICD-9. 
There was no difference between the hebephrenic and undifferentiated sub-types. 
 
Another study which examined the difference in outcomes between sub-groups, and used 
a procedure which was similar to that applied in the earlier piece of work, was conducted 
by Kendler and his colleagues (1994). In this research, outcomes were assessed from 
clinical (e.g., chronicity and hospitalization) and functional (e.g., occupation and social 
interaction) perspectives. It was reported that paranoid schizophrenia had a substantially 
better outcome than the other categories of the disorder. However, as in the case of the 
previous work, this study was not prospective, and did not involve an independent 
assessment of diagnosis and outcome. In addition, the number of patients with the 
catatonic sub-type was limited, with only 4 individuals diagnosed as having this category 
of the illness by both the DSM-III and the ICD-9. Accordingly, it was difficult to reach a 
conclusion where this form of the illness was compared to the others.  
 
On top of these 2 main studies, Fenton and McGlashan also conducted research which 
aimed to establish the longitudinal stability and prognostic value of a similar 
classification system (Fenton & McGlashan, 1991a). In this study, neither the DSM nor 
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the ICD schemes were used for the classification. Instead, diagnostic criteria based on 
items from Tsuang-Winokur’s work and the DSM-III were developed and used. The issue 
examined was the differences in short and long-term outcomes between the sub-types, 
with regard to clinical course (e.g., chronicity and hospitalization) and social functioning 
(e.g., occupation and social interaction). As in Kendler’s study (Kendler, Gruenberg, & 
Tsuang, 1984), no statistically significant distinction was found in short-term outcome 
between the sub-types. So far as the long-term outlook was concerned, differences were 
revealed in the paranoid, hebephrenic, and undifferentiated categories (Table 7). However, 
this study’s design is also retrospective. Moreover, the stability of the sub-types was 
unsatisfactory. Indeed, on the basis of the diagnostic criteria used therein, only 66% of all 
patients remained in the same sub-group over the 2 time points of the assessment (kappa 
coefficient = 0.44).  
 
Table 7: Summary of the differences in long-term outcome shown in 
Fenton’s paper (Fenton & McGlashan, 1991a). 
 Significant Post Hoc 
Differences at P < 0.05 
Hospital time since discharge 
Frequency of social contact 
Time symptomatic since discharge 
Sum global outcome since discharge 
Clinical global outcome, No. (%) fair, good, recovered 
Current living situation, No. (%) sheltered or with family of 
origin 
P > H, U > H 
P > H, U > H 
P > H, U > H 
P > H, U > H 
P > H, U > H 
P > H, U > H 
P: Paranoid sub-type; H: Hebephrenic sub-type; U: Undifferentiated sub-type. 
 
 
3.3 Controversies about other proposed classification systems 
As described in Chapter 2 (“The Classification of Schizophrenia”), 2 other classification 
systems, positive vs. negative and familial vs. non-familial schizophrenia, have been 
proposed, and attempts have been made to validate them. The value of these schemes is 
discussed below.  
 
3.3.1 Positive vs. negative schizophrenia 
As in the case of the DSM and ICD systems, the instability of diagnoses is the major 
problem. Deister and Marneros (1993) evaluated the long-term stability of the sub-types 
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(positive, negative, and mixed schizophrenia) therein, and revealed that an initial 
allocated category frequently changed over time (see Table 8). Indeed, in their study of 
positive/negative schizophrenia, the kappa value for the concordance of the sub-types 
between the first and second episodes was 0.21. Kay and Singh (1989) also examined the 
stability of positive and negative syndromes by assessing the correlation between drug-
free baseline and post-neuroleptic treatment for both positive and negative symptoms. 
The correlation coefficients for these symptoms (Pearson product-moment correlation 
coefficient (Pearson’s r) = 0.37 and 0.43, respectively) did not seem to be large enough to 
establish the stability thereof, although the correlations themselves were statistically 
significant.  
 
Table 8: Long-term stability of positive/negative schizophrenia shown in 
Deister’s study (Deister & Marneros, 1993). 
Initial sub-type Patients with  
stable course 
Positive schizophrenia (n = 50) 
Mixed schizophrenia (n = 20) 
Negative schizophrenia (n = 30) 
18 (36.0%) 
2 (10.0%) 
6 (20.0%) 
 
 
3.3.2 Familial vs. non-familial schizophrenia 
In order to provide theoretical and empirical support for the validity of this classification 
system, a review was completed in which 69 articles comparing familial and sporadic 
schizophrenic patients were analysed (Roy & Crowe, 1994). Despite a substantial number 
of comparisons between groups of patients with these forms of the disorder, very few 
differences were found in terms of clinical symptomatology, age of onset, pre-morbid 
functioning, outcome, and treatment response.  
 
With regard to the prognostic value of this distinction, 2 studies among the 69 articles 
reviewed examined long-term outcomes. One of these (Alda et al., 1991) compared 
clinical variables (i.e., illness course, residual symptoms and number and duration of 
hospitalizations) between the 2 sub-types, while the other (Kendler & Tsuang, 1988) 
examined social factors (i.e., marital, residential and occupational status). However, 
neither study revealed any differences between the 2 sub-groups. In addition, other 
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research evaluated the response to neuroleptics, which was assessed by symptom severity 
before and after 6 weeks of treatment with no less than 600mg/day of chlorpromazine 
equivalents. No differences were found in the improvement of symptoms between the 2 
groups. 
 
3.4 Summary 
Concepts relating to sub-types of schizophrenia are proposed in the DSM-IV and ICD-10, 
which are, in turn, derived from the conceptualisation by Kraepelin. Nevertheless, there is 
little empirical support for the predictive value of these systems. Moreover, diagnoses 
made with these schemes demonstrate little longitudinal stability. Likewise, the clinical 
validity of 2 other classification systems, positive vs. negative and familial vs. non-
familial schizophrenia, has not yet been established. It is, therefore, questionable whether 
these approaches are useful, either clinically, or for research purposes.  
  39
Chapter 4: Psychosocial Factors and Psychosis 
 
4.1 Overview 
As described in Chapter 1 “Classification in Psychiatry”, the first step in the development 
or validation of a new classification system is to identify and describe syndromes (or sub-
types) by ‘clinical intuition’ or cluster analysis. This process should commence with the 
selection of potential variables that can be used to describe the conditions (Kendell, 1989). 
In this chapter, the psychosocial and clinical factors which have been proved to be 
associated with psychosis are explained, and a new conceptualisation for the 
classification of this disorder, in which these same elements are employed, is described. 
 
4.2 Vulnerability-stress model 
In the vulnerability-stress hypothesis of schizophrenia (Nuechterlein et al., 1994; 
Nuechterlein & Dawson, 1984; Zubin & Spring, 1977), vulnerabilities and stresses are 
thought to combine to produce the characteristics of the disorder. The precise symptoms 
(e.g., voices or delusions) and combinations thereof (e.g., any of the clinical sub-groups 
described later) which occur are determined by the nature of the vulnerabilities and 
stresses experienced. People who are susceptible due to genetic weighting, poor obstetric 
care, and negative schemas may become psychotic through the occurrence of 
environmental stressors such as drug use, trauma, or the accumulation of social problems. 
These negative schemas, the lack of support, the use of hallucinogens, and a generally 
impoverished social environment in which there is victimization, will then act to maintain 
psychotic symptoms. 
 
4.3 Psychosocial factors associated with psychosis 
With regard to the vulnerability-stress model, some specific psychosocial factors have 
been demonstrated to be associated with psychosis or schizophrenia (Cantor-Graae, 2007). 
These include ethnic minority or migration (Boydell et al., 2001; Cantor-Graae & 
Pedersen, 2007), childhood trauma (Janssen et al., 2004), borderline personality (Miller et 
al., 1993), drug misuse (Talamo et al., 2006), stressful life events (Cullberg, 2003), and 
stress sensitivity (Myin-Germeys et al., 2001; Myin-Germeys & van Os, 2007). For 
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instance, in terms of the relationship between migration and schizophrenia, immigration 
has been shown to be linked to the development of the illness. Indeed, in one meta-
analysis (Cantor-Graae & Selten, 2005), it was found that the overall relative risk of 
developing schizophrenia in first and second-generation immigrants in Europe and 
Australia was 2.9 (95% confidence interval (CI) = 2.5-3.4). The association between 
other psychosocial factors and schizophrenia and psychosis will be discussed below.  
 
4.3.1 Trauma and psychosis 
It has been suggested that trauma is linked to psychosis (Morrison, Read, & Turkington, 
2005). Indeed,  various studies have demonstrated that there is a high incidence of trauma 
in the histories of individuals with this condition (Bebbington et al., 2004; Mueser et al., 
1998; Read et al., 2005). It has also been shown that early childhood trauma increases the 
risk for positive psychotic symptoms (Janssen et al., 2004). In that research, data was 
derived from a general population sample of 4,045 subjects, aged 18-64 years, and the 
baseline reported childhood abuse was predictive of the development of positive 
psychotic symptoms associated with the need for care (Odds ratio (OR) = 7.3, 95% CI = 
1.1-49.0). Indeed, several lines of evidence suggest that there is an association between 
trauma and psychosis. 
 
Nevertheless, others have suggested that the evidence that childhood trauma causes 
psychosis is controversial and contestable (Morgan & Fisher, 2007). These researchers 
insisted that the findings from studies which demonstrated a relationship between early 
trauma and psychosis were not totally consistent, and had a number of methodological 
limitations. For instance, in many of the population-based studies which aimed to 
demonstrate the relationship between childhood trauma and psychotic symptoms, sexual 
abuse was assessed with a single question, and no account was taken of timing, duration, 
or the severity of the abuse, and no distinction was made between childhood and adult 
exposure thereto.  
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The evidence is even more controversial when it comes to which type of trauma is the 
most powerful predictor of later psychiatric symptoms. Childhood trauma is generally 
classified into 4 categories: sexual, physical, and emotional abuse and neglect (Morgan & 
Fisher, 2007). Read and Argyle reported a high incidence of physical and sexual abuse in 
particular, in patients with psychosis (Read & Argyle, 1999). It has also been noted that 
physical abuse is associated with positive psychotic symptoms, while sexual abuse is 
specifically related to hallucinations (Kilcommons & Morrison, 2005). In another study, 
in which data from a general population sample of over 8,000 individuals in the US was 
analysed, physical abuse was shown to predict psychosis, while sexual abuse or neglect 
was not (Shevlin, Dorahy, & Adamson, 2007). Although very few articles can be found 
which have explored a link between childhood emotional abuse and psychosis, there is 
one which suggested that physical neglect and emotional abuse demonstrate a significant 
correlation with dissociative symptoms in patients with schizophrenia spectrum disorders 
(Schafer et al., 2006). 
 
In conclusion, there is an increasing amount of evidence which suggests that there is an 
association between childhood trauma and psychosis, although it should be interpreted 
cautiously. Further research is, therefore, clearly needed into which type of trauma best 
predicts the development of psychotic symptoms. 
 
4.3.2 Borderline personality and psychosis 
Although the evidence of an association between borderline personality and psychotic 
symptoms is not strong, some studies and case reports (Suzuki et al., 1998) have 
suggested that psychosis can be related to this personality disorder. Dowson and his 
colleagues demonstrated that the DSM-III diagnosis of borderline personality disorder 
(BPD) predicts the past experience of psychotic phenomena, 2 of which are “smelling 
things that other people couldn’t” and “thoughts were taken out of your head” (Dowson 
et al., 2000). Furthermore, it was revealed that 27% of patients with BPD (n = 92) had 
had psychotic episodes, typically lasting many weeks (Miller et al., 1993). 
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Nevertheless, in clinical practice, patients with a diagnosis of schizophrenia can 
demonstrate characteristics of borderline personality, even before their first psychotic 
episodes. Moreover, the co-morbidity of BPD with schizophrenia or other psychotic 
disorders should be taken into consideration. This is particularly the case when cognitive 
behavioural therapy (CBT) is conducted with patients with schizophrenia, since co-
morbid BPD could have a major impact on the treatment plan. There is one study which 
examined the impact of co-morbid BPD on patients with schizophrenia (Kingdon et al. in 
submission).  In it, the Childhood Trauma Questionnaire (CTQ) (Bernstein et al., 1997) 
was administered to people with schizophrenia who did, or did not, have co-morbid BPD. 
It was demonstrated that sexual and emotional abuse is more associated with individuals 
who have this co-morbidity than those who do not. On the other hand, it was also found 
that the difference between these patient groups was less, although still, significant, with 
regard to childhood physical abuse. 
 
In conclusion, it has been suggested in some studies that BPD predicts the development 
of psychotic symptoms. Accordingly, the existence of co-morbid BPD with schizophrenia 
should be considered when CBT is conducted with schizophrenic patients. It also seems 
to be important to provide a definition of a sub-group of psychosis, or schizophrenia, with 
co-morbid BPD. Moreover, co-morbid BPD with schizophrenia is predictive of the 
existence of childhood sexual or emotional abuse. 
 
4.3.3 Drug misuse and psychosis 
Co-morbid substance misuse is common among patients with schizophrenia, both in the 
UK and elsewhere (Talamo et al., 2006). Although it should be taken into account that 
different types of substances have been included in studies (e.g., cannabis, stimulants), 
the prevalence of substance use disorders (SUD) in patients with schizophrenia has been 
estimated to be around 33%, and even as high as 60% (Fowler et al., 1998). This latter 
percentage is almost five times as great as drug abuse rates in the general population 
(Regier et al., 1990; Talamo et al., 2006). In fact, it has been suggested that schizophrenia 
patients ‘self-medicate’ after the onset of the illness to relieve negative symptoms, 
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depression, and the adverse effects of their medication (Addington & Duchak, 1997; 
Dixon et al., 1991; Fowler et al., 1998). In other words, substances are used by patients to 
relieve boredom, facilitate social interactions, or for novelty purposes (Talamo et al., 
2006), although some data has disproved this theory (D'Souza et al., 2005; Salyers & 
Mueser, 2001; Sevy et al., 1990). Alternatively, SUD (especially cannabis abuse) may 
either precede, and even precipitate, psychosis (Hambrecht & Hafner, 1996; Zammit et 
al., 2002), or the neuropathophysiology of psychosis may increase vulnerability to SUD 
(Abi-Dargham, 2004; Chambers, Krystal, & Self, 2001; Green et al., 1999; Lieberman, 
Kane, & Alvir, 1987). Indeed, it has been suggested that psychosis could be induced by 
cannabis (Fergusson, Horwood, & Ridder, 2005), amphetamine (Angrist et al., 1974; 
Angrist & Gershon, 1970), including its synthetic derivatives N-Methyl-3,4-
methylenedioxyamphetamine (Ecstasy) (Landabaso et al., 2002; Morgan, 2000; van 
Kampen & Katz, 2001), and cocaine (Brady et al., 1991; Shaner et al., 1998; Sherer et al., 
1988). Moreover, it has also been proposed that lysergic acid diethylamide (LSD) induces 
psychosis (Vardy & Kay, 1983), although the number of studies which have examined 
the causal relationship between use of the substance and the onset of this condition is 
limited. Illicit drug use has also been revealed to be one of the key factors identified by 
patients as leading to the onset of their psychosis (Dudley et al., 2009). 
 
Alternatively, in terms of the influence of substance misuse on patients with psychotic 
disorders, poor long-term clinical outcomes have been shown to be related to the co-
morbid use of drugs (Dixon, 1999; Green, 2005; Mueser et al., 1990). Indeed, with regard 
to the association between cannabis use and the clinical outcomes of individuals with 
psychosis, a systematic review (Zammit et al., 2008) was conducted to examine whether 
cannabis affects the outcome of psychotic disorders. In this study, cannabis use was, 
fairly consistently, demonstrated to be linked to an increased rate of relapse or 
rehospitalization and reduced treatment adherence.  
 
It has also been suggested that co-morbid substance use is associated with more 
prominent positive psychotic symptoms (D'Souza et al., 2005; Green et al., 1999; 
Lieberman, Kane, & Alvir, 1987; Lysaker et al., 1994; Negrete et al., 1986; Rosenthal, 
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Hellerstein, & Miner, 1994), impulsive or aggressive behaviours (Green, 2005; Walsh, 
Buchanan, & Fahy, 2002), and the risk of suicide (Hawton et al., 2005). At the same time, 
it is also significantly associated with the young and the male gender (DeQuardo, 
Carpenter, & Tandon, 1994; Mueser et al., 1990; Zammit et al., 2002).  
 
With regard to the link between co-morbid substance use and pre-morbid adjustment in 
patients with schizophrenia, Arndt and his colleagues (1992) found that the former was 
related to better pre-morbid adjustment. In that study, a cohort of 131 schizophrenic 
patients was divided into 2 groups by their co-morbid substance misuse, and the pre-
morbid adjustment level was compared between them. As a result, the pathological users 
(n = 64) experienced better pre-morbid adjustment than the non-users (n = 67), although 
both groups were similar in terms of current symptomatology and clinical history. The 
same study also revealed that only alcohol and, to some extent, cannabis use contributed 
to this effect, while stimulants or hallucinogens did not. 
 
Alternatively, from the perspective of the treatment of patients with co-morbid 
schizophrenia and substance abuse, approaches which are specific to such a condition 
have been developed and seem to be effective (Barrowclough et al., 2001; Haddock et al., 
2003). Indeed, motivational interviewing, combined with individual CBT and family or 
caregiver intervention, was shown to be beneficial for such people. This randomised 
controlled trial (RCT) (Haddock et al., 2003) compared the effects of motivational 
intervention combined with individual CBT and routine care, and routine care alone, on 
patients with co-morbid schizophrenia and substance use. It was revealed that the newly 
developed treatment not only resulted in significant improvements in patient functioning 
(assessed with the Global Assessment of Functioning Scale: GAF) when compared to the 
routine treatment, but that these benefits lasted for up to 18-months. These findings were 
supported by another RCT (James et al., 2004), which highlighted that an approach 
specifically targeting substance misuse in people with psychosis could be employed in a 
group-based intervention, and would be beneficial in reducing substance misuse. 
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In terms of a diagnosis of drug induced psychosis and schizophrenia, the diagnostic 
criteria for the latter in the DSM-IV excludes patients with psychotic symptoms that are, 
apparently, due to the direct physiological effects of a substance (American Psychiatric 
Association, 2000). Nevertheless, a number of patients with psychotic symptoms and co-
morbid substance use could, and should, be diagnosed as suffering from schizophrenia, 
even using the DSM-IV criteria, because they either start to use the substance after the 
onset of their psychosis, or continue to have these symptoms long after they have stopped 
using it. In such a situation, it might be useful to conceptualise a sub-type of patients with 
schizophrenia, whose substance misuse precedes the onset of psychotic symptoms. 
Indeed, by defining this sub-group, it would become possible to compare clinically 
important characteristics, such as long-term clinical outcome and response to a 
pharmacological or psychological treatment, between this sub-group and others. In 
addition, intensive treatment for drug misuse might be more effective for patients with 
this sub-type.  
 
In conclusion, co-morbid substance use has been associated with psychotic symptoms 
and an unfavourable clinical outcome in schizophrenia. Moreover, specific approaches, 
developed to target substance misuse in people with psychosis, have been shown to be 
effective. It, therefore, seems to be useful to conceptualise a sub-group of patients with 
the illness, whose substance misuse precedes the onset of their psychotic symptoms. 
 
4.3.4 Pre-morbid adjustment and psychosis 
It has been suggested that pre-morbid adjustment would be a useful way of identifying 
sub-types within the heterogeneous syndrome of schizophrenia. It was demonstrated by 
Strauss and Carpenter (1974) that past employment function and social relationships were 
the best predictors of respective outcome functions in patients with the disease. Indeed, it 
was empirically demonstrated that a deterioration in pre-morbid functioning is associated 
with the development of negative symptoms in schizophrenia (Kelley et al., 1992). In 
another study, conducted by Gupta et al. (1995), it was found that poor pre-morbid 
adjustment was significantly associated with the prominence of negative symptoms, an 
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early age of onset, educational problems, chronicity, and neurological soft signs. The link 
between pre-morbid social impairment and early age of onset was also demonstrated in a 
study by Hollis (2003). In addition, Larsen and his colleagues used the pre-morbid 
adjustment scale (PAS) (Cannon-Spoor, Potkin, & Wyatt, 1982) to examine 335 patients 
experiencing their first episode of non-affective psychosis, and revealed that those with a 
stable social course, compared to those with a deteriorating one, had a shorter duration of 
untreated psychosis, were older, had more friends, and had fewer negative symptoms. 
Furthermore, patients with a stable academic course were older at admission (Larsen et 
al., 2004). On the other hand, schizophrenic patients with good pre-morbid functioning 
are more likely to commit suicide (Pompili et al., 2007).  
 
In terms of the association between pre-morbid function and treatment response in the 
first episode of schizophrenia, it was proposed that good pre-morbid adjustment is linked 
to a better response to pharmacological treatment and fewer extrapyramidal symptoms 
(Rabinowitz et al., 2006). In that study, 530 patients with schizophrenia who were treated 
with risperidone or haloperidol were assessed by the PAS and categorized into 3 groups, 
‘stable good’ (n = 251), ‘stable poor’ (n = 198), and ‘declining’ (n = 81). Response to 
pharmacological treatment, which was evaluated by the Positive and Negative Syndrome 
Scale (PANSS) (Kay & Singh, 1989) and the Clinical Global Impressions (CGI) scale 
(NIMH, 1985), was then compared between them. Consequently, a significantly greater 
improvement was demonstrated in the ‘stable-good’ group than the ‘stable-poor’ one. 
This difference was found on the mean change in the PANSS total, the positive, negative 
and general psychopathology scales, and in CGI severity and improvement. On the other 
hand, patients in the ‘declining’ group improved the least among these 3 categories. 
 
In conclusion, it may be useful to propose a sub-type of schizophrenia with poor pre-
morbid adjustment, early age of onset, and prominent negative symptoms. It might also 
be helpful to define a further sub-group with good pre-morbid adjustment, late age of 
onset, and fewer negative symptoms.  
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4.3.5 Stressful life events and psychosis 
An interaction between events which occur in an individual’s life and the onset or relapse 
of their illness has been observed in many psychiatric disorders, including schizophrenia 
(Kingdon & Turkington, 1994). Falloon commented that ‘the impact of life stress on the 
course of schizophrenia has been observed frequently. In 1913 Emil Kraepelin remarked 
that remissions were often terminated by changes in the patient’s environment’ (Falloon, 
1984).   
 
So far as empirical support for the link between stressful life events and psychosis is 
concerned, it was suggested in one study that very recent life events trigger onset (Brown 
& Birley, 1968). Furthermore, in other explorative work conducted by Cullberg (2003), it 
was found that significant releasing factors could be observed in the majority of cases of 
first episode psychosis patients. Indeed, this research proposed that a stressful life event 
would be regarded as a more or less important boosting factor for psychosis, although it 
may not be considered to be the ‘cause’.  
 
Van Os et al. (1994) also demonstrated the influence of life events on the subsequent 
course of psychosis. In this prospective study, the existence of stressful life events in the 
3 months before onset was suggested to be associated with milder symptom severity and 
less time spent in hospital. This research also demonstrated that the presence of the life 
events were linked to less need of anti-psychotic maintenance medication over the 
follow-up period and more time in complete remission in patients with schizophrenia. 
However, there may be two major limitations in this study, namely recall bias relating to 
patients’ report about the existence of stressful life events, and difficulty in the 
demonstration of the causal relationship between such events and the clinical features in 
psychosis or schizophrenia.  
 
For such a situation, the category of acute and transient psychotic disorder (ATPD) was 
created by the WHO (F23 of ICD-10), with it being proposed that the diagnosis thereof is 
associated with a negative life event preceding the first episode, good social adaptation, 
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reduced psychological impairment, and fine global function (Marneros et al., 2003). This 
description suggests that a negative event, which precedes initial psychotic symptoms, 
may predict a favourable prognosis in patients with schizophrenia or psychosis. 
 
In conclusion, the existence of a significant life event which precedes the first episode 
might predict a favourable prognosis, although it is difficult to demonstrate a causal 
relationship between such an event and the development of psychotic symptoms. 
 
4.3.6 Significance of specific psychosocial factors that have been revealed in 
studies of acute and transient psychotic disorder (ATPD) 
The new category of ATPD was introduced by the WHO (F23 of ICD-10) (World Health 
Organization, 1992). There is one prospective longitudinal case control study thereof, 
which revealed the differences and similarities between ATPD and schizophrenia 
(Marneros et al., 2003). In this research, inpatients with the former were compared to 
matched controls with ‘positive’ schizophrenia and with mentally healthy controls. It was 
suggested that individuals with ATPD and schizophrenia were similar (but different to 
the healthy control) in terms of the prevalence of coming from a ‘broken home’ and a 
family history of mental disorders, while ATPD patients had better pre-morbid social 
adjustment than those with schizophrenia. Moreover, those with ATPD more frequently 
displayed rapidly changing symptoms in the index episode and had experienced a 
negative life event preceding it. Comparisons between patients with ATPD and its related 
disorders, as well as those with schizophrenia, were made in other studies which 
identified more acute onset, less non-schizoid pre-morbid personality, and greater 
precipitating stress as the features of the former disorder (McCabe, 1975; Stephens, 
Shaffer, & Carpenter, Jr., 1982). 
 
Nevertheless, the facts that diagnoses of ATPD are not stable, and that a considerable 
proportion of these patients go on to develop schizophrenia over the course of the illness, 
does make the situation more complicated in terms of the relationship between the 2 
conditions (Jorgensen, 1985; Jorgensen et al., 1997).  In this kind of situation, Suda and 
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her colleagues (2005) demonstrated that the lack of an acute upsurge in insomnia in an 
early phase of the episode, and poor pre-morbid heterosexual relationships, predict the 
later development of schizophrenia in patients who are currently diagnosed with ATPD.  
 
If all these data on ATPD and schizophrenia are taken into consideration, it seems 
possible to propose a sub-group of schizophrenia or psychosis which is characterized by 
acute onset, good pre-morbid social function, and heterosexual relationships. The 
existence of stressful life events in the period leading up to an acute upsurge of insomnia, 
which precedes the first episode, might also be included in the diagnostic criteria for this 
sub-type.  
 
4.3.7 Stress sensitivity and psychosis 
Sensitivity to stress has been recognized as a component of schizophrenia ever since the 
term was first proposed by Bleuler (1911). In other words, it has long been considered to 
be an area of vulnerability that is associated with the onset and relapse of schizophrenia 
and other psychotic disorders (Myin-Germeys et al., 2001). Two types of study have now 
cast light on this area of evaluating the ‘daily hassles’ of life (Norman & Malla, 1991) 
and recording unsettling experiences (Myin-Germeys et al., 2001). In fact, Malla and his 
colleagues (1990) suggested that comparatively minor daily stressors can have a 
significant effect on patients with schizophrenia. On the other hand, Myin-Germeys and 
others (2001) investigated the emotional reactivity of patients with psychosis to daily life 
stress as a vulnerability marker for psychotic illness. They demonstrated that individuals 
with psychosis had a more intense emotional reaction to subjective appraisals of stress in 
daily life than the control subjects. Stress sensitivity, including social anxiety, was also 
shown to be one of the key factors which people believed led to the onset of their 
psychotic symptoms (Dudley et al., 2009). 
 
In conclusion, stress sensitivity is considered to be a component of vulnerability which is 
related to the onset and relapse of schizophrenia and other psychotic disorders.   
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4.4 Age and mode of onset as important clinical factors in schizophrenia 
Along with the psychosocial elements which were described above, two clinical factors 
relating to onset of schizophrenia, namely age and mode thereof, have also been proved 
to be associated with clinical features of the illness (Dernovsek & Tavcar, 1999; Harrison 
et al., 1996). Indeed, early age at onset was suggested to be associated with chronic 
course of the disorder (Krausz & Muller-Thomsen, 1993), frequent rehospitalizations 
(Eaton et al., 1992), less favourable prognosis (Hafner & Nowotny, 1995), and poorer 
response to treatment (Meltzer et al., 1997). On the other hand, with regard to the mode 
of onset, an insidious onset was demonstrated to predict a longer duration of first or 
subsequent episodes (Wiersma et al., 1998). Association between the insidious onset and 
more negative symptoms was also suggested in patients with schizophrenia (Fenton & 
McGlashan, 1991b; Larsen et al., 1996). Moreover, both the age (Gupta et al., 1995) and 
mode (Bailer, Brauer, & Rey, 1996; Larsen et al., 1996) of onset was indicated to be 
linked to pre-morbid functioning . In fact, good pre-morbid functioning was proved to be 
associated with both the lateness and acuteness of the onset. 
 
Therefore, as discussed above (see section 4.3.4, “Pre-morbid adjustment and psychosis”), 
it may be useful to propose two sub-types of schizophrenia; one is with poor pre-morbid 
adjustment, early age of onset, and prominent negative symptoms, while the other is with 
good pre-morbid adjustment, late age of onset, and fewer negative symptoms. 
Furthermore, it might be reasonable to use the mode of onset as an additional factor for 
distinction between these two sub-groups. That is to say, an insidious onset may also be 
included in the definition of the former sub-type, while an acute onset may become an 
element in the conceptualisation of the latter. 
 
4.5 Significant psychosocial factors from patients’ perspectives 
Some of the psychosocial factors described above have also been revealed to be 
important from the perspective of those with psychosis. Indeed, Dudley and his 
colleagues (2009) investigated the factors that patients believed led to the onset of their 
symptoms. In this study with 21 patients with psychosis, 4 main factors were identified as 
being perceived causal factors for the onset of the condition: the drug related explanation 
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(e.g., use of illegal drugs), the adult trauma explanation (e.g., sexual assault and physical 
violence as an adult), the personal sensitivity explanation (e.g., social anxiety and an 
inability to deal with problems), and the developmental vulnerability explanation (e.g., 
abusive experiences in childhood [but not sexual abuse]). In other words, people with 
psychosis believe that the psychosocial factors referred to did cause the onset of their 
symptoms. The findings suggest that these kinds of explanations could be comfortably 
accepted by the patients and, importantly, may be less stigmatising.   
 
4.6 A concept of clinical sub-groups integrating psychosocial factors 
Due to both the lack of practically useful concepts of sub-types of schizophrenia which 
have been previously established, and the significance of the psychosocial and 
psychopathological factors mentioned in previous sections, it is worth integrating these 
elements into a concept of the sub-types of the illness.  In fact, the conceptualisation of 4 
sub-groups of schizophrenia – drug related, traumatic, anxiety, and stress sensitivity - was 
established on the basis of the model produced by Kingdon and Turkington (2005).  
 
This classification scheme for individuals with schizophrenia employed a multi-
dimensional approach. Most of the previous attempts to sub-group the disorder have been 
dependent upon only one aspect of this psychiatric phenomenon, such as its symptoms, 
cognitive deficit, or neurological anatomical issues. Nevertheless, the criteria proposed 
are based equally on age and mode of onset, pre-morbid adjustment, and aetiology, such 
as drug-misuse and traumatic experience. Theoretically, these factors never change after 
the onset of schizophrenia, and may contribute to the stability of the classification. This 
approach may, therefore, lead to a holistic and more precise understanding of those with 
this specific mental disorder. 
 
4.7 Summary 
The vulnerability-stress model is deemed useful for understanding the association 
between psychosocial factors and psychosis or schizophrenia. Some specific psychosocial 
factors, such as trauma and stress sensitivity, have been shown to be related to psychosis. 
In such a situation, a new classification system, in which these psychosocial factors were 
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integrated, was put forward. This employs these elements to identify and describe each of 
the 4 sub-types proposed.  
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Chapter 5: Description of the Four Sub-groups of Schizophrenia  
 
5.1 Overview 
As described in the previous chapter, the conceptualisation of the 4 sub-groups of 
schizophrenia, which arose from clinical observations in the development and use of 
cognitive behavioural therapy, was developed by integrating psychosocial factors into the 
classification scheme (Kingdon & Turkington, 2005). In this chapter, a description of 
each of the 4 sub-groups - drug related, traumatic, anxiety, and stress sensitivity - is 
presented. 
 
5.2 Description of the four sub-groups of schizophrenia 
Drug Related Sub-group: 
The core characteristic of this sub-group is that the individual will have used at least 1 of 
the hallucinogens/stimulants listed below in the 2 weeks before the onset of the first 
psychotic episode.  
 
List of hallucinogens/stimulants 
Amphetamine, cocaine, LSD, ecstasy, cannabis, and others1 
 
Age of onset will usually be in their teens or 20s, and mode of onset is either acute or 
insidious. With regard to lifetime patterns of social interaction, individuals with this sub-
type will tend to be relatively sociable (Arndt et al., 1992), having many friends at school 
and possibly a number of partners or wives/husbands. Moreover, the symptom patterns 
will tend to be diverse, with negative ones being less prominent (D'Souza et al., 2005; 
Green et al., 1999; Lieberman, Kane, & Alvir, 1987; Lysaker et al., 1994; Negrete et al., 
1986; Rosenthal, Hellerstein, & Miner, 1994).  
 
                                                 
1 Any other types of drugs which are known to cause psychotic symptoms (e.g., diethylpropion) can be 
included. 
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The conceptualisation of this sub-type is supported by the suggested differences between 
patients with and without co-morbid substance misuse that are discussed in Chapter 4 
(see section 4.3.3, “Drug misuse and psychosis”). 
 
Traumatic Sub-group: 
The core characteristic of this sub-group is that the person meets the criteria for co-
morbid borderline personality disorder, and has also experienced childhood sexual or 
emotional abuse. 
 
Additionally, the age of onset will usually be in the patients’ teens or 20s, and the mode 
of onset2 is either acute or insidious. In terms of lifetime patterns of social interaction, 
individuals with this sub-type will tend to have chaotic relationships with others (e.g., 
severe conflicts with their families, and unstable sexual relationships with many 
boy/girlfriends). With regard to symptom patterns, abusive hallucinations (auditory or 
visual) may well occur in those in this sub-group. 
 
The conceptualisation of this sub-type is supported by research findings wherein 
childhood trauma is linked to psychosis (Morrison, Read, & Turkington, 2005). Moreover, 
as described in Chapter 4 (see section 4.3.2, “Borderline personality and psychosis”), in 
patients with schizophrenia, sexual and emotional abuse is more associated with the 
individuals who have co-morbid BPD than with those who do not (Kingdon et al. in 
submission).  
 
Anxiety Sub-group: 
The core characteristic of this sub-group is that the individual has had good peer 
relationships in early adolescence, and will have generally developed close relationships 
with a partner or spouse. Age of onset will usually be in the patients’ 30s or older, and the 
                                                 
2 Mode of onset is defined as the period between the first reported symptom or noticeable behavioural 
change and the patient’s subjective peak of this first episode. The subjective peak means the point at which 
distress at the psychotic symptoms is at its height. ‘Acute’ onset means that the period is less than 1 months 
whereas ‘insidious’ onset means that it is as long as, or longer, than 1 months. 
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mode of onset is likely to be acute. In terms of the lifetime pattern of social interaction, 
those in this sub-group are relatively sociable, having had both many friends at school, 
and partners or wives/husbands, before onset. In many cases, individuals will have 
experienced stressful life events immediately preceding the psychotic symptoms 
(generally considered to be within 3 months of onset). So far as symptom patterns are 
concerned, delusions (especially those that are systematized or well organized) are 
prominent. In addition, hallucinations (auditory, visual, or with other modals) occur, but 
are less to the fore, as are negative symptoms.  
 
This sub-type was established in order to classify the patients with schizophrenia who had 
experienced the psychosocial factors associated with a good clinical outcome which are 
described in Chapter 4 (see sections 4.3, “Psychosocial factors associated with psychosis” 
and 4.4, “Age and mode of onset as important clinical factors in schizophrenia”). 
 
The conceptualisation of this category overlaps, to some extent, with Kraepelin’s 
description of paranoia (Kraepelin, 1919). However, patients with hallucinations, or other 
symptoms which are characteristic of those suffering from schizophrenia, including 
confusion of speech and stereotyping, are excluded from the concept behind paranoia. 
We, therefore, proposed the concept of anxiety psychosis which can be applied to 
individuals with schizophrenia.    
 
Stress Sensitivity Sub-group: 
The core characteristic of this sub-group is that the individual is more stress sensitive3 
and less sociable. Age of onset is usually in the patients’ teens or early 20s, and the mode 
of onset is likely to be insidious. In terms of lifetime patterns of social interaction, those 
with this sub-type are less sociable, having few friends, (even in childhood), and do not 
have partners or wives/husbands. With regard to symptom patterns, negative symptoms 
are prominent, even in the first episode, whereas a range of positive symptoms occur as 
well.  
                                                 
3 ‘Stress sensitive’ means that emotional reactivity is high to daily life stress, or ‘daily hassles’ (Myin-
Germeys et al., 2001; Myin-Germeys & van Os, 2007) 
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This sub-type was established to classify patients with schizophrenia who had 
experienced the psychosocial factors associated with a poor clinical outcome which are 
described in Chapter 4 (see sections 4.3, “Psychosocial factors associated with psychosis” 
and 4.4, “Age and mode of onset as important clinical factors in schizophrenia”). 
 
Although the conceptualisation of schizophrenia in the DSM-IV is based upon that of 
dementia praecox proposed by Kraepelin (1919), the former is broader than the latter, and 
the patients diagnosed with schizophrenia by the DSM-IV have a more heterogeneous 
clinical presentation than those with dementia praecox. As mentioned in Chapter 2 (“The 
Classification of Schizophrenia”), this is mainly due to Bleuler’s expansion of the 
concept. Nevertheless, the discrepancy of the conceptualisations of dementia praecox and 
schizophrenia in the DSM-IV cannot be fully explained by this historical process in the 
development of the initial concept of schizophrenia. For instance, Schneider (1959) 
emphasised that the categorisation of schizophrenia should be based upon the nature of 
symptoms, rather than their content, and it initially seemed that the definition could be 
made tighter by doing so. However, the first-rank symptoms proposed by Schneider have 
proved to be less specific than was initially hoped. For example, they have been 
demonstrated as occurring in association with trauma (Ross & Joshi, 1992), as well as in 
those whose first psychotic experience was due to the effects of stimulant and 
hallucinogenic drugs. The inclusion of the second group became increasingly important 
from the 1960s onwards, and led to a substantial increase in the numbers of those who 
could be included within the diagnostic category (Kingdon et al., 2008a; Kingdon et al., 
2008b) It might, therefore, be useful to define one sub-group of schizophrenia which 
corresponds to the original conceptualisation of dementia praecox. Accordingly, the 
concept behind the stress sensitivity sub-type better reflects that of dementia praecox than 
it does that of schizophrenia in the DSM-IV or the ICD-10. 
 
5.3 Differentiation between the anxiety and stress sensitivity sub-types 
As described in the previous chapter, late and acute onset, good pre-morbid social 
function and heterosexual relationships, the existence of stressful life events, and an acute 
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upsurge in insomnia preceding the onset or recurrence of the first episode of 
schizophrenia have been found to be associated with good outcomes in patients with that 
illness. Moreover, some of these factors have been revealed to be related to each other in 
such individuals. These characteristics are employed for differentiating between the 
anxiety and the stress sensitivity sub-types. In other words, the diagnostic criteria for the 
anxiety category were designed to include late and acute onset, good pre-morbid function, 
including good sociability in early or late adolescence and an experience of heterosexual 
relationships, and the existence of stressful life events which are followed by an acute 
upsurge in insomnia and the first psychotic episode. On the other hand, the diagnostic 
criteria for the stress sensitivity sub-type consist of early and insidious onset, poor pre-
morbid function, including poor sociability since early adolescence and a lack of pre-
morbid heterosexual relationships, and an absence of stressful life events preceding the 
onset of the first episode (Appendix A). 
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Chapter 6: Stigmatisation of Patients with Diagnoses of Schizophrenia 
 
6.1 Background 
The term schizophrenia has consistently proved difficult to use with many patients, who 
reject it either on the basis of the associations that it now has with aggressive behaviour 
and a deteriorating symptom course, or because they do not consider themselves to be ill 
(British Psychological Society, 2000). It is, therefore, clear that a diagnosis of 
schizophrenia is associated with a great degree of stigma (Angermeyer & Matschinger, 
2003). This makes it difficult for patients with this condition to accept their diagnoses. 
What is even worse is when patients deny the need for treatment because of its 
association with this unacceptable diagnosis. Indeed, it is suggested that insight into the 
need for treatment is at least as important as insight into the fact that an individual has an 
illness (Rathod et al., 2005). In any case, it is a common experience for psychiatrists to 
either disagree with a patient about the diagnosis, or negotiate an acceptable alternative 
term, which is imprecise but less stigmatising. Developing terms which might be 
acceptable and meaningful to both psychiatrists and patients would, therefore, be a step 
forward in communication and therapy. 
 
6.2 Impact of this concept of sub-grouping schizophrenia on research and in 
clinical practice 
The concept of sub-grouping schizophrenia based upon the vulnerability-stress model 
could be valuable for both research and in clinical practice. Firstly, this scheme could 
establish a basis for the further study of the characteristics of each sub-type. In other 
words, although additional investigations are required, this classification system may lead 
to more precise prognoses and more appropriate therapeutic interventions. Secondly, a set 
of terms which may be acceptable, and less stigmatising, as an alternative to that of  
schizophrenia could be provided. Indeed, by accurately defining and introducing these 
terms for the sub-groups, it may become possible for both psychiatrists and patients to 
discuss this disorder more openly and constructively (Kingdon et al., 2007).   
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Indeed, a study conducted by Kingdon et al. (2008b) suggested that patients with a 
diagnosis of schizophrenia, as well as their carers and mental health staff, considered that 
the current terminology was impairing communication and increasing stigmatisation, and 
that alternatives needed to be sought. In that research, patients with schizophrenia (n = 
27) were shown 5 cards which described the 4 sub-groups and schizophrenia, as well as a 
sixth which simply stated 'none of these'.  Participants were then asked to consider which 
description best matched their experiences, with particular reference to how their 
problems had begun. It was demonstrated that patients were more positive about the 
terms used for the 4 sub-groups than the word, schizophrenia. Furthermore, the 4 terms 
which were put forward as defining the 4 sub-groups of the disorder, according to the 
concepts of Professors Kingdon and Turkington, were also shown to reduce the negative 
attitudes of medical students to it (Kingdon et al., 2008a). In that particular study, 
attitudes to schizophrenia in a sample of medical students (n = 241) were compared to 
their attitudes to the proposed groups and to the alternative terminology (Kingdon et al., 
2008a).  
 
Although the concept of sub-grouping may well be useful, the sub-types still require 
validation. Indeed, the validity of this classification scheme should be established with 
the procedures proposed by Kendell (1989), as described in Chapter 1 (see section 1.4, 
“Procedure for validating a classification system”). Nevertheless, the validity of the 
categories cannot be established unless the diagnosis thereof is reliable. Therefore, it is 
also important to improve the reliability of the diagnosis. A semi-structured interview, as 
discussed in the next chapter (Chapter 7, “Semi-structured Interview for Sub-grouping 
Schizophrenia”), can be considered to be a promising tool for improving the reliability of 
collected data. 
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Chapter 7: Semi-structured Interview for Sub-grouping Schizophrenia 
 
Even though the concept for categorizing the disorder has been established, it may still be 
difficult to sub-group patients according thereto. The conceptualisation is not useful on its 
own, and requires a number of devices which may facilitate its practical use. The semi-
structured interview is a promising tool, and would be valuable both when it comes to 
applying the concept in research or clinical use, and improving the reliability of a 
diagnosis (Richardson SA, Dohrenwend BS, & Klein D, 1965; Tsuang, Woolson, & 
Simpson, 1980). A semi-structured interview contains questions which are posed by an 
interviewer, and explains how to assess a respondent’s answers thereto. Such devices 
could minimise discrepancies in the assessments made by different interviewers, and 
assist them in reproducing the same judgements when they have to undertake the 
questioning twice.   
 
Tsuang defines a structured (standardized) interview as follows: ‘Standard questions are 
asked in a predetermined order, and the set of available responses is often fixed’ (Tsuang, 
Woolson, & Simpson, 1980). Structured interviews can be further divided into 2 
categories, ‘scheduled’ and ‘non-scheduled’ (Richardson SA, Dohrenwend BS, & Klein 
D, 1965). Tsuang’s definition would correspond to a scheduled standardized interview, 
whereas a semi-structured one is equivalent to a non-scheduled standardized interview, 
which indicates the specific information to be obtained, but allows for flexibility in the 
form and sequence of the questions (Helzer, 1983). These instruments may improve the 
validity and reliability of the relevant clinical information obtained during the assessment 
process (Calinoiu & McClellan, 2004). 
 
Therefore, in the study herein, a semi-structured clinical interview for psychosis sub-
groups (SCIPS) was developed to facilitate research into both the concept of 
schizophrenia sub-groups and the clinical application thereof, and to achieve an 
acceptable degree of reliability for such classifications. 
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Chapter 8: Potential External Validators of the Sub-types in the Current 
Study 
 
8.1 Overview 
As described in Chapter 1 (see section 1.4, “Procedure for validating a classification 
system”), specific external validators are needed to assess the construct validity of the 
sub-types in the present study (see Table 1). Nevertheless, such validators are still to be 
identified. Indeed, specific variables which are not included in the original diagnostic 
criteria, and differ between the sub-types, should be identified and then utilised for the 
validation of these categories. Three variables, namely evaluative beliefs, fear of negative 
evaluations from others, and depression were identified as possible validators. 
 
8.2 Criteria for the identification of the candidates to be validators 
The criteria, which consist of 4 items, were used to identify candidates to be the 
validators examined in the present study (Table 9).  
 
Table 9: The criteria for the identification of candidates for the validators. 
1. A variable which is not included in the SCIPS. 
2. A variable which is expected to differ among the sub-types. 
3. A variable which is suggested as being associated with the intensity of psychotic 
symptoms (e.g., delusions and hallucinations). 
4. A variable which is indicated as being a target for cognitive behavioural therapy 
(CBT). 
 
As described briefly in Chapter 1 (see section 1.4, “Procedure for validating a 
classification system”), if a classification system is valid and clinically relevant, then the 
sub-types of schizophrenia should differ in some specific variable that is relevant in 
research or clinical practice, and is not included in the original diagnostic criteria. Thus, 
items 1) and 2) should be included therein. In addition, item 3) was included in the 
criteria because variables which are related to the intensity of psychotic symptoms would 
influence clinical outcome and response to treatment. On the other hand, item 4) was 
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included because the concept behind the sub-groups was originally developed to be 
applied to CBT for the sub-types, and validators which indicate the difference in 
responses to this form of treatment would be clinically relevant and useful.   
 
Three variables, which were: evaluative beliefs, the fear of negative evaluations from 
others, and depression, were confirmed as fulfilling the criteria described above.  
 
Temperament, pre-morbid or co-morbid schizotypal or schizoid personality disorder, and 
neurobiological variables including results of neuroimaging testing were also considered 
to be the candidates. However, these variables were not assessed in the present study, 
mainly because a large amount of time would be required to implement these types of 
evaluation for each participant. Furthermore, the diagnostic criteria for schizotypal or 
schizoid personality disorder and the stress sensitivity sub-type do overlap to some extent 
(i.e., both criteria include poor social relationships as an item). This was also the reason 
why these sorts of personality disorders were not used as the external evaluators in this 
thesis.   
 
8.3 Evaluative beliefs 
Evaluative, or schematic, beliefs can be defined as the way in which people make 
judgements or evaluate themselves and other people (Fowler et al., 2006). These beliefs 
are considered to be a central process in mediating an individual’s adaptation to the social 
world, and form a part of a basic human response to social stresses and threats (Gilbert, 
1992). Indeed, moment-to-moment evaluations of the self and others are suggested as 
being associated with current external events, current mood and cognitive state, and 
memory processes in the form of schema which synthesise past reactions (Beck, 1976; 
Gilbert, 1992; Teasdale & Barnard, 1993). In other words, these evaluative beliefs might 
be a key component of stress sensitivity, as described in Chapter 4 (see section 4.3.7, 
“Stress sensitivity and psychosis”), and the levels of these beliefs may be higher in 
patients with the stress sensitivity sub-type. 
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The evaluative beliefs can be assessed with a high construct validity by using the Brief 
Core Schema Scale (see Appendix D) (Fowler et al., 2006). Negative evaluative beliefs 
about the self were shown to be associated with persecutory delusions, even after the 
confounding effects of depression and low self-esteem were controlled (Smith et al., 
2006). Moreover, evaluative beliefs are a main target of CBT in a wide range of mental 
illnesses, including schizophrenia and other psychotic disorders (Wright et al., 2008). 
 
Evaluative beliefs have been implicated to be associated with stress sensitivity and thus, 
in hypothesis, useful to differentiate between the anxiety and stress sensitivity sub-types. 
Social stress is thought to be one of the key elements of stress. For example, Myin 
Germeys (2001) described that social stress can be divided into 4 components, namely, 1. 
Event related, 2. Acivity related, 3. Thought related and 4. Social element. Therefore, a 
stress sensitive person would be more likely to have social anxiety. For example, 
according to Rusch’s study (2009), social anxiety predicted lower self-esteem in patients 
with mental illness. At the same time, according to Fowler’s work (2006), negative 
evaluative beliefs about self are significantly associated with self-esteem. Accordingly, 
negative evaluative beliefs about self may be higher in patients with stress sensitivity sub-
type than in those with anxiety sub-type. 
 
8.4 Fear of negative evaluation from others (FNE) 
The fear of negative evaluation from others can be defined as apprehension about 
receiving negative appraisal from other people (Watson & Friend, 1969). FNE has been 
considered to be a crucial cognition in social anxiety disorder (Collins et al., 2005; Endler 
et al., 1991; Schlenker & Leary, 1982; Winton, Clark, & Edelmann, 1995), and might 
also be involved in the development and maintenance of symptoms other than social 
anxiety (Kingsep, Nathan, & Castle, 2003; O'Connor et al., 2002; Swoboda et al., 2003). 
In other words, this cognition might be an important element in stress sensitivity, as 
described in Chapter 4 (see section 4.3.7, “Stress sensitivity and psychosis”), and the 
levels of these beliefs may be higher in patients in the stress sensitivity sub-group.  
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In terms of the relationship between high FNE and subclinical paranoid ideations, it has 
been demonstrated that the former is one of the best predictors of the latter in a non-
clinical population (Martin & Penn, 2001). In this study of a student group (N = 193) 
(Martin & Penn, 2001), greater paranoid ideation, measured by the Paranoia Scale 
(Fenigstein & Vanable, 1992), was associated with a higher score in the BFNE (Pearson’s 
r = 0.39, p < 0.01). Nevertheless, the direct relationship between high FNE and psychotic 
symptoms in patients with schizophrenia and other psychotic disorders is still to be 
demonstrated.  
 
The FNE can be assessed by using the Brief Fear of Negative Evaluation Scale (see 
Appendix E) which has high reliability and validity (Rodebaugh et al., 2004). The FNE 
might also be a significant target for CBT for those suffering from schizophrenia 
(Kingsep, Nathan, & Castle, 2003). This study suggests that when group CBT for social 
anxiety is conducted with these patients, the improvement of positive symptoms in those 
with this illness is associated with a reduction in FNE.  
 
FNE has been implicated to be associated with stress sensitivity and thus, in hypothesis, 
useful to differentiate between the anxiety and stress sensitivity sub-types. As discussed 
above, a stress sensitive person would be more likely to have social anxiety. On the other 
hand, FNE is considered to be a crucial cognition in social anxiety disorder (Collins 
2005). Therefore, extent of FNE may be higher in patients with stress sensitivity sub-type 
than in those with anxiety sub-type. 
 
8.5 Depression 
A body of evidence from epidemiological, questionnaire, experimental, and treatment 
studies support the notion that low mood can contribute to the development of psychotic 
symptoms (Drake et al., 2004; Freeman & Garety, 2003; Hafner et al., 2005; Iqbal et al., 
2000; Krabbendam et al., 2005; Smith et al., 2006). In addition, it has been suggested that 
the enduring effect of psychotherapy, which enables clients to effectively manage their 
sensitivity to stress, may contribute to a reduction in depressive symptoms (Hawley et al., 
2007; Zuroff & Blatt, 2006). It is, thus, implied that the level of depression is greater in 
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patients with the stress sensitivity sub-type of schizophrenia. At the same time, 
depression is also a significant target for CBT, even when it is associated with 
schizophrenia or other psychotic disorders (Iqbal et al., 2000; Wright et al., 2008). The 
Beck Depression Inventory-II (BDI-II) (see Appendix F) (Beck, Steer, & Brown, 1996) 
was used for the assessment of this condition in the present study. 
 
Depression may be useful to differentiate between the anxiety and stress sensitivity sub-
types. On the basis of its definition, individuals with higher stress sensitivity would show 
higher emotional reactivity to daily life stress, or ‘daily hassles’ (Myin-Germeys et al., 
2001). This means that a stress sensitive person would more likely to become depressive 
due to daily life stress. Therefore, level of depression may be higher in patients with 
stress sensitivity sub-type than in those with anxiety sub-type. 
 
8.6 Summary 
Criteria were developed and used for the identification of candidates for external 
validators. Three variables: evaluative beliefs, fear of negative evaluations from others, 
and depression were identified as possibilities which would both fulfil the criteria, and 
could be used to establish the construct validity of the sub-types of schizophrenia.  
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Chapter 9: Summary of Chapters 1 to 8 Providing the Background to This 
Thesis 
As described in the previous chapters, schizophrenia has long been considered to be 
remarkably heterogeneous, and there have been a number of attempts to identify sub-
groups of this disorder which are more homogeneous. Nevertheless, most of these have 
not been used in either research or clinical practice to any great extent, because diagnoses 
by way of these strategies would be unstable over time and impractical.  
 
In such circumstances, the vulnerability-stress model has led to the development of a new 
concept of sub-grouping schizophrenia into 4 sub-types – drug related, traumatic, anxiety, 
and stress sensitivity. This conceptualisation is quite promising, not only because it may 
provide stable and practical diagnoses, but also because the terminology used therein is 
useful when it comes to destigmatising those who are currently diagnosed with 
schizophrenia. 
 
In order to adapt this concept for practical use, this project set out to prepare a semi-
structured interview for making diagnoses according to it and examine its reliability and 
validity. This assessment tool could then facilitate the evaluation of the validity of this 
classification system. In other words, the sub-types in this system may be demonstrated 
as being different in terms of their external validators. Three psychopathological 
variables – evaluative belief, FNE, and depression – could be assessed during this process 
of validation. Moreover, longitudinal stability and a distinctive course or outcome or 
treatment response can be established for the sub-types determined with the interview.  
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Chapter 10: Method 
 
10.1 Justification for the present study 
As discussed above, the classification of schizophrenia continues to be problematic. The 
illness has a remarkably heterogeneous clinical presentation, and although a number of 
classification schemes for sub-types thereof have been developed, they lack the empirical 
support required for clinical validity and utility. In these circumstances, and based upon 
the vulnerability-stress model (Kingdon et al., 2008a; Kingdon et al., 2008b), the concept 
of 4 sub-groups of schizophrenia - drug related, traumatic, anxiety, and stress sensitivity- 
was established. This system employs a multi-dimensional approach. In other words, the 
criteria proposed are based equally on age and mode of onset, pre-morbid adjustment, and 
aetiology, such as drug-misuse and traumatic experiences. Theoretically, these factors 
never change after the onset of psychosis, and may contribute to the stability of the 
classification. At the same time, significant prognostic value is also anticipated, because 
the factors used for classification purposes have been shown to predict clinical outcome, 
as discussed in Chapter 4 (“Psychosocial Factors and Psychosis”). 
     
The primary aim of this thesis was to develop a semi-structured interview to aid the 
diagnosis of schizophrenia according to the classification system described in Chapter 5 
(“Description of the Four Sub-groups of Schizophrenia”). The factors to be included were 
decided following a careful review of the potential variables discussed in Chapter 4 
(“Psychosocial Factors and Psychosis”). A semi-structured clinical interview for 
psychosis sub-groups (SCIPS) was then developed by integrating these elements. 
Thereafter, inter-rater reliability and concurrent validity of this assessment tool were 
evaluated, and longitudinal stability of the classification over a 6 month period was also 
examined. In addition, a preliminary assessment of construct validity of the distinction 
between the anxiety and stress sensitivity sub-types was conducted through the 
exploration of their potential differences. These 2 particular sub-groups were chosen for 
this purpose because there may be an overlap in the concepts behind them, and 
differentiating between them, thus, seemed to be especially important. Accordingly, and 
as discussed in Chapter 8 (“Potential External Validators of the Sub-types in the Current 
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Study”), external evaluators, which had been hypothesised to differentiate between these 
2 specific sub-types, were chosen to be utilised herein. These validators, namely negative 
and positive evaluative beliefs, fear of negative evaluation from others (FNE), and 
depression were carefully chosen, again as described in Chapter 8. During this process, 2 
cross-sectional studies were also conducted to highlight the clinical significance of the 
FNE. Moreover, the prognostic quality of the distinction was extensively analysed by 
comparing clinical outcomes between these 2 sub-types. 
 
10.2 Study design 
The main body of this research employed a systematic cross-sectional design, which was 
based on the collection of data from a consecutive sample of patients who were recruited 
from outpatient clinics and psychiatric hospitals. Three cross-sectional studies (with 
patients suffering from schizophrenia in the UK and Japan, and the non-clinical 
population in Japan) were conducted for the purpose of this thesis. To establish the 
longitudinal stability of the classification, a prospective follow-up piece of work was also 
carried out. In addition, a retrospective cohort study, evaluating the association between 
the sub-types and clinical outcome, was conducted. For this latter research, a detailed 
retrospective audit of the participants’ case notes was performed to collect data about 
clinical outcomes. In addition, the SCIPS was used to determine the patients’ sub-types. 
 
10.3 Objectives of the study 
1. The following aims were identified for the cross-sectional study in the UK and in 
Japan: 
 
1.1 The primary aims were to: 
1.1.1 Establish the inter-rater reliability and concurrent validity of the English and 
Japanese versions of the SCIPS. That is to say, the null hypotheses examined were: 
1) There is no statistically significant concurrence in the SCIPS diagnoses between 
two independent raters (for the inter-rater reliability). 
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2) There is no statistically significant concurrence between the SCIPS diagnosis and 
sub-groups determined with the highest achievable validity (for the concurrent 
validity). 
1.1.2 Confirm the sensitivity and specificity of the SCIPS diagnosis for each of the 4 sub-
types in the UK and in Japan. 
 
1.2 The secondary aims were to:  
1.2.1 Determine if the anxiety and stress sensitivity sub-types differed in their 
psychopathological characteristics (i.e., evaluative beliefs and fear of negative evaluation 
from others in the UK and evaluative beliefs, fear of negative evaluation from others and 
depression in Japan).  
1.2.2 Examine if the sub-types determined with the SCIPS were not related to those 
determined with the DSM-IV; 
1.2.3 Determine if the FNE was associated with the severity of delusional ideations, in 
order to confirm the clinical significance of FNE as a potential external validator of the 
classification scheme implicated in the cross-sectional study with the non-clinical 
population in Japan. 
 
2. The aim of the longitudinal study with patients suffering from schizophrenia in Japan 
was to establish if the sub-types determined with the SCIPS were stable over a 6 month 
period. That is to say, the null hypothesis examined was that there is no statistically 
significant concurrence between the two SCIPS diagnoses for each patient determined on 
2 different days with an interval of at least 6 months. 
 
3. The following aims were identified for the retrospective cohort study in Japan: 
3.1 The primary aim was to establish whether the anxiety and stress sensitivity sub-types 
differed in relation to the total duration of patient hospitalization during the period of 3 
years after the date of the first admission and the length of the first hospitalization. That is 
to say, the null hypothesis examined was that there is no statistically significant 
difference in these 2 variables between the 2 sub-types. 
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3.2 The secondary aim was to determine if the anxiety and stress sensitivity sub-types 
differed with regard to the risk of patients self harming. 
 
4. The aim of the cross-sectional study with the non-clinical population in Japan was to 
determine if the FNE was associated with delusional thinking; the purpose being to find 
supporting evidence of the clinical significance of FNE as a potential external validator of 
the classification scheme. That is to say, the null hypothesis examined was that there is no 
statistically significant association between the FNE and delusional thinking in the 
sample. 
 
 
The cross-sectional studies, which aimed to establish an association between the FNE and 
delusional thinking in both the non-clinical population (objective 5, described above) and 
patients with schizophrenia (objective 2.2.3, described above) in Japan, were independent 
of the other research, which was attempting to directly develop and assess the 
psychometric properties of the SCIPS. For the purpose of clarity, the method used in 
these 2 studies are not described in detail in this chapter, instead being included in 
Chapter 12 (“Relationship between the Fear of Negative Evaluation from Others and 
Delusions”). 
 
10.4 Settings 
Given that the SCIPS aimed to identify sub-groups of patients with schizophrenia seen in 
clinical settings, it was decided that the study in the UK would be conducted at an adult 
community mental health service. Accordingly, people with schizophrenia were recruited 
at the psychiatric outpatient clinics and psychiatric hospitals that were part of the 
Hampshire NHS Trust. In Japan, it was decided that the research would be conducted in 
psychiatric hospitals with both outpatient clinics and psychiatric beds. Community mental 
health teams are not as developed in Japan as in the UK, and the former country’s 
psychiatric hospitals function more like community mental health out-patient clinics. 
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10.5 Participant eligibility criteria 
Patients were recruited for the study if they: 
• Were aged 18-65 in the UK and 21-65 in Japan 
• Had schizophrenia and other psychotic disorders (i.e., schizoaffective disorder, 
schizophreniform disorder and delusional disorder) diagnosed according to the 
DSM-IV  
 
NB.  
1. It was originally intended that patients aged between 18 and 65 would also be 
recruited in Japan. However, the eligibility criteria were changed on the basis of 
advice from the ethics committee of the Graduate School of Medicine at Nagoya City 
University. 
 
2. Because the main purpose of this thesis was to evaluate the psychometric properties 
of the SCIPS for patients with schizophrenia, most of the analyses were conducted by 
excluding those with a diagnosis of schizoaffective disorder, schizophreniform 
disorder and delusional disorder, unless otherwise stated. 
 
Patients were not recruited for the study if: 
• They expressed a wish not to participate and/or were unable to give informed 
consent 
• There was evidence of an organic central nervous system disorder 
• They had mental retardation (with a documented IQ of less than 70, or a history of 
special needs education) 
• They had severe psychotic symptoms which made it difficult for them to complete 
the questionnaire 
 
NB.  
Patients were not excluded from the study even if there was co-morbid substance 
misuse. 
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10.6 Sample size 
The issue of sample size was considered in detail prior to the commencement of data 
collection, and the relevant calculations are described in each chapter containing the 
results of each investigation. In outline, it was planned that at least 40 patients would be 
recruited for a preliminary small-scale investigation in the UK. Of these 40 participants, 
the SCIPS interview was conducted twice with at least 20 of them to examine inter-rater 
reliability. At the same time, sub-groups were determined with the highest achievable 
validity (as described below) for a minimum of 20 patients, in order to assess the 
concurrent validity of the SCIPS diagnosis (using the English version of the test). The 
results of this preliminary study in the UK were then taken into consideration, with the 
decision being made that at least 100 participants would be required for the research in 
Japan. Data from at least 30 of this sample of 100 was used to evaluate the inter-rater 
reliability of the SCIPS diagnosis (using the Japanese version thereof). In order to assess 
the concurrent validity of the SCIPS diagnosis (with the Japanese version of the 
interview), sub-groups were determined with the highest achievable validity (as described 
below) for the greatest possible number of the patients recruited in Japan. 
 
 
10.7 Determination of the sub-groups with the highest achievable validity 
In order to evaluate the concurrent validity, specificity and sensitivity of the SCIPS 
diagnosis, sub-groups with the highest achievable validity were determined for the 
participants and then compared with the SCIPS outcomes. In the UK study, DK, who was 
one of those who had originally conceptualised the 4 sub-types and was blind to the 
SCIPS diagnosis, collected appropriate information by reading case notes and then 
classified the patients. DK also interviewed the participants if there was not enough 
information in their notes and it was possible to see the individuals concerned. Such data 
included age and mode of onset, symptom profiles, experience of substance misuse, 
childhood trauma, co-morbid borderline personality disorder, pre-morbid adjustment, and 
significant life events. For classification purposes in the study in Japan, a rater who was 
blind to the SCIPS diagnoses gathered the necessary data by reading case notes, 
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interviewing the patients’ psychiatrists and having several discussions with DK, who was 
also blind to the SCIPS outcomes.  
 
10.8 Measures 
Along with the sub-types which were obtained by using the SCIPS, the following critical 
measures were also identified: socio-demographic characteristics; severity of delusional 
ideations, (which is one of the most important psychotic symptoms); the psychological 
characteristics which are potential external validators of the SCIPS diagnoses; and mood. 
Broad measures of clinical outcome were also identified. 
 
The most appropriate measure of each variable was identified by the following 
procedure: a literature search was conducted using the Medline and Psycinfo databases. 
The key words used included ‘measurement’, ‘assessment’ and relevant variable 
descriptors, such as schizophrenia, evaluative beliefs and fear of negative evaluation. 
Significant papers relating to classification and the use of cognitive behavioural therapy 
(CBT) for schizophrenia were also reviewed, and renowned researchers in these fields 
were contacted for their input and advice about measurement selection. Potential 
measures for each variable were then systematically reviewed and examined according to 
the following criteria: psychometric quality, prior use within the schizophrenia field, 
relevance of sub-scales, language, length, and whether the measure was assumed to have 
sufficient utility within a research setting (see Appendix B for a sample of a systematic 
review record).  
 
Following this procedure, the following scales were selected for use in this study:  
 
10.8.1 Socio-demographic information 
Socio-demographic information relating to age, gender, marital status, ethnicity and 
educational history was gathered in interviews with the participants.  
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10.8.2 Age at the time of the first psychotic episode and the number of years since 
then 
Data about patient age at the time of the first psychotic episode was mainly obtained from 
case notes. If there was not enough information in the notes, a psychiatrist, social worker, 
or nurse who was responsible for the patient was consulted. A researcher who was blind 
to the participants’ sub-types was the individual responsible for reviewing the case notes 
and extracting the relevant data.  
 
The number of years since the age at onset of the first psychotic episode was calculated 
by subtracting the age at the time of this event from a patient’s current age.  
 
10.8.3 Severity of delusional ideations 
The 21item Peters Delusions’ Inventory (PDI-21) (see Appendix C) (Peters et al., 2004):  
This questionnaire was designed to measure the unusual subjective beliefs and 
experiences which relate to the dimension of delusional ideation in the general population 
(Peters et al., 2004; Peters, Joseph, & Garety, 1999). Indeed, it has been shown that the 
Japanese version of the PDI could assess delusional experiences in the general population 
with significant validity and reliability (Yamasaki et al., 2004). 
The 21original questions are derived from items used in the Present State Examination to 
assess delusional symptoms (Wing, Cooper, & Sartorius, 1974), and each of them is 
comprised of 3 sub-scales (distress, pre-occupation and conviction) which are, in turn, 
answered on a 5-point scale (1-5). A ‘Yes’ answer to each item is followed by an 
assessment of these 3 sub-scales, while a ‘No’ answer automatically leads to a zero (0) 
score for each of them. The PDI-21 score is obtained by assigning 1 to each ‘Yes’ answer 
and 0 to each ‘No’ answer, and distinguishes psychotic patients from healthy subjects 
(Verdoux & van Os, 2002). The score correlates well with the Brief Psychiatric Rating 
Scale (BPRS) (Verdoux & van Os, 2002) and the Positive and Negative Syndrome Scale 
(PANSS) (Yamasaki et al., 2004) in patients with a confirmed diagnosis of schizophrenia, 
but who are stable clinically (Khazaal et al., 2006; van Os et al., 1999). The PDI-21 can, 
thus, be considered to be one of the ‘best-available’ tools with which to assess the 
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presence of delusions in both patients with schizophrenia, as well as in a normal 
population. 
 
10.8.4 Candidate external validators 
10.8.4.1 The Brief Core Schema Scale (BCSS) (see Appendix D) (Fowler et al., 
2006):  
The BCSS contains 24 items concerning beliefs about the self and others that are 
answered on a 5-point scale (0-4). Four scores are obtained which represent beliefs about 
the negative-self (NS: 6 items), negative-others (NO: 6 items), positive-self (PS: 6 items), 
and positive-others (PO: 6 items) (Fowler et al., 2006). The content of the negative-self 
component, as globally negative self-descriptors of personality, is derived from the self-
devaluative words used by Teasdale and Dent (1987) and, subsequently, by Teasdale and 
Cox (2001). The 4 scores assessed in this scale are compared in this study. The BCSS 
was originally developed to evaluate the core schema of patients with schizophrenia or 
psychosis. It has been translated into Japanese, and both the English and Japanese 
versions thereof demonstrate strong evidence of construct and criterion validity (Fowler 
et al., 2006; Yamauchi, Sudo, & Tanno, 2009). The BCSS was chosen for a number of 
reasons: it is a brief, well validated questionnaire that measures evaluative beliefs; it has 
originally been developed for use within the field of psychosis; and its Japanese version 
exists.  
 
 
10.8.4.2 Brief Fear of Negative Evaluation Scale (BFNE) (see Appendix E) 
(Rodebaugh et al., 2004):  
The BFNE is a self-reporting questionnaire which assesses the degree to which people 
worry about how they are perceived and evaluated by others. It is a shortened version of 
the original 28 item, Fear of Negative Evaluation scale (FNE), and contains 12 items 
which are answered on a 5-point scale (0 = not at all characteristic of me, 4 = extremely 
characteristic of me) (Watson & Friend, 1969). The FNE score is provided by the sum of 
the scores of the 12 items, and there is strong evidence of its construct and criterion 
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validity (Leary, 1983; Rodebaugh et al., 2004). This scale was also used for patients with 
schizophrenia in research which demonstrated the effectiveness of CBT in managing the 
social anxiety of those diagnosed as suffering from this mental disorder (Kingsep, Nathan, 
& Castle, 2003). The BFNE was translated into Japanese, and a back translation thereof 
was carried out to achieve maximum reliability and validity (Ishikawa, Sasaki, & Fukui, 
1992). The BFNE was selected for a number of reasons: it is a brief, well validated 
questionnaire that measures fear of negative evaluation from others; its Japanese version 
exists; and it has previously been used within the field of psychosis.  
 
10.8.4.3 Mood 
Beck Depression Inventory (BDI-II) (see Appendix F) (Beck, Steer, & Brown, 1996):  
The BDI-II is a self-reporting 21 item, 4-point scale (0-3) for the assessment of 
depression  (Beck, Steer, & Brown, 1996), wherein mood is analysed over the fortnight 
prior to taking the test. It has also been used for patients with schizophrenia (Rector, 
Seeman, & Segal, 2003; Smith et al., 2006). Internal consistency, reliability, criterion 
validity and factor validity of the Japanese version of the BDI-II have also been 
established (Kojima et al., 2002). This measure was selected because it is a brief, well 
validated measure of depression widely used in psychological research. 
 
10.8.5 DSM sub-types 
DSM sub-types were determined according to the DSM-IV diagnostic criteria by a rater 
who conducted the first assessment of each participant. The Structured Clinical Interview 
for the DSM-IV Axis I Disorders (SCID-I) (First & Gibbon, 2004) was used for this 
purpose. If this was difficult to do with only the information obtained directly from the 
patient, a psychiatrist, social worker, or nurse who was responsible for this individual was 
consulted to ensure that enough information was collected to be able to make a diagnosis. 
 
10.8.6 Clinical outcome 
Data about the past hospitalization of the members of the sample was mainly obtained 
from their case notes, but to improve the quality of the information collected in this way, 
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comparisons were made between what was learnt from these notes and what was 
discovered from the patients. In this process, the participants were asked about their 
history of hospitalizations, including the names of all of the relevant establishments, and 
the frequency of their stays. If there was a discrepancy between the data in the case notes 
and what the patients said, a psychiatrist, social worker, or nurse who was responsible for 
the individual concerned was consulted. Data was excluded if it was difficult to judge 
whether it was correct, even after consultation with professionals. A researcher who was 
blind to patient sub-types was responsible for reviewing the case notes, extracting the 
data and determining if it should be omitted, in the circumstances described above. 
 
10.8.6.1 Two variables for the comparison related to hospitalization 
Variable 1: Total time [the number of days] spent in hospital in the 3 year period after the 
date of first admission: 
This variable is thought to be one of the most important components of clinical outcome, 
and is determined for each patient by calculating the total duration of all hospitalizations 
in a 3 year period after the date of his/her first admission. Data was excluded if the 
development of psychotic episodes was obviously not the cause of the hospital stay (e.g., 
treatment of physical illness and training in blood sugar control).  
 
Variable 2: Duration [the number of days] of the first hospitalization: 
This variable is also a good indicator of short-term clinical outcome. The data was 
collected from the case notes as described above. As in the case of variable 1, information 
was excluded if the development of psychotic episodes was obviously not the cause of 
the hospital admission. 
 
In terms of the time unit of the variables 1 and 2, the number of days was counted for 
each of them. 
 
10.8.6.2 History of self harming 
Data about self harming was obtained from patients’ case notes, and collated using the 
Structured Clinical Interview for the DSM-IV Axis II Disorders (SCID-II, section for 
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borderline personality disorder, item 97) (First & Gibbon, 2004). In order to confirm 
whether they had actually hurt themselves at least once after the onset of their first 
episode of schizophrenia, participants were asked 2 additional questions - (1. “Did you 
really hurt yourself or did you just threaten to do so?” and 2. “Did you hurt yourself after 
the onset of your psychotic symptoms?”). To improve the quality of the data, 
comparisons were made between the information in the case notes and that obtained in 
the SCID interviews. If there was a discrepancy, a psychiatrist, social worker, or nurse 
who was responsible for the patient was consulted. A researcher who was blind to the 
patients’ sub-types was responsible for reviewing the case notes and extracting the data. 
In terms of the history of self harming, those who had actually hurt themselves at least 
once after the onset of their first episode of schizophrenia were rated as positive, while 
those who only did so beforehand, or did not actually harm themselves at all, were rated 
as negative.  
 
10.9 Procedure 
Figures 1 and 2 set out the outlines of the studies conducted in the UK and Japan, 
respectively. 
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10.9.1 Recruitment of participants in the UK 
Seven consultants, who usually saw their patients at 3 different psychiatric outpatient 
clinics (Cannon House, Bay Tree House, and College Keep in Southampton) and at 3 
psychiatric hospitals (Royal South Hants Hospital in Southampton, Melbury Lodge in 
Winchester, and Ravenswood House in Fareham), were asked to nominate individuals 
with schizophrenia and other psychotic disorders (i.e., schizoaffective disorder, 
schizophreniform disorder, and delusional disorder) who might be suitable for the project. 
The patients were first asked by their consultants whether they would be willing to 
participate in the study, and, if they agreed, they were then contacted by one of the 
researchers. Information sheets (Appendix G) were given to all potential participants at 
that time. They were also provided with an overview of the assessment process, and were 
told about the study, its objectives and what their participation would involve. At this 
time, potential subjects were also given the opportunity to ask questions, and were 
reassured that a decision to not take part would not affect their access to services or 
treatment. Those who wished to be involved were asked to complete questions 1 -5 of the 
consent form (see Appendix H). At that time, patients were also reminded that the audio 
taping of part of the interview was related to quality control, and they could refuse to co-
operate with this element and still take part in the study.  
 
During this recruitment period (October 2007-August 2008), 51 patients were selected 
and referred to take part in the project by their consultants, and were then formally 
invited to participate. Of these, 45 agreed and 6 declined. Clinically experienced and 
trained research personnel confirmed the subjects’ diagnoses using the SCID (sections for 
psychotic disorders and borderline personality disorder) (First & Gibbon, 2004). Forty-
two of the patients were diagnosed with schizophrenia, and 3 with schizoaffective 
disorder, delusional disorder and bipolar disorder. Of the sample of 42, 33 were male 
(78.6%) and 9 were female (21.4%). They ranged in age from 18 to 64, with the mean 
being 42.1 (Standard deviation (SD) = 12.3, median = 42.0). The median for the number 
of years the patients had spent in formal education was 11.0 (Inter-quartile range (IQR) = 
10.0-13.0). Twenty-five of the participants were single (59.5%), 8 were married or living 
with a partner (19.0%), and 9 were divorced/separated (21.4%). In terms of ethnic 
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breakdown, 39 patients (92.9%) were white British, 1 (2.4%) was African and 2 (4.7%) 
were Asian. Thirty-five (83.3%) were outpatients and 7 were inpatients (16.7%). Table 
10 sets out this demographic data.  
 
YK conducted the first interviews for 39 of the 42 participants, and DU questioned the 
other 3. 
10.9.2 Assessment of the inter-rater and test-retest reliability of a diagnosis with the 
English version of the SCIPS 
In order to assess inter-rater reliability, the SCIPS interview was carried out twice for 
each participant by 2 independent raters who were blind to each other’s diagnoses. The 
results were then compared. YK, KK, SS and DU, who are clinically experienced and 
trained research personnel, conducted these interviews. A patient’s first and second 
interviews were carried out on 2 different days, with an interval of at least 2 weeks 
between them, in order to assess test-retest reliability, as well as inter-rater reliability. Of 
the 42 individuals who were diagnosed with schizophrenia, 41 completed the first SCIPS 
interview. Of the 41, 36 were asked to take the second interview, and 30 of these agreed 
to make appointments for this purpose. Five were not asked because they lived some 
distance away from Southampton. Of the 30 who made appointments, 20 attended and 
completed the second interview. Of these 20 participants, 16 (80.0%) were male and 4 
(20.0%) female. Their mean age was 41.7 years (SD = 11.2, median = 41.0), and 10 were 
single (50.0%), 4 were married or living with a partner (20.0%), and 6 were 
divorced/separated (30.0%). In terms of ethnic breakdown, 19 (95.0%) were white British 
and 1 (5.0%) was African. All of the participants were outpatients, and 2 (10.0%) met the 
criteria for borderline personality disorder (Table 10).  
 
YK carried out the second interviews with 3 of the 20 participants, and SS and KK did so 
for 6 and 11 of them, respectively.  
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10.9.3 Assessment of the concurrent validity of a diagnosis with the English version 
of the SCIPS 
In order to evaluate the concurrent validity of a SCIPS diagnosis, the sub-types 
determined with the initial interviews were compared to those with the highest achievable 
validity. Among the 41participants, who completed the first SCIPS interview, the first 21 
individuals recruited from Cannon House, Bay Tree House, College Keep and the Royal 
South Hants Hospital were sub-grouped with the highest achievable validity as described 
above. Of these 21 participants, 17 (81.0%) were male and 4 (19.0%) female. The mean 
age was 37.1 (SD = 11.4, median = 38.0), 14 were single (66.7%), 5 were married or 
living with a partner (23.8%) and 2 were divorced/separated (9.5%). In terms of ethnic 
breakdown, 20 (95.2%) were white British and 1 (4.8%) was African. Nineteen were 
outpatients (90.5%), 2 inpatients (9.5%), and 2 (9.5%) met the criteria for borderline 
personality disorder (Table 10). 
 
Table 10: Participant demographics (Study in the UK). 
 Participants for 1st 
interview (n = 42) 
Participants for 2nd 
interview (n = 20) 
Participants sub-
grouped with the 
highest achievable 
validity (n = 21)  
Mean age (SD) 
Median age (IQR) 
Median years in 
education (IQR) 
Male, No. (%) 
Outpatients, No. (%) 
Mean years after the 
age of onset (SD) 
Median years after 
the age of onset 
(IQR) 
The SCIPS interview 
completed, No. (%) 
42.1 (12.3) 
42.0 (33.0-51.0) 
11.0 (10.0-13.0) 
 
33 (78.6) 
35 (83.3) 
16.1 (8.3) 
 
15.0 (9.0-22.0) 
 
 
41 (97.6) 
41.7 (11.2) 
41.0 (33.0-50.8) 
11.0 (10.0-13.0) 
 
16 (80.0) 
20 (100.0) 
15.1 (9.8) 
 
14.0 (9.0-17.0) 
 
 
20 (100.0) 
37.1 (11.4) 
38.0 (28.0-46.0) 
11.0 (10.0-13.0) 
 
17 (81.0) 
19 (90.5) 
11.6 (6.7) 
 
12.0 (5.5-16.5) 
 
 
21 (100.0) 
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10.9.4 Recruitment of participants in Japan 
Participants were recruited from 3 psychiatric hospitals (Kusunoki Mental Hospital, 
Yagoto Hospital, and Minamichita Hospital) in Aichi, Japan, all of which have 
psychiatric beds, day care units and outpatient clinics. All of the psychiatrists working in 
these hospitals were asked to nominate patients with schizophrenia and other psychotic 
disorders (i.e., schizoaffective disorder, schizophreniform disorder, and delusional 
disorder) who might be suitable for the project. During the recruitment period (September 
2008-October 2008) 129 patients were put forward by their consultants. Information 
sheets were given to all potential participants when they were first approached by the 
researcher, and they were also given an overview of the assessment process at that time. 
Patients were told about the study, its objectives and what their participation would 
involve. They were also given the opportunity to ask questions, and were reassured that a 
decision to not take part would not affect their access to services or treatment. Those who 
did wish to become involved were asked to complete questions 1-4 of the consent form 
(these were Japanese translations of the questions contained in Appendix H). They were 
then formally invited to take part in the research, with 121 agreeing to do so and 8 
declining. Clinically experienced and trained research personnel confirmed the subjects’ 
diagnoses using the Structured Clinical Interview for the DSM-IV. Sub-types of 
schizophrenia were also determined for each participant according to the DSM-IV. Of the 
sample of 121 patients, 117 had schizophrenia and 4 were diagnosed with schizoaffective 
disorder. Of this 117, 76 were male (65.0%) and 41 were female (35.0%). Their ages 
ranged from 21 to 65, with the mean age being 44.5 (SD = 12.3, median = 43.0). The 
median for the number of years spent in education was 12.0 (IQR = 9.0-12.0); 86 
participants were single (73.5%), 8 were married or living with a partner (6.8%) and 13 
were divorced/separated (11.1%). Information about their marital status was unclear for 6 
individuals (5.1%), because they withdrew from the study at the start of their interviews. 
All of the participants were of Japanese origin, and 94 (80.3%) were outpatients and 23 
were inpatients (19.7%) (Table 11). 
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YK carried out the first interviews with 60 of the 117 participants and KK did so with the 
remaining 57. 
10.9.5 Assessment of the inter-rater and test-retest reliability of a diagnosis with the 
Japanese version of the SCIPS 
As in the study in the UK, and in order to assess inter-rater and test-retest reliability, the 
SCIPS interviews were conducted twice for each patient by 2 independent raters, YK and 
KK, who were blind to each other’s diagnoses. These first and second interviews were 
held on 2 different days with an interval of at least 2 weeks between them. The 
interviewers spent 6 days (2 for each of the 3 hospitals) recruiting patients for the second 
interviews. Of the sample of 117, 46 individuals (all of whom were either hospitalized, 
had appointments at outpatient clinics, or attended the day care units on these 6 days) 
were asked if they would be interviewed again and 35 agreed to do so. Of these 35 
participants, 18 (51.4%) were male and 17 (48.6%) female. Their mean age was 46.8 
years (SD = 10.7, median = 44.0), and 26 were single (74.3%), 4 were married or living 
with a partner (11.4%) and 5 were divorced/separated (14.3%). All of the subjects were 
of Japanese origin, and 31 of them (88.6%) were outpatients and 4 were inpatients 
(11.4%) (Table 11).  
 
YK carried out the interviews with 17 of the 35 patients who had agreed to be questioned 
again, and KK did so with the remaining 18. 
10.9.6 Assessment of the concurrent validity of a diagnosis with the Japanese 
version of the SCIPS 
In order to evaluate the concurrent validity of a SCIPS diagnosis, the sub-types which 
were determined with the first interviews were compared to those with the highest 
achievable validity. A determination of the sub-groups with this highest achievable 
validity (as described above) was attempted for all of the participants who completed the 
first SCIPS questionnaire (n = 107). Of the 107 individuals in this sample, 88 patients 
(82.2%) could be sub-grouped with the highest achievable validity, while not enough 
information was available, and sub-types could, therefore, not be determined, for 19 
participants (17.8%). 
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10.9.7 Evaluation of the longitudinal stability of the SCIPS diagnosis in Japan 
In order to establish if the sub-types determined with the SCIPS were stable over time, 
participants were recruited from day care units in the 3 hospitals in Japan. The 
researchers worked over 4 days (31st March-3rd April, 2009, 2 days in 1 hospital and 1 
day in each of the other 2), at least 6 months after the first interviews, to recruit subjects 
for follow-up questioning. A notice which sought such participation, and set out the likely 
dates, was displayed in advance (1 or 2 weeks before the dates of the interviews) at each 
of the day care units. All of the patients who had taken part in the initial interviews, and 
then went on to declare an intention to participate further in the assessment process, were 
interviewed again using the SCIPS. A total of 44 individuals declared an intention to be, 
and were, questioned again. Of these 44, according to the DSM-IV, 43 of them had 
schizophrenia and 1 had schizoaffective disorder. Of the 43 schizophrenics, 27 (62.8%) 
were male and 16 (37.2%) female. The mean age was 42.3 years (SD = 10.0, median = 
42.0) (Table 11); 31 were single (72.1%), 5 were married or living with a partner (11.6%) 
and 7 were divorced/separated (16.3%). All of the participants were of Japanese origin.  
 
YK did the follow-up interviews with 18 of the 43 in this sample, while KK did the 
remaining 25. 
 
Table 11: Participant demographics (Study in Japan). 
 Participants for 
1stinterview  
(n = 117) 
Participants for 
2nd interview  
(n = 35) 
Participants in 
6 month follow-up 
interview (n = 43) 
Mean age (SD) 
Median age (IQR) 
Median years in 
education (IQR) 
Male, No. (%) 
Outpatients, No. (%) 
Mean years after the 
age of onset (SD) 
Median years after 
the age of onset 
(IQR) 
The SCIPS interview 
completed, No. (%) 
44.5 (12.3) 
43.0 (35.0-55.0) 
12.0 (9.0-12.0) 
 
76 (65.0) 
94 (80.3) 
18.9 (12.0) 
 
18.0 (10.0-29.0) 
 
 
107 (91.5) 
46.8 (10.7) 
44.0 (39.0-58.0) 
12.0 (9.0-12.0) 
 
18 (51.4) 
31 (88.6) 
20.5 (11.6) 
 
19.0 (10.0-29.0) 
 
 
35 (100.0) 
42.3 (10.0) 
42.0 (37.0-51.0) 
12.0 (9.0-12.0) 
 
27 (62.8) 
43 (100.0) 
16.7 (10.3) 
 
17.0 (8.0-25.0) 
 
 
43 (100.0) 
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10.9.8 Data collection and the assessment process 
After giving their consent, participants were provided with the additional research 
questionnaires (BCSS, BFNE and PDI-21 in the UK study, and BCSS, BFNE, PDI-21 
and BDI-II in the Japanese study) to complete and were interviewed using the SCIPS. 
The whole process took about an hour per respondent. In the current study, the patients 
were instructed to assess the BFNE and PDI-21 over the past month, because in our 
previous use of these scales, we noticed that the BFNE and the PDI-21 scores of patients 
with schizophrenia sometimes changed within a few months or a year, apparently in 
conjunction with the changes in their symptomatology, whereas no instruction was given 
to the students with regard to the period which the assessment of these scales covered. 
Thus, it should be noted that the scores of BFNE and PDI-21 cannot be compared directly 
between the student sample and the patient sample, because the instruction for the 
patients about how to complete these scales was different to that for the students in terms 
of the time period which they covered. The SCIPS interview element of the process was 
repeated for some of the patients who had completed the first assessment (20 in the UK 
and 35 in Japan). To assess the inter-rater and test-retest reliability thereof, these 2 
interviews were conducted by 2 independent raters on 2 different days, with an interval of 
at least 2 weeks between them. The SCIPS interview part of the process was then 
repeated for some of those who had completed the first assessment in Japan, in order to 
assess the longitudinal stability of the classifications (n = 43). This interview was carried 
out at least 6 months after the date of the first assessment, and took about 10 minutes per 
participant. Confidentiality was guaranteed in terms of the answers given, and written 
informed consent was obtained from each subject. The sections for psychotic disorders in 
the SCID-I and for borderline personality disorder in the SCID-II were applied to all of 
the participants in order to confirm the diagnoses.   
 
Clinical outcome data relating to hospitalization and a history of self harming was 
collected using the procedure described above (see section 10.8.6, “Clinical outcome”).  
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10.10 Ethics approval 
The Isle of Wight, Portsmouth & South East Hampshire Research Ethics’ Committee 
(REC) approved the protocol for the study in the UK. The ethics committee of the 
Graduate School of Medicine at Nagoya City University, in turn, approved the protocol 
for the research in Japan. Participants were enrolled in the study only where consent was 
unambiguously given. The identification of respondents, as a result of any kind of 
analysis, was not possible because of the use of codes. All of the information has been, 
and will be, kept strictly confidential. 
 
10.11 Pilot work and quality control 
The draft questionnaires, information sheets and consent forms were all checked by a 
member of the general public to ensure that all of the items in the measures, as well as the 
content of the forms, were understandable to a lay audience. All of the researchers who 
collected the data were clinicians who are experienced in the clinical practice of 
psychiatry, and the use of both the DSM-IV diagnostic criteria and the SCID-I and -II. 
Prior to the start of data collection, these researchers were trained in how to administer 
the interviews and questionnaires by the principal investigator. Throughout the period of 
data collection, the researchers held regular meetings and frequently discussed any 
relevant issues (once a week, on average).  The aim of these sessions was to clarify rating 
queries and maintain standards. 
 
10.12 Statistical methods 
Data were analysed using the Statistical Package for the Social Sciences, version 15 
(SPSS Inc, 2006), and Stata, version 8 (StataCorp, 2005). Primary analyses were 
conducted for the participants who had a diagnosis of schizophrenia, because the primary 
objectives of this thesis were to both test the psychometric properties of the SCIPS, as 
well as assess the validity of the classification scheme when applied to patients with this 
psychiatric disorder. 
 
In Chapter 12 (“Relationship between the Fear of Negative Evaluation from Others and 
Delusions”): 
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1. In order to determine if the FNE was associated with delusional thinking, Pearson 
product-moment correlation coefficients (Pearson’s r) were calculated to evaluate the 
association between the PDI, BFNE, and BDI-II scores. Linear regression analyses 
were conducted to assess if the BFNE scores continued to be associated with the PDI 
scores once the confounding effects of depression were controlled. Spearman rank 
correlation coefficients (Spearman’s r) were also calculated to examine the 
relationship, in scores, between the BFNE and the 6 factors of the PDI-21(Preti, 
Sardu, & Piga, 2007).  
 
In Chapter 13 (“Psychometric Evaluation of the English and Japanese Versions of the 
SCIPS”): 
 
2. Kappa coefficients were calculated with regard to the assessment of the inter-rater 
reliability and concurrent validity of the SCIPS.  
3. The sensitivity and specificity of the SCIPS diagnoses were calculated by preparing 
2x2 tables for each of the 4 sub-types. 
 
In Chapter 14 (“Six Month Stability of the SCIPS Diagnosis: A Longitudinal Study in 
Japan”): 
 
4. Kappa coefficients were calculated to examine the longitudinal stability of the sub-
types which were determined with the SCIPS. 
 
In Chapter 15 (“Construct Validity of the Conceptualisation of the Anxiety and Stress 
Sensitivity Sub-types: A Preliminary Study in the UK”) and Chapter 16 (“Construct 
Validity of the Conceptualisation of the Anxiety and Stress Sensitivity Sub-types: A 
Study with a Larger Sample in Japan”): 
 
5. The Mann-Whitney U Test was employed to determine if the anxiety and stress 
sensitivity sub-types differed in their psychopathological characteristics (i.e., 
evaluative beliefs, fear of negative evaluation from others, and depression). This non-
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parametric test was chosen for this purpose because all of the variables analysed were 
not normally distributed. 
6. The Chi-square test or the Fisher’s exact test was conducted to assess if the sub-
types determined with the SCIPS were related to those determined with the DSM-IV. 
 
In Chapter 17 (“Predictive Value of the Conceptualisation of the Anxiety and Stress 
Sensitivity Sub-types”): 
 
7. The Mann-Whitney U Test was employed to examine if the anxiety and stress 
sensitivity sub-types differed in their clinical outcome (total time spent in hospital 
over a period of 3 years after the date of first admission [variable 1] and the length of 
the first hospitalization [variable 2]). This non-parametric test was chosen for this 
purpose because all of the variables analysed were not normally distributed. 
8. The Chi-square test was conducted, and relative risk (RR) was calculated, to 
examine if the anxiety and stress sensitivity sub-types differed in terms of the risk of 
self-harm. 
 
10.13 Data management 
All data was entered into a database using Microsoft Office Excel 2003, and was double 
entered to check for systematic errors. The error rates for all of the questionnaires were 
acceptable at 0.1%. 
 
10.14 Missing values 
Upon completion, questionnaires were examined for missing data and, where possible, 
participants were asked to answer any questions they had missed. All of the missing data 
was excluded from the statistical analyses. 
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Chapter 11: Development of the English and Japanese Versions of the 
SCIPS 
 
11.1 Overview 
As discussed in Chapters 4 (“Psychosocial Factors and Psychosis”) and 5 (“Description 
of the 4 Sub-groups of Schizophrenia”), the vulnerability-stress model led to the 
development of the new concept of sub-grouping schizophrenia into 4 sub-types: drug 
related, traumatic, anxiety and stress sensitivity (Kingdon & Turkington, 2005). In order 
to adapt this for practical use, a semi-structured interview for the purpose of making 
diagnoses was developed. This interview is known as a Semi-structured Clinical 
Interview for Psychosis Sub-groups (SCIPS), and an original English version thereof was 
translated into Japanese to be used with natives of that country. In this chapter, the 
characteristics of the SCIPS are discussed, as is its development, structure, and mode of 
operation. 
 
11.2 Development of a semi-structured clinical interview for psychosis sub-groups 
(SCIPS)  
The SCIPS was initially developed, and the first draft version thereof was then prepared. 
Four psychiatrists, who had extensive clinical experience with the diagnosis and 
treatment of schizophrenia, were asked to review the existing version of this assessment 
tool and final refinements thereto were made on the basis of the recommendations made. 
As a result of this process, the second version of the SCIPS, to be used for research 
purposes (Appendix A), was established with high face validity. 
 
11.3 Preparation of the Japanese version of the SCIPS 
The Japanese version of the SCIPS was prepared by translating the English document 
into Japanese. YK, one of the founders of the SCIPS, did this first, and then, MI, who had 
no knowledge of this English version, back translated the Japanese document into English. 
Next, DK, the other originator of the SCIPS, examined the differences between the 
original English version and the back translation. If he concluded that there were 
significant differences in some places between these 2 versions, DK told YK which 
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sentence in the Japanese document should be modified and back translated again. This 
process was repeated until there were no critical differences between the original version 
and the back translation. Thereafter, four psychiatrists who had extensive clinical 
experience of the diagnosis and treatment of schizophrenia, and could understand 
Japanese, were asked to review this Japanese version, and confirmed that high face 
validity was sustained, even after translation. 
 
11.4 Terminology used in the SCIPS 
11.4.1 Limitation on the use of the word ‘psychosis’ in the thesis 
The SCIPS was developed on the basis of the assumption that it would be extensively 
applied to patients with psychotic disorders other than schizophrenia. In addition, the 
interview attempts to reduce the stigma associated with the word ‘schizophrenia’ by 
using the term ‘psychosis’ to apply to individuals with the illness.  Thus, the word 
‘psychosis’ is used in this tool instead of the phrase ‘sub-type of schizophrenia’. However, 
as described in Chapter 2 (“The Classification of Schizophrenia”), the conceptualisation 
of psychosis is broader than that of schizophrenia. This means that the use of the word 
‘psychosis’ might be ambiguous when it is applied to a sub-type of schizophrenia, at least 
from a scientific perspective. Moreover, and as explained in Chapter 10 (“Method”), the 
key objectives of this thesis were to test the psychometric properties of the SCIPS, and 
assess the validity of the classification scheme when applied to patients with a diagnosis 
of schizophrenia. Therefore, the utilisation of the word ‘psychosis’ was deliberately 
limited in this study, and the terms ‘sub-type’ or ‘sub-group’ were used instead. 
 
11.4.2 Definition of late and early age at onset 
The term ‘late age at onset of schizophrenia’ has been used inconsistently (Luoma et al., 
2008). For instance, the international consensus (Howard et al., 2000) recommends that 
the term ‘late onset schizophrenia’ is used in cases where ‘the onset occurs between age 
40 and 60’. Alternatively, age at onset between 20 and 29 years were defined as young-
onset by Schulz et al. (2000). 
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In such circumstances, a study (Schurhoff et al., 2004) carried out an admixture analysis 
to demonstrate that an age at onset is a marker identifying schizophrenia sub-types. In the 
study, it was proved that the observed distribution of the age at onset was a mixture of 
two separate Gaussian distributions, with a cut-off point of 28 years for the two sub-types. 
 
Accordingly, in the SCIPS (item 1-1), a cut-off point of 30 years is used for the 
differentiation between the early and late age onset. Figure 3 presents the distribution of 
age of onset in the present study (in the UK and Japanese samples). 
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Figure 3: Distribution of age of onset in the present study. 
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11.4.3 Definition of acute and insidious onset 
In a number of studies for which mode of onset was assessed (Harrison et al., 1996; 
Morgan et al., 2006; Singh et al., 2000), distinction of the acute and insidious onset was 
made with a cut-off point of 1 month. The same cut-off point (= 1 month) was also used 
for the differentiation between the acute and insidious onset in the SCIPS (item 1-2).  
 
In the UK sample for the present study, the numbers of patients with acute onset and 
insidious onset were 11 (26.2%) and 26 (61.9%) respectively. 5 (11.9%) could not give 
enough information about their mode of onset. Of the 11 whose onset was acute, 4 were 
with drug related sub-type and 6 were with anxiety category. The sub-type could not be 
determined for one of the participants because he could not give enough information 
about the timing of his use of stimulants/ hallucinogens. Of the 26 whose onset was 
insidious, 9 were with drug related sub-type, 2 were with traumatic category, 3 were with 
anxiety sub-group, and 12 were with stress sensitivity sub-type. On the other hand, in the 
Japanese sample, the numbers of patients with acute onset and insidious onset were 31 
(29.0%) and 75 (70.1%) respectively. 1 (0.9%) could not give enough information about 
his mode of onset. Of the 31 whose onset was acute, 1 were with drug related sub-type, 
14 were with anxiety category, and 16 were with stress sensitivity sub-group. Of the 75 
whose onset was insidious, 4 were with drug related sub-type, 1 were with traumatic 
category, 12 were with anxiety sub-group, and 58 were with stress sensitivity sub-type. 
 
11.5 Structure of the current version of the SCIPS  
The second English and the first Japanese versions of the SCIPS have a common 
structure and include the same items. The second version (Appendix A) is comprised of 3 
sections: the SCIPS interview, a rating sheet, and the diagnostic criteria for the sub-
groups, and 3 appendices. The interview includes items with which to obtain relevant 
information for the sub-grouping of patients, and has 3 sub-sections: 1. onset of 
psychosis; 2. social functioning; and 3. factors related to psychosis. Each section contains 
questions to be put to the respondents and instructions about how to rate each item. The 
rating of these items is recorded on the rating sheet, and enables each patient to be sub-
typed by using the diagnostic criteria. Appendix 1 of the SCIPS is the Social 
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Readjustment Rating Scale and Questionnaire (SRRSQ) (Holmes & Rahe, 1967). This 
can be used as a list of the major life events with which to rate items 1-3: triggers of the 
first psychotic episode. Appendix 2 is the Diagnostic Criteria for Borderline Personality 
Disorder in DSM-IV, and can be used to make a diagnosis of that condition. Appendix 3 
is the Diagnostic Guidelines for Psychosis Sub-types. This guideline is a comprehensive 
overview of the concept of the sub-types of schizophrenia which are utilised in the 
instrument. The characteristics of each are described therein to enable clinicians and 
researchers to understand the general idea behind the SCIPS and its conceptualisation.  
 
11.6 Items and questions in the interview section of the SCIPS 
The first section of the SCIPS interview concerns the onset of psychosis, and begins by 
listing the psychotic symptoms which have been experienced by a respondent. Item 1-1 is 
used to determine age of onset by asking how old a patient was when he/she first 
experienced psychosis. Item 1-2 aims to identify the mode of onset, with respondents 
being asked about when they first noticed that something was wrong in the lead up to the 
first episode of the illness. Mode of onset is also determined by asking the interviewee 
about how much time passed between when he/she first noticed that something was 
wrong and the subjective peak of this first episode. The term, subjective peak, means the 
point at which the respondent’s subjective distress about his/her psychotic symptoms is at 
its height. The precise definition of mode of onset has been described in a previous study 
(Morgan et al., 2006), and was referenced in order to develop this item herein. Mode of 
onset of less than 1 month is rated as acute, while that equal to or more than 1 month is 
rated as insidious.  
 
Item 1-3 aims to identify stressful life events which could lead to psychotic symptoms. 
This is especially important when seeking to differentiate between the anxiety and stress 
sensitivity sub-types of schizophrenia. Whether a life event is major or not is determined 
according to the SRRSQ (Holmes & Rahe, 1967), and on the basis thereof, events with a 
score of at least 40 are considered to be significant. Furthermore, whether a major life 
event has led to the development of psychotic symptoms and is, thus, considered to be 
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stressful, is estimated by identifying whether what happened changed a respondent’s 
sleeping patterns. 
 
The second section of the SCIPS interview concerns social functioning, and was 
developed mainly by referencing the Pre-morbid Adjustment Scale (PAS) (Cannon-Spoor, 
Potkin, & Wyatt, 1982). Item 2-1 aims to identify pre-morbid changes in work or school 
performance. The pre-morbid period is defined as being up to 2 years before the onset of 
the first episode. Changes which started within 6 months of this time are rated as acute, 
while those which began more than 6 months before onset are rated as gradual. 
 
Items 2-2 and 2-3 concern pre-morbid social relationships, and are particularly important 
for the diagnosis of the stress sensitivity sub-type. Item 2-2 aims to assess relationships 
since early adolescence, while item 2-3 evaluates marital and/or sexual relationships. 
 
The third section of the SCIPS interview concerns factors related to psychosis. Item 3-1 is 
used to identify the use of illicit drugs, and the type thereof, if applicable. Both the 
current and the previous Drug Use Scale (DUS) (Drake et al., 1990) were referenced to 
develop this item. The misuse of drugs just before the onset of a first episode (within 2 
weeks) is rated as positive for this item, whereas other time-scales (after or well before 
onset) is rated as negative. 
 
Item 3-2 relates to early traumatic experiences. As mentioned before, in one study which 
compared the characteristics of patients with both schizophrenia and borderline 
personality disorder to those with schizophrenia only (Kingdon et al. in submission), it 
was found that emotional and sexual abuse in childhood were more associated with the 
dual diagnosis of the former condition. The difference between these patient groups was 
less marked, although still significant, when it came to childhood physical abuse. 
Accordingly, the existence of early emotional and sexual abuse is dealt with in this item, 
with the Childhood Trauma Questionnaire (CTQ) (Bernstein et al., 1997) being 
referenced in the preparation thereof. 
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Individuals who have disclosed their childhood trauma should be carefully supported and 
followed up. Thus, item 3-2 also provides two questions to take action to this issue; one is 
for clarifying if they have already discussed their childhood trauma with their care 
managers, psychiatrists or therapists, and the other is for asking them if information about 
the trauma could be passed onto their care managers, psychiatrists or therapists when 
necessary. 
 
11.7 Rating sheet for the SCIPS 
The rating sheet is designed to both record the data collected with the SCIPS interview 
and facilitate the diagnosis of the sub-groups. The ratings for most of the items are 
dichotomized, and recorded by simply circling one of a number of pre-determined 
options on the sheet. With particular regard to the ratings for the items involved in the 
differentiation between the anxiety and stress sensitivity sub-types (items 1-1, 1-2, 1-3, 2-
2 and 2-3), the rating ‘1’ applies to a diagnosis of anxiety, while the rating ‘0’ relates to 
stress sensitivity. Two specific numbers: (A) number of items which are rated as ‘1’ and 
(B) those which are rated as ‘0’, are used to differentiate between these 2 sub-groups. 
Item 2-1 is not included for the reasons described in Chapter 13 (see section 13.5.1, 
“Omission of item 2-1 from the SCIPS”). A table for these 2 numbers is prepared on this 
sheet, and they are counted and recorded therein.  
 
11.8 Basic concept of the diagnostic criteria for the SCIPS sub-groups 
The diagnostic criteria for the SCIPS sub-groups are in 2 parts, one for making a 
diagnosis that a patient belongs to the drug related and traumatic categories, and the other 
to enable a differentiation between the anxiety and stress sensitivity forms of the disease. 
For a diagnosis of the former 2 sub-types, the ratings for items 3-1 and 3-2, respectively, 
are used. In the SCIPS interview, the ratings for the items in sections 1 and 2 (Items 1-1, 
1-2, 1-3, 2-2 and 2-3) help to differentiate between the anxiety and stress sensitivity sub-
types.  
 
In the drug related/traumatic part of the criteria, if the rating for item 3-1 “precipitating 
use of hallucinogens” is 1 ‘Yes’, the patient is put into the former sub-group. If the 
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ratings for both items 3-2 “traumatic experience” and 3-3 “borderline personality 
disorder” are 1 ‘Yes’, the patient is put into the traumatic category. On the other hand, if 
the ratings for either of these 2 items are ‘No’, the patient is not assigned to this latter 
sub-group. The rating of 0 ‘not discussed’ is treated as missing for item 3-2. The criteria 
do allow for the co-existence of the drug related and traumatic categories, whereas the 
anxiety and stress sensitivity classifications should not exist with any other sub-types. A 
hierarchical approach is used in this system, meaning that a diagnosis that a patient 
belongs to the drug related and/or traumatic sub-groups precedes consideration of their 
status in the anxiety and stress sensitivity forms of the illness. In other words, these latter 
criteria are only applied to the patients who have been excluded from the drug related and 
traumatic categories. 
 
In the latter part of the criteria, which are set out in the table entitled “Scores for 
differentiation between the anxiety and the stress sensitivity sub-groups” on the rating 
sheet, (A) number of items which are rated as ‘1’ and (B) items which are rated as ‘0’, are 
considered for the purpose of differentiation between these 2 sub-types. A patient is 
assigned to the former sub-group if (A) (number of items which are rated as ‘1’) is equal 
to or more than the pre-determined cut-off point. Alternatively, the patient is assigned to 
the latter sub-group if (B) (number of items which are rated ‘0’) is equal to or more than 
the cut-off point which is pre-determined for this parameter. The diagnostic criteria for 
both of these categories are designed so that these 2 sub-types cannot coexist. To ensure 
that this is, indeed, the case, the cut-off point for (B) was determined by the following 
formula: 
 
[Cut-off point for (B)] = [Total number of items involved in the diagnostic process] – 
[Cut-off point for (A)] + 1 
 
In this formula, the total number of items involved in the diagnostic process is 5. 
 
The ways in which the cut-off points set out in the final version of the SCIPS were 
determined are discussed in Chapter 13 (see section 13.5.2, “The best diagnostic criteria 
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for making a distinction between the anxiety and stress sensitivity sub-groups (English 
version)”). 
 
11.9 Conclusion 
The English version of the SCIPS was developed to enable the sub-grouping of patients 
with schizophrenia into 4 sub-types, namely, drug related, traumatic, anxiety and stress 
sensitivity. Thereafter, a Japanese version of the test was prepared by translating the 
English document. The 2 versions share a common structure and include the same items. 
The SCIPS is made up of 3 sections: the SCIPS interview, a rating sheet, and the 
diagnostic criteria for the sub-groups, and 3 appendices. The information obtained by 
using the SCIPS interview is recorded on the rating sheet, and the diagnostic criteria are 
designed to produce an accurate diagnosis of which category a patient belongs to by 
using the ratings recorded on the rating sheet.  
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Chapter 12: Relationship between the Fear of Negative Evaluation from 
Others and Delusions 
 
12.1 Overview 
As described in Chapter 8 (“Potential External Validators of the Sub-types in the Current 
Study”), the fear of negative evaluation from others (FNE) is one of the most promising 
ways of establishing the construct validity of the stress sensitivity sub-type of 
schizophrenia, especially in terms of how it is differentiated from the anxiety sub-type. 
Indeed, the FNE is expected to differentiate between these 2 categories of the illness, and 
is not included in the diagnostic criteria of the SCIPS. In addition, clinical significance is 
implied by one study which has revealed that FNE is one of the best predictors of 
paranoid ideation in a non-clinical population (Martin & Penn, 2001). Nevertheless, such 
evidence is not in itself robust enough to prove the psychopathological significance of 
this association in patients with schizophrenia, since the sample used was non-clinical, 
and other confounding factors for the association (e.g., depression) were not considered. 
Accordingly, the link between the levels of FNE and delusional ideation was examined in 
both the non-clinical and clinical samples, and depression was acknowledged as the 
confounding factor in the analyses which followed. The results of the study are discussed 
in this chapter.  
 
12.2 Aims of this study 
The aims of this study are to examine the hypotheses described below: 
1. Delusional ideation is directly associated with FNE in the normal population. 
2. Delusional ideation is directly associated with FNE in patients with schizophrenia. 
3. FNE continues to be independently associated with delusional ideation in the normal 
population once the confounding effect of depression is controlled, whilst there would 
be associations between low mood and the severity of delusional ideation. 
4. FNE continues to be independently associated with delusional ideation in patients 
with schizophrenia once the confounding effect of depression is controlled, whilst 
there would be associations between low mood and the severity of delusional ideation. 
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12.3 Procedure 
Participant recruitment 
Student sample: 
282 undergraduate students, who were studying pharmaceutical science at Nihon 
Pharmaceutical University, were asked, and agreed, to anonymously complete our 
questionnaires, which included demographic questions about age and sex, the PDI-21, the 
BFNE and the BDI-II. The participants were initially approached by a teacher when they 
were attending lectures. Of the 282 individuals, 140 were male (49.6%) and 142 female 
(50.4%). Their age ranged from 18 to 40 years, with the mean age being 21.0 years (SD = 
3.5) and the median age 21.0 (IQR = 19.0-22.0). All of the subjects were of Japanese 
origin, and were selected because it was assumed that such a group would be healthy.  
 
Patient sample: 
The same patient sample, which had been recruited for the assessment of the inter-rater 
reliability and concurrent validity of the SCIPS, was employed for this study (see Figure 
2). The descriptive data and the procedure for the recruitment of the sample are described 
in Chapter 10 (see section 10.9, “Procedure” and Table 11).  
 
12.4 Measures 
The participants were informed that the questionnaire was not an examination; that there 
were no right or wrong answers; that they did not have to take part in it if they did not 
want to; and that they could withdraw from the study at any time. Confidentiality was 
guaranteed in terms of the answers given to the questionnaire. Each participant 
subsequently received a booklet containing the following questionnaires, which he/she 
was asked to complete: 
 
The Brief Fear of Negative Evaluation Scale (BFNE) (Collins et al., 2005) 
The 21-item Peters et al. Delusions Inventory (PDI-21) (Peters et al., 2004)  
The Beck Depression Inventory II (BDI-II) (Beck, Steer, & Brown, 1996) 
 
Details of the scales have been provided in Chapter 10 (see section 10.8, “Measures”). 
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12.5 Sample size 
To be able to produce a statistically significant correlation coefficient of at least 0.3 with 
a two-sided test at the 5% level and with a power of 80% would require a minimum 
sample of 85 individuals. To allow for missing data, we aimed to recruit 100 individuals 
to each of our student-volunteer and patient groups. All sample sizes were calculated 
using the nQuery advisor 7.0. 
 
12.6 Statistical analysis 
All of the data was analysed using Microsoft Office Excel and the statistical package, 
SPSS for Windows (version 15). Pearson product-moment correlation coefficients were 
calculated to evaluate the association between the PDI, BFNE, and BDI-II scores. Linear 
regression analyses were carried out to assess if the BFNE score continued to be 
associated with the PDI scores once the confounding effects of depression were 
controlled. Spearman rank correlation coefficients were calculated in order to examine 
the relationship in scores between the BFNE and the 6 factors of the PDI-21(Preti, Sardu, 
& Piga, 2007).  
 
12.7 Results 
12.7.1 The mean scores of all of the scales assessed in this study 
Table 12 presents the mean scores of the PDI-21, BFNE, and BDI-II questionnaires in the 
student and patient samples.  
 
Table 12: Mean scores for all of the scales assessed in this study. 
 Student sample (n = 282) Patient sample (n = 117) 
PDI-21 score 
BFNE total score 
BDI-II total score 
6.43 (SD = 4.29, n = 228) 
23.93 (SD = 10.59, n = 241) 
14.34 (SD = 9.72, n = 235) 
5.44 (SD = 4.95, n = 106) 
17.55 (SD = 10.14, n = 107) 
14.03 (SD  = 10.07, n = 105) 
 
12.7.2 The relationship between depression, fear of negative evaluation and 
delusional ideation 
In the student sample, the BDI-II (Pearson’s r = 0.46, p < 0.001) and the BFNE 
(Pearson’s r = 0.37, p < 0.001) results were related to the PDI-21 score, and these 
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relationships were statistically significant. The BDI-II and the BFNE were also associated 
with each other (Pearson’s r = 0.49, p < 0.001) (Table 13). Moreover, in the patient 
sample, the BDI-II (Pearson’s r = 0.44, p < 0.001) and the BFNE (Pearson’s r = 0.33, p = 
0.002) results were related to the PDI-21 score. An association was also found between 
the BDI-II and the BFNE outcomes (Pearson’s r = 0.36, p < 0.001) (Table 14). 
 
Table 13: Pearson’s bivariate correlation (two-tailed probabilities) between 
delusional ideations, depression and fear of negative evaluation from 
others in the student sample. 
 BDI-II BFNE 
PDI-21 score 
BDI-II 
0.46 (95%CI = 0.35-0.55, n = 228) 0.37 (95%CI = 0.25-0.48, n = 223) 
0.49 (95%CI = 0.39-0.59, n = 220) 
 
 
Table 14: Pearson’s bivariate correlation (two-tailed probabilities) between 
delusional ideations, depression and fear of negative evaluation from 
others in the patient sample. 
 BDI-II BFNE 
PDI-21 score 
BDI-II 
0.44 (95%CI = 0.28-0.59, n = 105) 0.33 (95%CI = 0.14-0.49, n = 106) 
0.36 (95%CI = 0.18-0.52, n = 105) 
 
 
12.7.3 Linear regression analyses to control the confounding effects of depression  
Linear regression analyses were used to evaluate a model in both the student and patient 
samples. In this model, the BFNE and BDI-II scores were entered as independent 
variables, and the dependent variable was the PDI-21 score. The adjusted R squared (R2) 
for these models in the student and patient samples were 0.24 and 0.21, respectively. In 
the student sample, the un-standardized regression coefficient for the BFNE was 0.08 
(95%CI = 0.03-0.14, p = 0.002), while that for the BDI was 0.16 (95%CI = 0.10-0.22, p < 
0.001) (Table 15). In the patient sample, the un-standardized regression coefficients for 
the BFNE and the BDI were 0.09 (95%CI = 0.001-0.18, p = 0.048) and 0.19 (95%CI = 
0.09-0.28, p < 0.001) respectively (Table 16). 
Table 15: Linear regression for the PDI-21 score in the student sample: with 
the BFNE and BDI-II scores as independent variables (n = 213). 
Independent variable Un-standardized 
Coefficients 
t value p value 95% CI 
BFNE 
BDI-II 
0.08 
0.16 
3.07 
5.12 
0.002 
< 0.001 
0.03-0.14 
0.10-0.22 
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Table 16: Linear regression for the PDI-21 score in the patient sample: with 
the BFNE and BDI-II scores as independent variables (n = 105). 
Independent variable Un-standardized 
Coefficients 
t value p value 95% CI 
BFNE 
BDI-II 
0.09 
0.19 
2.01 
4.03 
0.048 
< 0.001 
0.001-0.18 
0.09-0.28 
 
 
12.7.4 The relationship between the fear of negative evaluation and each of the 6 
factors of the PDI-21 
Spearman rank correlation coefficients were calculated in order to examine the 
association between the fear of negative evaluation and each of the 6 factors of the PDI-
21 that had been suggested by Preti and his colleagues (Preti, Sardu, & Piga, 2007)(Table 
17). In the student sample, the BFNE was mildly related to factors 1: schizophrenia 
(Spearman’s r = 0.32, p < 0.001), 2: paranoid (Spearman’s r = 0.32, p < 0.001), 3: 
psychotic depression (Spearman’s r = 0.36, p < 0.001), 4: manic bipolar (Spearman’s r = 
0.22, p = 0.001) and 5: paranormal beliefs (Spearman’s r = 0.25, p < 0.001) (Table 17). 
Alternatively, in the patient sample, the BFNE was moderately related to factor 3: 
psychotic depression (Spearman’s r = 0.44, p < 0.001), and was mildly associated with 
factors 1: schizophrenia (Spearman’s r = 0.30, p = 0.002), 2: paranoid (Spearman’s r = 
0.37, p < 0.001), 4: manic bipolar (Spearman’s r = 0.20, p = 0.036) and 5: paranormal 
beliefs (Spearman’s r = 0.33, p = 0.001). 
 
Table 17: Spearman’s correlation coefficients (two-tailed probabilities) 
between the fear of negative evaluation from others and the 6 factors of the 
PDI-21. 
 Student sample Patient sample 
Factor 1: schizophrenia 
Factor 2: paranoid 
Factor 3: psychotic depression 
Factor 4: manic bipolar 
Factor 5: paranormal beliefs 
Factor 6: mystic delusions 
0.32 (p < 0.001, n = 227) 
0.32 (p < 0.001, n = 229) 
0.36 (p < 0.001, n = 229) 
0.22 (p = 0.001, n = 232) 
0.25 (p < 0.001, n = 229) 
0.07 (p = 0.296, n = 230) 
0.30 (p = 0.002, n = 106) 
0.37 (p < 0.001, n = 106) 
0.44 (p < 0.001, n = 106) 
0.20 (p = 0.036, n = 106) 
0.33 (p = 0.001, n = 106) 
0.08 (p = 0.430, n = 106) 
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12.8 Conclusion 
The association between the FNE and delusional ideations was significant, both in the 
non-clinical sample and in patients with schizophrenia, even after depression was 
controlled as a confounding factor. These results indicate that the FNE is associated with 
the development of delusions and is clinically significant. Indeed, FNE may be a key 
target for CBT in schizophrenia, with it being used to reduce delusional symptoms. 
Moreover, FNE could also be a suitable candidate as an external validator which can be 
used to establish the construct validity of the illness’s sub-types. A more detailed 
discussion of the results presented herein is contained in Chapter 18 (“Discussion”). 
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Chapter 13: Psychometric Evaluation of the English and Japanese Versions 
of the SCIPS 
 
13.1 Overview 
As described in Chapter 10 (“Method”) and Chapter 11 (“Development of the English 
and Japanese Versions of the SCIPS”), both versions of the SCIPS tool were developed 
as a way of classifying patients with schizophrenia into 4 sub-groups: drug related, 
traumatic, anxiety and stress sensitivity. It was, then, necessary to validate the developed 
interview, before its use in clinical or research settings. Indeed, and in general, a 
structured or semi-structured interview cannot be valuable if it has low inter-rater 
reliability, concurrent validity, diagnostic sensitivity, or specificity. In this chapter, these 
psychometric properties of the SCIPS (both the English and Japanese versions) were 
evaluated. In this process, cut-off points for a number of the items which were involved 
in the differentiation between the anxiety and stress sensitivity sub-types were treated as a 
variable. Then, the most appropriate cut-off point was determined by assigning 5 values 
(1-5) to it and comparing their impact on the psychometric properties of the test. 
 
13.2 Aims of this study 
The aims of this study are as follows; 
1. To establish the inter-rater reliability and concurrent validity of a SCIPS diagnosis (in 
both its English and Japanese versions). 
2. To determine the best diagnostic criteria for making a distinction between the anxiety 
and stress sensitivity sub-types. 
3. To evaluate the sensitivity and specificity of a SCIPS diagnosis (in both its English 
and Japanese versions). 
 
13.3 Procedure 
Participant recruitment 
The procedure for the recruitment of the participants and the descriptive data about them 
are described in Chapter 10 (see section 10.9, “Procedure”; also see Figure 1 and 2, and 
Tables 10 and 11).  
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13.4 Sample size 
There is no formal method for the sample size calculation of kappa statistics. Therefore, 2 
experts (an epidemiologist and a statistician) were consulted, with it being initially agreed 
that samples containing a minimum of 20 individuals were needed to use kappa 
coefficients to evaluate the inter-rater reliability and concurrent validity of a SCIPS 
diagnosis. In order to assess the diagnostic sensitivity and specificity thereof, sub-groups 
with the highest achievable validity were determined for the largest possible number of 
participants who were recruited for the other study, which is presented in Chapter 15 
(“Construct Validity of the Conceptualisation of the Anxiety and Stress Sensitivity Sub-
types: A Preliminary Study in the UK”) and Chapter 16 (“Construct Validity of the 
Conceptualisation of the Anxiety and Stress Sensitivity Sub-types: A Study with a Larger 
Sample in Japan”). Explanations of how to determine the sub-groups with the highest 
achievable validity can be found in Chapter 10 (see section 10.7, “Determination of the 
sub-groups with the highest achievable validity”). 
 
13.5 Results 
13.5.1 Omission of item 2-1 from the SCIPS 
Although we had assumed that most patients with schizophrenia experienced changes in 
work or school performance before the first episode thereof, we discovered that many of 
our sample answered ‘no deterioration had happened’ or ‘cannot remember’ for item 2-1 
of the SCIPS interview (see Appendix A). For instance, the interviewers rated ‘no 
deterioration’ for 5 participants and ‘impossible to rate because the participant could not 
remember’ for 4 others of the 42 people recruited for the UK project. Similarly, in the 
Japanese sample, the interviewers rated ‘no deterioration’ for 29 respondents and 
‘impossible to rate because the participant could not remember’ for 2 others among the 
sample of 107. This meant that the ratings of these 9 participants (21.4%) in the UK and 
31 (29.0%) in Japan for this item had to be treated as ‘missing’, because they would make 
very little contribution to the differentiation between the anxiety and stress sensitivity 
sub-types. Moreover, the kappa coefficient for item 2-1 was low in the English version 
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(kappa coefficient = 0.22, 95%CI = 0.02-0.43) (see Table 21), and as a consequence, we 
ultimately decided to omit this item from the SCIPS.  
 
13.5.2 The best diagnostic criteria for making a distinction between the anxiety and 
stress sensitivity sub-types (English version) 
The diagnostic criteria for the anxiety and stress sensitivity sub-types were determined as 
described in Chapter 11 (see section 11.8, “Basic concept of the diagnostic criteria for the 
SCIPS sub-groups”). Values ranging from 1 to 5 were assigned to the cut-off point for 
(A) (number of items which had to be rated as ‘1’ for the diagnosis of the anxiety sub-
type), and the kappa coefficients for inter-rater reliability and concurrent validity were 
calculated for each cut-off point (Table 18). Both inter-rater reliability (kappa coefficient 
= 0.93, 95%CI = 0.66-1.20, agreement ratio = 95.0%) and concurrent validity (kappa 
coefficient = 0.73, 95%CI = 0.47-1.00, agreement ratio = 76.2%) were greatest when the 
cut-off point was 3. Table 19 presents cross tables that were used for the calculation of 
the inter-rater reliability and concurrent validity of the SCIPS diagnosis for the 
participants in the UK with this optimum cut-off point. In the second interview, the sub-
type could not be determined for one of the participants because he could not give enough 
information about the timing of his use of stimulants/ hallucinogens. 
 
 
Table 18: Inter-rater reliability and concurrent validity of the SCIPS 
diagnosis calculated with 5 cut-off points. 
Cut-off point Kappa coefficient for 
inter-rater reliability (95%CI) 
Kappa coefficient for  
concurrent validity (95%CI) 
1 0.82 (0.49-1.15) 0.45 (0.20-0.71) 
2 0.79 (0.52-1.06) 0.52 (0.26-0.78) 
3 0.93 (0.66-1.20) 0.73 (0.47-1.00) 
4 0.86 (0.59-1.13) 0.61 (0.35-0.86) 
5 0.85 (0.57-1.13) 0.54 (0.30-0.79) 
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Table 19: Cross tables used for the calculation of the inter-rater reliability 
and concurrent validity of the SCIPS diagnosis for the participants in the 
UK. 
 
For the inter-rater reliability 
 2nd SCIPS diagnosis 
Drug 
related 
Traumatic Anxiety Stress 
sensitivity 
Subtype not 
determined 
Total 
1st SCIPS 
diagnosis 
 
 
Drug 
related 
6 0 0 0 1 7 
Traumatic 0 1 0 0 0 1 
Anxiety 0 0 6 0 0 6 
Stress 
sensitivity 
0 0 0 6 0 6 
Total 6 1 6 6 1 20 
 
For the concurrent validity 
 Diagnosis with highest achievable validity 
Drug 
related 
Traumatic Anxiety Stress 
sensitivity 
Total 
1st SCIPS 
diagnosis 
 
Drug related 6 0 0 1 7 
Traumatic 0 2 0 0 2 
Anxiety 0 0 4 1 5 
Stress 
sensitivity 
1 0 1 5 7 
Total 7 2 5 7 21 
 
13.5.3 Inter-rater reliability and concurrent validity of a diagnosis made with the 
Japanese version of the SCIPS 
Kappa coefficients for the inter-rater reliability and concurrent validity of the sub-types 
determined with the Japanese version of the SCIPS were 0.73 (95%CI = 0.49-0.97, 
agreement ratio = 82.9%, n = 35) and 0.83 (95%CI = 0.65-1.00, agreement ratio = 92.1%, 
n = 88) respectively. The diagnostic criteria determined with the English version, as 
described above (cut-off point = 3), were used to make a diagnosis. Table 20 presents 
cross tables that were used for the calculation of the inter-rater reliability and concurrent 
validity of the SCIPS diagnosis for the participants in Japan. 
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Table 20: Cross tables used for the calculation of the inter-rater reliability 
and concurrent validity of the SCIPS diagnosis for the participants in Japan. 
 
For inter-rater reliability 
 2nd SCIPS diagnosis 
Drug 
related 
Traumatic Anxiety Stress 
sensitivity 
Total 
1st SCIPS 
diagnosis 
 
Drug related 4 0 0 0 4 
Traumatic 0 0 0 0 0 
Anxiety 0 0 13 1 14 
Stress 
sensitivity 
0 0 3 12 17 
Total 4 14 16 13 35 
 
For concurrent validity 
 Diagnosis with highest achievable validity 
Drug 
related 
Traumatic Anxiety Stress 
sensitivity 
Total 
1st SCIPS 
diagnosis 
 
Drug related 4 0 0 0 4 
Traumatic 0 1 0 0 1 
Anxiety 0 0 19 2 21 
Stress 
sensitivity 
0 0 5 57 62 
Total 4 1 24 59 88 
 
 
13.5.4 Inter-rater reliability of the ratings for each item of the SCIPS 
The kappa coefficients were calculated (Table 21) for the ratings produced by 2 
independent raters for each item in the SCIPS.  
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Table 21: Kappa coefficients (95%CI) of the ratings for each item of the 
SCIPS provided by 2 independent raters (English and Japanese versions). 
Item English version (n = 20) Japanese version (n = 35) 
1-1. Age at 1st episode 
1-2. Mode of onset 
1-3. Triggers 
2-1. Deterioration in 
performance prior to onset 
2-2. Social relationships 
since early adolescence 
2-3. Pre-morbid close 
relationships  
3-1. Precipitating use of 
hallucinogens   
3-2. Traumatic experience 
3-3. Borderline personality 
disorder 
0.89 (0.45-1.32) 
0.47 (0.18-0.75) 
1.00 (0.56-1.44) 
0.22 (0.02-0.43) 
 
0.57 (0.14-1.00) 
 
0.50 (0.12-0.88) 
 
0.89 (0.49-1.30) 
 
0.90 (0.46-1.33) 
N/A 
0.88 (0.55-1.21) 
0.13 (-0.19-0.44) 
0.72 (0.38-1.05) 
0.43 (0.21-0.65) 
 
0.28 (-0.04-0.59) 
 
0.71 (0.38-1.04) 
 
1.00 (0.67-1.33) 
 
0.55 (0.25-0.84) 
N/A 
 
The ratings for item 3-3 in the first interviews using the SCID-II were commonly used for 
the inter-rater reliability of the two SCIPS diagnoses. 
 
13.5.5 Sensitivity and specificity of the SCIPS diagnosis in the UK 
Table 22 sets out the sensitivity and specificity of the SCIPS diagnosis for each of the 4 
sub-types of schizophrenia in the UK. A 2 x 2 table for each sub-type that was used to 
calculate sensitivity and specificity is presented in Table 23. 
 
Table 22: Sensitivity and specificity of the SCIPS diagnosis for participants 
in the UK (n = 21). 
Sub-type Sensitivity (95% CI) Specificity (95% CI) 
Drug related 
Traumatic 
Anxiety 
Stress sensitivity 
0.86 (0.60-1.12) 
1.00 (1.00-1.00) 
0.80 (0.45-1.15) 
0.86 (0.67-1.04) 
0.93 (0.79-1.06) 
1.00 (1.00-1.00) 
0.94 (0.82-1.06) 
0.71 (0.38-1.05) 
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Table 23: The 2x2 tables used for the calculation of the sensitivity and 
specificity of the SCIPS diagnosis for participants in the UK (n = 21). 
 
Drug related sub-group 
 Diagnosis with the highest achievable validity 
Positive Negative Total 
SCIPS diagnosis 
 
Positive 6 1 7 
Negative 1 13 14 
Total 7 14 21 
 
 
Traumatic sub-group 
 Diagnosis with the highest achievable validity 
Positive Negative Total 
SCIPS diagnosis 
 
Positive 2 0 2 
Negative 0 19 19 
Total 2 19 21 
 
 
Anxiety sub-group 
 Diagnosis with the highest achievable validity 
Positive Negative Total 
SCIPS diagnosis 
 
Positive 4 1 5 
Negative 1 15 16 
Total 5 16 21 
 
 
Stress sensitivity sub-group 
 Diagnosis with the highest achievable validity 
Positive Negative Total 
SCIPS diagnosis 
 
Positive 12 2 14 
Negative 2 5 7 
Total 14 7 21 
 
13.5.6 Sensitivity and specificity of the SCIPS diagnosis in Japan 
Table 24 sets out the sensitivity and specificity of the SCIPS diagnoses for each of the 4 
sub-groups in Japan. A 2x2 table which was used to calculate these elements for each 
sub-type is presented in Table 25. 
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Table 24: Sensitivity and specificity of the SCIPS diagnosis for participants 
in Japan (n = 88). 
Sub-type Sensitivity (95% CI) Specificity (95% CI) 
Drug related 
Traumatic 
Anxiety 
Stress sensitivity 
1.00 (1.00-1.00) 
1.00 (1.00-1.00) 
0.79 (0.63-0.95) 
0.97 (0.92-1.01) 
1.00 (1.00-1.00) 
1.00 (1.00-1.00) 
0.97 (0.93-1.01) 
0.83 (0.69-0.97) 
 
Table 25: 2x2 tables used for the calculation of sensitivity and specificity of 
the SCIPS diagnosis for participants in Japan. 
 
Drug related sub-group 
 Diagnosis with the highest achievable validity 
Positive Negative Total 
SCIPS diagnosis 
 
Positive 4 0 4 
Negative 0 84 84 
Total 4 84 88 
 
 
Traumatic sub-group 
 Diagnosis with the highest achievable validity 
Positive Negative Total 
SCIPS diagnosis 
 
Positive 1 0 1 
Negative 0 87 87 
Total 1 87 88 
 
 
Anxiety sub-group 
 Diagnosis with the highest achievable validity 
Positive Negative Total 
SCIPS diagnosis 
 
Positive 19 2 21 
Negative 5 62 67 
Total 24 64 88 
 
 
Stress sensitivity sub-group 
 Diagnosis with the highest achievable validity 
Positive Negative Total 
SCIPS diagnosis 
 
Positive 57 5 62 
Negative 2 24 26 
Total 59 29 88 
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13.6 Conclusion 
Psychometric properties, namely inter-rater reliability and concurrent validity, were 
examined and established for the SCIPS (English and Japanese versions) in this study. 
Furthermore, the SCIPS diagnoses for patients with schizophrenia revealed high 
sensitivity and specificity. Indeed, these results confirmed that the SCIPS can be used for 
further investigation of the validation of the classification scheme which has been 
adopted therein. A more detailed discussion about the results presented in this chapter is 
contained in Chapter 18 (“Discussion”). 
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Chapter 14: Six Month Stability of the SCIPS Diagnosis: A Longitudinal 
Study in Japan 
 
14.1 Overview 
As described in Chapter 3 (“Arguments on the Classification of Schizophrenia”), the 
instability of the diagnoses has been suggested as a reason why the utility of the sub-types 
defined by the DSM and ICD systems is reduced. It is, therefore, valuable to establish the 
stability of a new classification system over time. In this chapter, the results of a 
prospective follow-up study, which was conducted to establish the stability of the sub-
types discussed herein, are described. Indeed, if it is proved that the sub-types determined 
with the SCIPS do not change over time, this classification scheme could be regarded as 
being more significant. On the other hand, any classification system that is unstable over 
time would be less useful. Accordingly, and in order to establish the stability of the sub-
type diagnoses, the SCIPS interview was carried out twice on 2 different days, with an 
interval of at least 6 months between them. The results of this study are discussed in this 
chapter. 
 
14.2 Aims of this study 
The aim of this study is to examine whether the sub-types determined with the SCIPS 
change over a period of 6 months. 
 
14.3 Procedure 
Participant recruitment 
The procedure for the recruitment of participants and the descriptive data about them are 
described in Chapter 10 (see section 10.9, “Procedure”; also see Figure 2 and Table 11).  
 
14.4 Sample size 
There is no formal method for sample size calculation for kappa statistics. We, therefore, 
consulted 2 experts (an epidemiologist and a statistician), with it being agreed initially 
that samples comprising a minimum of 20 individuals were needed to use kappa 
coefficients to evaluate the longitudinal stability of the SCIPS diagnoses. 
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14.5 Results 
14.5.1 Participant demographics: prevalence of the sub-types according to the 
follow-up SCIPS interview 
Table 26 sets out the prevalence of the sub-types according to the follow-up SCIPS 
interviews for the stability study. 
 
Table 26: Prevalence of the sub-types according to the SCIPS follow-up 
interviews. 
Drug related 
Traumatic 
Anxiety 
Stress sensitivity 
Not determined 
2 (4.6%) 
0 (0.0%) 
10 (23.3%) 
31 (72.1%) 
0 (0.0%) 
 
14.5.2 Six month stability of the SCIPS diagnosis 
Of the 43 patients, 37 (86.0%) remained in the same sub-group and stable over the 6 
month period. The kappa coefficient for the stability of the determined SCIPS diagnoses 
was 0.69 (95%CI = 0.46-0.92, n = 43). In particular, both (100.0%) of the 2 patients 
diagnosed with the drug related sub-type in the first assessment remained in the same 
sub-group over the 6 month period. 8 (75.0%) of the 12 diagnosed with the anxiety sub-
type were also stable, while diagnoses of 4 (25.0%) changed to the stress sensitivity sub-
group. On the other hand, 27 (93.1%) of the 29 with the stress sensitivity sub-type 
remained in the same sub-group, while 2 (6.9%) moved to the anxiety category. 
 
14.6 Conclusion 
This part of the study revealed that the SCIPS diagnoses for 3 of the 4 sub-types, namely 
drug related, anxiety and stress sensitivity, were stable over a period of at least 6 months. 
A more detailed discussion of the results in this chapter is contained in Chapter 18 
(“Discussion”). 
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Chapter 15: Construct Validity of the Conceptualisation of the Anxiety and 
Stress Sensitivity Sub-types: A Preliminary Study in the UK 
  
15.1 Overview 
Although the conceptualisation of the 4 sub-types of schizophrenia has already been 
developed, it still requires validation. Indeed, its construct validity, including prognostic 
quality, has not been established. In this chapter, the results of a cross-sectional study, 
which was conducted to establish the construct validity of the categories, anxiety and 
stress sensitivity, are set out. This research involved the evaluation of the difference in 
the levels of potential external validators, as discussed in Chapter 1 (“Classification in 
Psychiatry”). There were 3 such validators, namely negative and positive evaluative 
beliefs, the fear of negative evaluation from others (FNE) and depression (see Chapter 8, 
“Potential External Validators of the Sub-types in the Current Study”). These variables 
were compared between the anxiety and stress sensitivity sub-groups. The work was 
divided into 2 stages, a preliminary study in the UK (in which negative and positive 
evaluative beliefs and FNE were employed as external validators) and a study with a 
larger sample in Japan (in which negative and positive evaluative beliefs, FNE and 
depression were compared between the sub-types). The data about the SCIPS diagnoses 
that was obtained in the first assessment was used in this study, and the results are 
discussed in this chapter.  
 
15.2 Aims of this study 
The aims of this study are to examine 2 primary and 1 secondary hypotheses which are 
described below: 
Primary hypotheses: 
1. Patients with the stress sensitivity sub-type of schizophrenia have higher levels of 
negative evaluative beliefs (negative-self and negative-others) than those in the 
anxiety sub-group. 
2. Patients with the stress sensitivity sub-type of schizophrenia have lower levels of 
positive evaluative beliefs (positive-self and positive-others) than those in the 
anxiety sub-group. 
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Secondary hypothesis: 
Individuals in the stress sensitivity sub-group have a higher fear of negative evaluation 
from others than those in the anxiety sub-group. 
 
15.3 Procedure 
Participant recruitment 
The procedure for the recruitment of participants and the descriptive data about them are 
described in Chapter 10 (see section 10.9, “Procedure”; also see Figure 1 and Table 10).  
 
15.4 Measures 
The Brief Core Schema Scale (BCSS) (Fowler et al., 2006) 
The Brief Fear of Negative Evaluation Scale (BFNE) (Collins et al., 2005) 
Details of the scales are provided in Chapter 10 (see section 10.8, “Measures”). 
  
15.5 Sample size 
The available information was not enough to enable us to calculate what sample size was 
needed to detect significant differences between the anxiety and stress sensitivity sub-
types with regard to the BCSS and FNE scores. Accordingly, it was initially agreed that a 
pilot study should be carried out with a sample of a minimum of 40 individuals. We 
expected that this research would provide important information with which to calculate 
the appropriate sample size for a larger study of this same issue.  
 
15.6 Results 
15.6.1 Prevalence of the sub-types 
According to the first SCIPS interview using the determined diagnostic criteria, the 
numbers of participants in the 4 sub-groups were as follows: 13 (31.0%) drug related, 2 
(4.8%) traumatic, 10 (23.8%) anxiety and 15 (35.7%) stress sensitivity. The sub-types 
could not be determined for 2 of the participants because 1 of them did not complete the 
interview and the other could not give enough information about the timing of his use of 
stimulants/ hallucinogens. 
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15.6.2 Distribution of the BCSS and BFNE scores in the sample in the UK 
As set out in Figures 4 and 5, the 4 scores in the BCSS scale, and the total score of the 
BFNE, did not reveal a pattern of normal distribution. Accordingly, the Mann-Whitney U 
Test, (a type of non-parametric test for 2 independent samples), was conducted to assess 
the differences between the 2 sub-groups. Table 27 presents the mean scores and the 
median for the variables assessed in this study. 
 
Table 27: The mean scores and the median for the variables assessed in 
this study (the UK sample). 
Variables Mean scores (SD) Median (IQR) 
NS-BCSS (n = 40) 
PS-BCSS (n = 40) 
NO-BCSS (n = 40) 
PO-BCSS (n = 40) 
BFNE (n = 42) 
4.85 (5.02) 
9.63 (7.01) 
7.78 (6.50) 
10.33 (6.39) 
25.26 (11.76) 
3.50 (1.00-6.00) 
8.50 (3.00-15.75) 
7.00 (3.00-12.00) 
10.00 (5.25-15.00)  
23.00 (17.00-33.25) 
 
NS-BCSS: BCSS score which represents beliefs about negative-self; 
PS-BCSS: BCSS score which represents beliefs about positive-self; 
NO-BCSS: BCSS score which represents beliefs about negative-others; 
PO-BCSS: BCSS score which represents beliefs about positive-others. 
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Figure 4: Distribution of BCSS scores in the UK sample. 
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Figure 4 continued. 
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Figure 5: Distribution of BFNE scores in the UK sample. 
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15.6.3 Differences in the BCSS and BFNE scores between the anxiety and stress 
sensitivity sub-types 
The p values for the differences (Mann-Whitney U Test) between the scores for the 
negative-self, positive-self, negative-others, and positive-others evaluative beliefs were 
0.882 (anxiety < stress sensitivity), 0.333 (anxiety > stress sensitivity), 0.427 (anxiety < 
stress sensitivity), and 0.348 (anxiety > stress sensitivity) respectively. On the other hand, 
the p value for the discrepancy between the BFNE scores was 0.317 (anxiety < stress 
sensitivity). Although these differences were not statistically significant, some trends 
were demonstrated in terms of the distinctions between the anxiety and stress sensitivity 
categories. For example, the FNE and the positive-self evaluative belief scores appeared 
higher in the stress sensitivity sub-type. Furthermore, the discrepancy in the BFNE scores 
between these 2 classifications seemed to be detected with statistical significance in a 
larger sample. 
 
15.7 Conclusion 
Although they were not statistically significant, some appreciable trends were found in 
the differences in the level of evaluative beliefs and FNE, which were consistent with our 
hypotheses. Conducting a study to examine if these distinctions were confirmed in a 
larger sample, therefore, seemed worthwhile, and was subsequently planned and carried 
out. The results are described in Chapter 16 (“Construct Validity of the Conceptualisation 
of the Anxiety and Stress Sensitivity Sub-types: A Study with a Larger Sample in Japan”). 
A more detailed discussion of the findings presented in this chapter is contained in 
Chapter 18 (“Discussion”). 
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Chapter 16: Construct Validity of the Conceptualisation of the Anxiety and 
Stress Sensitivity Sub-types: A Study with a Larger Sample in Japan 
 
16.1 Overview 
Although some differences between the anxiety and stress sensitivity sub-types were 
suggested in the preliminary study described in Chapter 15 (“Construct Validity of the 
Conceptualisation of the Anxiety and Stress Sensitivity Sub-types: A Preliminary Study 
in the UK”), these were not statistically significant, and the construct validity of these 2 
sub-groups was not established. In particular, the levels of fear of negative evaluation 
from others (FNE) and positive-self evaluative belief appeared to be higher in the stress 
sensitivity sub-type than in the anxiety sub-group, although the p values for these 
differences were greater than 0.05. In order to establish the validity of these categories, 
the levels of FNE and negative and positive evaluative beliefs were compared again in a 
larger sample in Japan. Difference in the extent of depression between the sub-groups 
was also examined in this sample. Furthermore, an additional analysis was conducted to 
examine if there was any association between the SCIPS and DSM sub-types. The data 
about the SCIPS diagnoses that was obtained in the first assessment was used in this 
study, and the results are discussed in this chapter.  
 
 
16.2 Aims of this study 
The aims of this research were essentially the same as in the preliminary study which is 
described in Chapter 15 (“Construct Validity of the Conceptualisation of the Anxiety and 
Stress Sensitivity Sub-types: A Preliminary Study in the UK”). However, when the 
hypotheses examined in this chapter were proposed, the results of the preliminary piece 
of work were taken into consideration, and modifications were made on the basis of what 
had been learnt. Accordingly, the aims of this study were to examine 1 primary, 4 
secondary and 1 additional hypotheses as described below: 
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Primary hypothesis: 
The stress sensitivity sub-group reveals a greater fear of negative evaluation from others 
than those in the anxiety sub-group. 
 
Secondary hypotheses: 
1. Patients with the stress sensitivity sub-type reveal higher levels of negative 
evaluative belief (negative-self and negative-others) than those in the anxiety sub-
group. 
2. Patients with the stress sensitivity sub-type reveal lower levels of positive 
evaluative belief (positive-self and positive-others) than those in the anxiety sub-
group. 
3. Patients with the stress sensitivity sub-type reveal higher levels of depression than 
those in the anxiety sub-group. 
4. Same as the primary hypothesis and secondary hypotheses 1 to 3, which were 
listed above, but when patients with a diagnosis of both schizoaffective disorder 
and schizophrenia are included. 
 
A hypothesis which was examined in an additional analysis states that there is no 
association between the SCIPS and DSM sub-types. 
 
16.3 Procedure 
Participant recruitment 
The descriptive data of the participants, as well as the procedure for their recruitment, are 
described in Chapter 10 (see section 10.9, “Procedure”; also see Figure 2 and Table 11).  
 
16.4 Measures 
The Brief Fear of Negative Evaluation Scale (BFNE) (Collins et al., 2005) 
The Brief Core Schema Scale (BCSS) (Fowler et al., 2006) 
Beck Depression Inventory II (BDI-II) (Beck, Steer, & Brown, 1996) 
Details of the scales are provided in Chapter 10 (see section 10.8, “Measures”). 
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16.5 Sample size 
We calculated the necessary sample size for detecting a significant difference in FNE 
equal to that found in the preliminary study in the UK with a two-sided test at the 5% 
level and with a power of 80%. It was calculated based on the description in Cohen 
(Cohen, 1988) and using the nQuery advisor 7.0, and the results of the preliminary study 
in the UK were utilised for this purpose. It was, therefore, initially agreed that samples 
comprising a minimum of 100 individuals were needed to make any comparisons. 
 
16.6 Results 
16.6.1 Prevalence of the sub-types 
The numbers of participants in the 4 sub-groups diagnosed with the SCIPS were as 
follows: 5 (4.7%) drug related, 1 (0.9%) traumatic, 26 (24.3%) anxiety and 75 (70.1%) 
stress sensitivity. Sub-types could not be determined for 10 of the 117 participants, 
because they pulled out of the project at the very beginning of the assessment and did not 
complete any of the questionnaires or the interview, including the SCIPS.  
 
16.6.2 Distribution of the BCSS and BFNE scores in the sample in Japan 
As shown in Figures 6 to 8, the scores in the BFNE, BCSS and BDI-II scales did not 
reveal a pattern of normal distribution. Thus, a Mann-Whitney U Test, (a kind of non-
parametric test for 2 independent samples), was conducted to assess the differences 
between the 2 sub-groups. Table 28 presents the mean scores and the median for the 
variables assessed in this study. 
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Table 28: The mean scores and the median for the variables assessed in 
this study (the Japanese sample). 
Variables Mean scores (SD) Median (IQR) 
BFNE (n = 107) 
NS-BCSS (n = 105) 
PS-BCSS (n = 106) 
NO-BCSS (n = 105) 
PO-BCSS (n = 104) 
BDI-II (n = 105) 
17.55 (10.14) 
6.34 (4.14) 
5.49 (5.07) 
2.60 (3.12) 
9.10 (5.93) 
14.03 (10.07) 
17.00 (9.00-24.00) 
6.00 (3.00-9.00) 
4.00 (1.00-8.25) 
1.00 (0.00-4.00) 
8.00 (4.25-12.00) 
13.00 (6.50-19.00) 
 
NS-BCSS: BCSS score which represents beliefs about negative-self; 
PS-BCSS: BCSS score which represents beliefs about positive-self; 
NO-BCSS: BCSS score which represents beliefs about negative-others; 
PO-BCSS: BCSS score which represents beliefs about positive-others. 
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Figure 6: Distribution of BFNE scores in the Japanese sample. 
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Figure 7: Distribution of BCSS scores in the Japanese sample. 
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Figure 7 continued. 
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Figure 8: Distribution of BDI-II scores in the Japanese sample. 
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16.6.3 Differences in the BFNE, BCSS and BDI-II scores between the anxiety and 
the stress sensitivity sub-types 
The p value for the differences (Mann-Whitney U Test) in the BFNE score was 0.678 
(anxiety > stress sensitivity). On the other hand, the p values for the differences in the 
scores for the evaluative beliefs: negative-self, negative-others, positive-self, and 
positive-others were 0.182 (anxiety > stress sensitivity), 0.981 (anxiety < stress 
sensitivity), 0.246 (anxiety < stress sensitivity), and 0.401 (anxiety < stress sensitivity) 
respectively. In addition, the p value for the difference in the BDI-II score was 0.260 
(anxiety > stress sensitivity). These differences were not statistically significant, and all 
of the hypotheses in this study were rejected. Indeed, even the difference in the BFNE 
score, which was suggested in the preliminary study, could not be detected. Possible 
reasons for these results are discussed in Chapter 18 (“Discussions”). 
 
When the participants with a diagnosis of schizoaffective disorder were included in the 
analysis, the p value for the differences (Mann-Whitney U Test) in the BFNE score was 
0.707 (anxiety > stress sensitivity). On the other hand, the p values for the differences in 
the scores for the evaluative beliefs: negative-self, negative-others, positive-self, and 
positive-others were 0.104 (anxiety > stress sensitivity), 0.322 (anxiety < stress 
sensitivity), 0.893 (anxiety > stress sensitivity), and 0.388 (anxiety < stress sensitivity) 
respectively. In addition, the p value for the difference in the BDI-II score was 0.133 
(anxiety > stress sensitivity). These differences were also not statistically significant. 
 
16.6.4 Comparison of the SCIPS and the DSM sub-types of schizophrenia 
A cross table for the comparison of the SCIPS and the DSM sub-types of schizophrenia is 
presented in Table 29. It was impossible to conduct a Chi square test with this table to 
examine the association between the SCIPS and DSM sub-types, because at least 5 
participants are needed in each cell of the table for the analysis. Accordingly, the anxiety 
and stress sensitivity categories of the SCIPS were chosen for the comparison and four 
2x2 tables for each of the DSM sub-types were prepared (Table 30). These 2 particular 
sub-groups were chosen for this purpose because there may be an overlap in the concepts 
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behind them, and differentiating between them, thus, seemed to be especially important, 
as discussed in Chapter 10 (see section 10.1, “Justification for the present study”). 
Thereafter, a Chi square test or Fisher’s exact test was conducted using each of the 4 
tables. No significant association was detected between the distinction of the two SCIPS 
sub-groups and any of the DSM sub-types (Table 31). Neither of the 2 statistical tests 
could not be conducted for the catatonic sub-group, because none of the participants were 
diagnosed with the sub-type. 
 
Table 29: Comparison of the SCIPS and the DSM sub-types of 
schizophrenia. 
 DSM IV subtypes  
 Paranoid Disorganised Catatonic Undifferentiated Residual Total 
SCIPS 
   Sub-types 
Drug  
  related 
Traumatic 
Anxiety 
Stress  
sensitivity 
Total 
 
 
3 
 
1 
13 
40 
 
57 
 
 
0 
 
0 
0 
1 
 
1 
 
 
0 
 
0 
0 
0 
 
0 
 
 
0 
 
0 
2 
3 
 
5 
 
 
2 
 
0 
11 
31 
 
44 
 
 
5 
 
1 
26 
75 
 
107 
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Table 30: Comparison of the distinction of the anxiety and stress sensitivity 
sub-groups, and each of the DSM sub-types of schizophrenia. 
 
Paranoid sub-type 
 DSM-IV paranoid sub-type 
Positive Negative Total 
SCIPS diagnosis 
 
Anxiety 13 13 26 
Stress sensitivity 40 35 75 
Total 53 48 101 
 
Disorganised sub-type 
 DSM-IV disorganised sub-type 
Positive Negative Total 
SCIPS diagnosis 
 
Anxiety 0 26 26 
Stress sensitivity 1 74 75 
Total 1 100 101 
 
Catatonic sub-type 
 DSM-IV catatonic sub-type 
Positive Negative Total 
SCIPS diagnosis 
 
Anxiety 0 26 26 
Stress sensitivity 0 75 75 
Total 0 101 101 
 
Undifferentiated sub-type 
 DSM-IV undifferentiated sub-type 
Positive Negative Total 
SCIPS diagnosis 
 
Anxiety 2 24 26 
Stress sensitivity 3 72 75 
Total 5 96 101 
 
Residual sub-type 
 DSM-IV residual sub-type 
Positive Negative Total 
SCIPS diagnosis 
 
Anxiety 11 15 26 
Stress sensitivity 31 44 75 
Total 42 59 101 
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Table 31: Association between the SCIPS and the DSM sub-types (df = 1). 
DSM sub-type Statistical test χ2   P value 
Paranoid 
Disorganised 
Catatonic 
Undifferentiated 
Residual 
Chi square test 
Fisher’s exact test 
N/A 
Fisher’s exact test 
Chi square test 
0.086 
N/A 
N/A 
N/A 
0.008 
0.769 
1.000 
N/A 
0.601 
0.931 
 
 
16.7 Conclusion 
No significant difference was shown in the evaluative beliefs and the FNE between the 
anxiety and stress sensitivity sub-types. That is to say, the trends found in the preliminary 
study in the UK were not reproduced in a statistically significant manner in Japan. Thus, 
all the hypotheses proposed were not approved in this study. In addition, no association 
was suggested between the SCIPS and DSM sub-types, and the discriminant validity was 
indicated for the distinction between the anxiety and stress sensitivity sub-types. A more 
detailed discussion on the results presented in this chapter is given in Chapter 18 
(“Discussion”). 
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Chapter 17: Predictive Value of the Conceptualisation of the Anxiety and 
Stress sensitivity Sub-types 
 
17.1 Overview 
Predictive value, or prognostic quality, is one of the main components which must be 
established to prove the construct validity of a classification system. It is, therefore, also 
important to establish the predictive value of the 4 sub-types. In this chapter, the results 
of a retrospective cohort study, which was conducted to establish the prognostic quality 
of the anxiety and stress sensitivity categories, are presented. Indeed, if it is revealed that 
the distinction between these 2 sub-groups could predict the difference in some clinically 
meaningful variables, such as clinical outcomes or future social functioning, it would be 
considered to be more significant. On the other hand, a classification system that has no 
predictive value may be less useful. Accordingly, in order to establish the predictive 
value of the sub-types, clinical outcomes in relation to hospitalization and the history of 
self harming were compared. The data about the SCIPS diagnosis that was obtained in the 
first assessment was used in this study, and the results are discussed in this chapter.  
 
17.2 Aims of this study 
The aims of this study are to examine 1 primary and 3 secondary hypotheses, as set out 
below: 
Primary hypothesis: 
Patients with the stress sensitivity sub-type of schizophrenia stay in hospital longer than 
those with the anxiety sub-type over a period of 3 years after the date of their first 
admission with the illness. 
 
Secondary hypotheses: 
1. The duration of the first hospitalization with schizophrenia is longer in those with the 
stress sensitivity sub-type than it is for those with the anxiety sub-type. 
2. Patients with the anxiety sub-type have a higher risk of self harming than those with 
the stress sensitivity sub-type. 
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3. Same as the primary hypothesis and secondary hypotheses 1 and 2, which were 
listed above, but when patients with a diagnosis of both schizoaffective disorder 
and schizophrenia are included. 
 
17.3 Procedure 
17.3.1 Participant recruitment 
The descriptive data of the participants, as well as the procedure for their recruitment, is 
set out in Chapter 10 (see section 10.9, “Procedure”; also see Figure 2 and Table 11).  
 
17.3.2 Data collection 
As described in Chapter 10 (see section 10.8, “Measures”), 2 variables for the 
hospitalization comparison, namely variable 1 “total time spent in hospital during the 
period of 3 years after the date of their first admission” and variable 2 “duration of the 
first hospitalization” were obtained from the participants’ case notes. In addition, 
information about earlier self harming was collected as a part of the SCID-II interview 
used for making diagnosis of borderline personality disorder in the first assessment. Of 
the 107 patients who completed the SCIPS interview, 56 provided information about 
variable 1 (52.3%), while data about variable 2 was available for 65 of them (60.7%). Six 
patients (5.6%) had not experienced hospitalization, 36 (33.6%) did not have enough 
information in their case notes, and 9 (8.4%) had been hospitalized for the first time in 
the last 3 years (and so variable 1 was not applicable). None but one (0.9%) was in their 
first hospitalization, when they were recruited for the study. Variable 1 was provided for 
this participant, because he had been hospitalized for more than 3 years. In addition, 
variable 2 of the patient was calculated by subtracting his first admission date from the 
current date and included in the analysis. Of the 56 for whom variable 1 did apply, 10 
were diagnosed as having the anxiety sub-type (17.9%), 43 were in the stress sensitivity 
group (76.8%) and 3 were in the drug related category (5.4%). Of the 65 patients for 
whom variable 2 was available, 11 were diagnosed with the anxiety sub-type (16.9%), 49 
with the stress sensitivity variant (75.4%) and 5 with the drug related condition (7.7%). 
None of the participants who provided information for variables 1 or 2 were diagnosed as 
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belonging to the traumatic sub-group. All of the 107 people who completed the SCIPS 
interview gave details about self harming. Of them, 64 (59.8%) self harmed after the 
onset of their first psychotic episode, while 43 (40.2%) did not. 
 
17.4 Sample size 
The available information was not enough to enable us to calculate what sample size was 
needed to detect significant differences between the anxiety and stress sensitivity sub-
types with regard to the variables which were selected for the comparison in this part of 
the study. Accordingly, it was initially agreed that a pilot study should be carried out with 
the same sample, which had been recruited for the assessment of the construct validity of 
the SCIPS diagnosis in Japan (see Chapter 16, “Construct Validity of the 
Conceptualisation of the Anxiety and Stress Sensitivity Sub-types: A Study with a Larger 
Sample in Japan”, and Figure 2). 
 
17.5 Results 
17.5.1 Distribution of the 2 variables related to hospitalization 
As shown in Figure 9, the 2 variables: total time [the number of days] spent in hospital 
over a period of 3 years after the date of first admission; and the duration [the number of 
days] of the first hospitalization, were not normally distributed. Accordingly, a Mann-
Whitney U Test was conducted to assess the differences between the 2 sub-groups. The 
median for variables 1 and 2 was 278.5 (IQR = 146.5-577.3) and 137.0 (IQR = 67.5-
290.5) respectively. 
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Figure 9: Distribution of the 2 variables related to hospitalization.
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1. In terms of the time unit used in this figure, the number of days was presented for the 
two variables. 
  
2. In the graphs for the 1st hospitalization (in the right-hand column on this page), a 
duration of the 1st hospitalization of longer than 1080 days (3 years) was counted as 
1080.  
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17.5.2 Differences in the 2 variables concerning hospitalization between the anxiety 
and stress sensitivity sub-types 
The p value for the discrepancies in variable 1: “total time spent in the hospital over a 
period of 3 years after the date of 1st admission” and variable 2 “duration of 1st 
hospitalization” were 0.811 (anxiety > stress sensitivity) and 0.141 (anxiety > stress 
sensitivity) respectively. These differences were not statistically significant and the 
primary hypothesis of this study was, therefore, rejected. Furthermore, these trends were 
contrary to the a priori expectations. Similar results were reproduced, even after cases 
with deviated levels of variables (variable 1 > 400 for the analysis of “total time spent in 
hospital over a period of 3 years after the date of 1st admission” and variable 2 > 400 for 
the analysis of “duration of 1st hospitalization”) were excluded. Possible reasons for these 
results are discussed in Chapter 18 (“Discussions”). 
 
When the participants with a diagnosis of schizoaffective disorder were included in the 
analysis, the p value for the discrepancies in variable 1 and variable 2 were 0.811 (anxiety 
> stress sensitivity) and 0.249 (anxiety > stress sensitivity) respectively. These 
differences were also not statistically significant. 
 
17.5.3 Differences in the risk of self harming between the anxiety and stress 
sensitivity sub-types 
A Chi square test was conducted, and revealed that the differences in the risk of self 
harming between the anxiety and stress sensitivity sub-types was not statistically 
significant (p = 0.110). Relative risk (RR) for self harming was 1.50 (anxiety > stress 
sensitivity, 95%CI = 0.61-3.69), which was also not statistically significant (Table 32). 
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Table 32: 2x2 Table used for the evaluation of the differences in the risk of 
self harming between the anxiety and stress sensitivity sub-types (patients 
with schizophrenia). 
 History of self harming 
Positive Negative Total 
SCIPS diagnosis 
 
Anxiety sub-type 14 12 26 
Stress sensitivity sub-
type 
27 48 75 
Total 41 60 101 
 
When the participants with a diagnosis of schizoaffective disorder were included in the 
analysis, the difference in the risk of self harming between the 2 sub-types was revealed 
to be statistically significant by the Chi square test (p = 0.044). The RR for self harming 
was 1.59 (anxiety > stress sensitivity, 95%CI = 0.66-3.81) which was not statistically 
significant (Table 33). 
 
Table 33: 2x2 Table used for the evaluation of the differences in the risk of 
self harming between the anxiety and stress sensitivity sub-types (patients 
with schizophrenia and schizoaffective disorder). 
 History of self harming 
Positive Negative Total 
SCIPS diagnosis 
 
Anxiety sub-type 17 12 29 
Stress sensitivity sub-
type 
28 48 76 
Total 45 60 105 
 
17.5.4 Differences in demographics as confounding factors between the anxiety and 
stress sensitivity sub-types 
In order to assess the influence of demographic parameters (i.e., age, sex, in or out-patient, 
and years after the age of onset of the first psychotic episode) as confounding factors 
(Table 34), the 2 sub-types were compared. Participants with a diagnosis of 
schizoaffective disorder were included in the analysis, and a Chi square test was 
conducted for gender in each of the 2 sub-categories, while Mann-Whitney U Test was 
carried out for the other 2 parameters. No statistically significant differences were found 
in terms of gender (χ2 = 1.6, df = 1, p = 0.204, n = 105) (Table 35), proportion of 
outpatients (χ2 = 2.2, df = 1, p = 0.141, n = 105) (Table 36), and years since the age of 
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onset (p = 0.662). However, the differences in age between the 2 groups were statistically 
significant (anxiety > stress sensitivity, p = 0.003). 
 
Table 34: Participant demographics in the 2 sub-groups (patients with 
schizophrenia and schizoaffective disorder in Japan). 
 Anxiety sub-type  
(n = 29) 
Stress sensitivity 
sub-type (n = 76) 
Mean age (SD) 
Median age (IQR) 
Male, No. (%) 
Outpatients, No. (%) 
Mean years after the 
age of onset (SD) 
Median years after 
the age of onset 
(IQR) 
50.5 (8.9) 
53.0 (42.0-58.0) 
16 (55.2) 
25 (86.2) 
20.0  (9.9) 
 
 
20.0 (11.0-28.5) 
42.3 (12.6) 
40.5 (32.0-53.8) 
52 (68.4) 
72 (94.7) 
19.3 (12.6) 
 
 
18.0 (10.0-29.0) 
 
 
Table 35: 2x2 Table used for the evaluation of the differences in sexuality 
between the anxiety and stress sensitivity sub-types (patients with 
schizophrenia and schizoaffective disorder). 
 Sex 
Male Female Total 
SCIPS diagnosis 
 
Anxiety sub-type 16 13 29 
Stress sensitivity sub-
type 
52 24 76 
Total 68 37 105 
 
 
Table 36: 2x2 Table used for the evaluation of differences in proportion of 
outpatients between the anxiety and stress sensitivity sub-type (patients 
with schizophrenia and schizoaffective disorder). 
 Outpatients Inpatients Total 
SCIPS diagnosis 
 
Anxiety sub-type 25 4 29 
Stress sensitivity sub-
type 
72 4 76 
Total 97 8 105 
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17.6 Conclusion 
No differences were found between the anxiety and stress sensitivity sub-types in the 
total time spent in hospital over a period of 3 years after the date of the first admission 
(variable 1) and the duration of the first hospitalization (variable 2). In addition, in terms 
of the risk of self harming, no statistically significant differences were found between 
these 2 sub-types, and the RR for self harming was also not statistically significant. 
Nevertheless, when the participants with a diagnosis of schizoaffective disorder were 
included, and a Chi square test was conducted again, a statistically significant difference 
was found in the risk of self-harm between the anxiety and stress sensitivity categories. 
Possible interpretations of these results are discussed in Chapter 18 (“Discussions”). 
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Chapter 18: Discussion 
 
18.1 Overview 
This discussion begins with a brief overview of the main findings of this thesis, and the 
demographics of the study’s samples are also considered. Since the results should be 
interpreted on the basis of the research’s methodological limitations, its strengths and 
weaknesses are discussed in so far as they relate to the properties of the SCIPS 
assessment tool, the study’s design and measurement selection. The key findings are then 
examined in terms of the relevant literature, and clinical implications are considered. 
Finally, suggestions for future research are highlighted. 
 
In this study, the SCIPS was developed as a way of sub-grouping patients with 
schizophrenia into 4 sub-categories (Chapter 11, “Development of the English and 
Japanese versions of the SCIPS”). The psychometric properties of the tool were then 
evaluated (Chapter 13, “Psychometric Evaluation of the English and Japanese versions of 
the SCIPS”). Kappa statistics were used to assess reliability, while both they and 
sensitivity and specificity were used to test validity. In this process, the optimum cut-off 
point for differentiation between the anxiety and stress sensitivity sub-types of the illness 
were determined. When the optimum cut-off point was used to make a distinction, both 
the English and Japanese versions of the SCIPS revealed high inter-rater and test-retest 
reliability, as well as high concurrent validity. 
 
In preparation for the assessment of the construct validity of the differentiation between 
the anxiety and stress sensitivity sub-types, the FNE was revealed to be associated with 
delusional thinking, and could, thus, be used as an external evaluator for classification 
purposes (Chapter 12, “Relationship between the Fear of Negative Evaluation from 
Others and Delusions”). This part of the study used a cross-sectional design for both the 
non-clinical and the patient samples. 
 
Thereafter, prospective research was conducted to establish the longitudinal stability of 
the sub-groups determined with the SCIPS. This part of the study revealed that the SCIPS 
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diagnoses for 2 of the 4 sub-types, namely drug related and stress sensitivity, were stable 
over a period of at least 6 months, though the stability of those for anxiety sub-type was 
not satisfactory. 
 
The scores of the selected psychometric scales (the BCSS and the BFNE for the UK 
sample, and the BCSS, BFNE and BDI-II for the Japanese sample) were compared 
between the anxiety and stress sensitivity categories, but no significant differences were 
found (Chapter 15, “Construct Validity of the Conceptualisation of the Anxiety and 
Stress Sensitivity Sub-types: A Preliminary Study in the UK”, and Chapter 16, 
“Construct Validity of the Conceptualisation of the Anxiety and Stress Sensitivity Sub-
types: A Study with a Larger Sample in Japan”). In addition, in terms of the relationship 
between the SCIPS and DSM sub-types, no significant association was detected between 
the distinction of the two SCIPS sub-groups, namely the anxiety and stress sensitivity 
sub-types, and any of the DSM sub-types. A cross-sectional design was used for this part 
of the study. 
 
A preliminary analysis of retrospective cohort data, which explored the differences 
between the anxiety and stress sensitivity sub-types in relation to hospitalization and the 
risk of self harming, was also conducted. Two variables, namely: 1) total time spent in 
hospital over a period of 3 years after the date of first admission and 2) duration of the 
first hospitalization, were compared between these 2 groups. Differences between them in 
terms of the risk of self harming were also examined. However, once again, no 
statistically supported differentiation was found, although when patients with a diagnosis 
of both schizoaffective disorder and schizophrenia were included in the analysis, the 
difference in the risk of self harming was revealed to be statistically significant by the 
Chi-square test. 
 
18.2 Is the sample used for the studies in this thesis representative of patients with 
schizophrenia? 
Subjects were recruited from psychiatric outpatient clinics and psychiatric hospitals in an 
adult community mental health service in the UK, and, in Japan, from psychiatric 
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hospitals which function like these community mental health teams. Accordingly, the 
patients included in the research were expected to be representative of those who are 
diagnosed with schizophrenia through the community mental health services in both 
countries.  
 
Our patient samples in the UK (χ2 = 7.5, df = 1, p = 0.006, n = 42) and Japan (χ2 = 5.3, df 
= 1, p = 0.021, n = 117) included more males than females, which is consistent with 
previously published studies (Lewine, Burbach, & Meltzer, 1984; Thornicroft et al., 
2004). Moreover, the demographics in terms of marital status were similar to those 
previously reported (Thornicroft et al., 2004); of the individuals who participated in this 
particular study and had diagnoses of schizophrenia (n = 404), 57% were men, 65% were 
single, and 17% were married. 
 
Other studies have suggested that there are no significant differences between males and 
females in terms of the prevalence of schizophrenia (Bhugra, 2005), and it is, indeed, still 
a matter of debate whether the proportion of men with the illness is greater than that in 
the female population. However, the fact that the percentage of men with schizophrenia 
in the samples in the current study is higher than in the general population,  may be 
explained by the influence of sampling bias. As described in Chapter 10 “Method”, 
patients who might be suitable participants in the research were nominated by their 
consultants (see sections 10.9.1, “Recruitment of participants in the UK” and 10.9.4, 
“Recruitment of participants in Japan”), meaning that not all of those diagnosed with 
schizophrenia at these institutions were recruited. Accordingly, it is possible that this 
process may have caused some imbalance in the proportion of males and females in the 
sample.  
 
Alternatively, the differences in the male/female split might also be related to 2 other 
factors. Firstly, the high number of men in the drug related sub-type may have increased 
the proportion of male patients in the sample. Indeed, in the UK, all of those put into this 
sub-group (n = 13) were men, and, if they were excluded from the analysis, the difference 
between the numbers of male and female participants was not statistically significant (χ2 
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= 1.8, df = 1, p = 0.145, n = 29). Similarly, in the sample in Japan, 4 of the 5 patients in 
the drug related sub-group were male (80.0%), and if they had been excluded from the 
analysis, the difference between the numbers of male and female participants was, again, 
not significant (χ2 = 3.6, df = 1, p = 0.058, n = 112).  
 
Secondly, the difference in the expression of schizophrenia between men and women 
might have caused some discrepancy. Evidence from a large body of literature 
demonstrates that the modal age at onset for men is between 18 and 25 years, whereas it 
is between 25 and the mid-30s for women (American Psychiatric Association, 2000). 
This means that the age at onset in the former gender is lower than in the latter. 
Consequently, at least in theory, if the lifetime prevalence of schizophrenia is the same in 
males and females, and this statistic is compared over the same range of ages, the 
presence of the illness may be greater in men than in women.  
 
Whatever the circumstances, the influence of sampling bias should always be carefully 
considered when the results in the present study are interpreted. For instance, patients 
who were either mentally unstable, or were reluctant to participate in the research, would 
have been excluded by their consultants. In other words, those whose ability to 
communicate was grossly impaired, or who had limited insight into their condition, were 
not included in the sample, which may have affected the representative nature thereof. 
 
Accordingly, so far as the psychometric properties of the SCIPS are concerned, although 
acceptable inter-rater reliability and concurrent validity were indicated in 2 different 
settings (i.e., the UK and Japan), the tool’s reliability and validity could have been 
enhanced if interviews has also been conducted with patients whose communication 
levels were impaired and with those who had limited insight into their mental health (this 
topic will be discussed in greater detail below).  
 
18.3 Strengths and weaknesses of the SCIPS 
The English version of the SCIPS was developed as a way of sub-grouping patients with 
schizophrenia into 4 sub-types: drug related, traumatic, anxiety and stress sensitivity, and 
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was revealed to have high face validity. The optimum cut-off point for differentiation 
between the latter 2 sub-groups was also determined in order to achieve the best inter-
rater reliability and concurrent validity, meaning that a SCIPS diagnosis obtained with 
these diagnostic criteria did have acceptable levels thereof. The test-retest reliability of 
the diagnosis was also established. As a consequence, this interview tool is able to be 
used effectively in both research and clinical settings.  
 
The Japanese version of the SCIPS was also established with high face validity. To 
prepare this test, the English example was translated into Japanese, and a back translation 
procedure was utilised, as described in Chapter 11 (see section 11.3, “Preparation of the 
Japanese version of the SCIPS”). Four psychiatrists who had extensive clinical 
experience with the diagnosis and treatment of schizophrenia, and could understand 
Japanese, reviewed that version, and the face validity of the interview was, ultimately, 
confirmed. The psychometric properties of this Japanese version were, then, tested, as 
had occurred with the English document. Inter-rater and test-retest reliability, concurrent 
validity, and the sensitivity and specificity of a diagnosis with this Japanese version of the 
tool were revealed to be acceptable. 
 
The determination of a SCIPS diagnosis was based equally on age and mode of onset, 
pre-morbid adjustment, and aetiology, such as drug-misuse and traumatic experience. A 
high level of stability is to be expected with this system, because these properties cannot 
change after the onset of the disease. At the same time, significant predictive value is also 
anticipated, because the factors used for classification purposes have been revealed to 
predict the clinical outcome of schizophrenia or psychosis (Chapter 4, “Psychosocial 
Factors and Psychosis”). 
 
However, as set out in Table 21 (Chapter 13, “Psychometric Evaluation of the English 
and Japanese Versions of the SCIPS”), the inter-rater reliability of some of the items in 
the tool (i.e., items 1-2, 2-2 and 2-3 of the English version and items 1-2 and 2-2 of the 
Japanese version) was comparatively low. Ambiguity about what was being asked and 
rated may have been the cause of this. Accordingly, the reliability of these items could be 
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improved by providing a more detailed description of the information required for the 
assessment of each of these elements. We, therefore, plan to make some further 
refinements, with the aim of improving the reliability of the SCIPS diagnoses.  
In a process of exploring the cause of the low inter-rater reliability for each of the items, 
it was noticed that one interviewer included the second or later psychotic episodes for the 
assessment of the mode of onset (item 1-2) in Japan. That is to say, the period taken for 
the development of schizophrenia until the peak of the whole course of the illness was 
rated as a mode of onset for some of the participants, though this item aimed to assess the 
interval between the start and the peak of the first psychotic episode. Accordingly, a 
specific explanation will be additionally given in the SCIPS to emphasise that item 1-2 
should be rated with regard to the first psychotic episode. 
  
Although the SCIPS assessment tool may be useful in both research and clinical settings, 
and may well also improve the reliability of the classification scheme, it is still debatable 
whether it would be applicable to all patients with schizophrenia. Indeed, most of the 
participants in the present study were outpatients, and all of them agreed to be 
interviewed twice. Accordingly, conducting the interview with those who are in hospital 
with relatively severe conditions and/or reluctant to talk about their situations may be 
more difficult. Consequently, further investigation might be appropriate to establish the 
reliability and validity of the SCIPS in a broader spectrum of patients with the illness, 
including individuals whose communication levels were impaired and with those who 
had limited insight into their mental health. 
 
Moreover, there may be a limitation in accuracy of the sub-types determined with the 
highest achievable validity in this study. Information from the case notes might have been 
imprecise to some extent and led to incorrect sub-grouping of the participants. In other 
words, the sub-groups determined with the SCIPS might have been more valid for some 
of the participants than those with the highest achievable validity used in the assessment 
of the concurrent validity. This may have reduced the magnitude of coincidence between 
the former and the latter (kappa coefficient = 0.73 in the UK and = 0.83 in Japan, for the 
concurrent validity), though the level thereof was still acceptable.    
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There are 6 other problems which may decrease the validity of the SCIPS’ diagnoses. 
Firstly, the stressful life events listed in the SRRSQ may not cover all of the patients’ 
relevant experiences. In other words, some significant and stressful events might be 
ignored in the process of making diagnosis with the SCIPS. Nevertheless, the SRRSQ is a 
well established scale, and has been widely used in clinical research (Abel et al., 1999; 
Lynch et al., 2005). Consequently, in order to achieve high reliability for the diagnoses in 
the current study, only the events included in the SRRSQ were rated as being stressful. 
However, in clinical terms in particular, life experiences which are not listed in this tool 
could also be rated as ‘stressful’ if it is apparent that they preceded the onset of a patient’s 
first psychotic episode and caused significant upset.  
 
Secondly, childhood traumatic experiences are assessed with a single question, and no 
account was taken of duration, or the severity of the abuse, in item 3.2. This may 
decrease the validity, and even the reliability, of an assessment of this item. However, 
questions about early childhood trauma may cause a great amount of stress in individuals 
who have had such experiences, and it is important for such questions to be addressed 
with minimum upset being brought about in a respondent. Moreover, it is also essential to 
maintain the clinical utility of the SCIPS by minimising the number of questions therein 
and total time taken for the interview. It was therefore decided not to include additional 
questions in the instrument relating to the childhood trauma. 
 
Thirdly, the influence of recall bias may have an impact on the validity of a diagnosis. 
Patients might not be able to correctly remember all of the information which is required, 
and may even give incorrect answers to the questions included in the SCIPS interview. 
This could lead to a misdiagnosis of the sub-types of schizophrenia. For instance, and in 
so far as we discussed this issue with all of the raters who interviewed the patients in this 
present study, a few of the participants (2 in the UK and around 5 in Japan) had difficulty 
in reporting the chronology of the start of their psychotic symptoms and their use of illicit 
drugs.   
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Fourthly, the conceptualisation of psychosis that emerged herein, and upon which this 
work is based, is on a vulnerability-stress continuum, which may lead to there being some 
difficulty in differentiating between the groups. This was particularly apparent with the 
anxiety and stress sensitivity categories, but refinement of the criteria did make allocation 
thereto both possible and reliable.  
 
Fifthly, it is questionable whether the drug related sub-group is homogeneous. The 
substances listed in the diagnostic criteria have a number of different characteristics in 
terms of their impact on patients. For example, in one study, cannabis use was revealed to 
be associated with greater pre-morbid adjustment, while the use of stimulants or 
hallucinogens was not (Arndt et al., 1992). These drugs do, however, have at least 1 
common feature - they all appear to be able to induce psychotic symptoms (Angrist et al., 
1974; Arndt et al., 1992). Furthermore, specific psychosocial interventions, which 
broadly target substance misuse in people with psychosis, have been developed and 
shown to be effective (Haddock et al., 2003; James et al., 2004; Wright et al., 2008). 
Nevertheless, sub-classification according to which kinds of drugs a patient uses might 
need to be considered in the future. The potential overlap between the traumatic and drug 
related groups may also need further exploration, although it did not emerge as a 
significant complicating factor in this study.   
 
Sixthly, the SCIPS diagnostic criteria do not allow for the co-existence of the anxiety or 
stress sensitivity classifications with any other sub-types. Though a hierarchical system is 
employed and the co-existence of the sub-types is not allowed in the current criteria, 
occurrence of such a situation should be taken into consideration in reality. Therefore, in 
the future, modified diagnostic criteria, in which the anxiety and stress sensitivity sub-
types could exist with other sub-groups, might have to be provided.  
 
In conclusion, the SCIPS is a promising tool with which to sub-group patients with 
schizophrenia according to this recently developed classification scheme. The semi-
structured interview achieves acceptable inter-rater and test-retest reliability, and 
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concurrent validity. Accordingly, it can now be used to test the validity of the 
classification itself.   
 
18.4 Strengths and weaknesses of the methodology: general issues 
18.4.1 Application of the SCIPS for evaluating the stability and construct validity of 
the classification scheme 
As discussed above, and with acceptable inter-rater reliability and concurrent validity, the 
SCIPS was developed as an instrument with which to sub-group patients with 
schizophrenia. Then, in order to evaluate the stability and construct validity of the 
classification scheme, the present study employed the tool to determine the sub-types of 
the participants’ illnesses. Thus, sufficient reproducibility and concurrent validity was 
expected, at least in terms of the sub-categories used herein.  
 
Nevertheless, the SCIPS does have limitations, as discussed above (see section 18.3, 
“Strengths and weaknesses of the SCIPS”), and these must be borne in mind whenever 
the interview element thereof is used in clinical or research settings. 
 
18.4.2 Selection of psychometric scales 
The use of standardized self-reporting questionnaires is one of the major strengths of this 
study. All of these have been previously used in psychotic disorders’ research and are 
available in both English and Japanese. All of them (both the English and Japanese 
versions) have good psychometric properties, and are of a reasonable length, meaning 
that they could be used as a part of the assessment process in this work.  
 
There is, however, a major problem with regard to the use of these questionnaires for the 
evaluation of the construct validity of the sub-types of schizophrenia. The BFNE, BCSS, 
PDI-21 and BDI-II scores of patients with the illness can change within a few months or 
a year, apparently in conjunction with alterations in their symptomatology. This means 
that these scales might not be suitable for assessing the construct validity of the sub-types, 
which are expected to be stable. Indeed, some of the participants told their interviewers 
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that their scores on these questionnaires had changed over time, and asked about which 
period they should base their answers upon. We, therefore, instructed people in the 
patients sample in the UK and Japan to respond to these self-report scales based upon 
how they had been feeling over a specified period prior to taking the tests (i.e., 1 month 
for the BFNE, BCSS and PDI-21, and 2 weeks for the BDI-II). Accordingly, when the 
protocol was prepared for this study, the importance of using questionnaires which were 
more stable over time should have been considered. 
 
18.4.3 Limitations of cross-sectional study design 
Although the cross-sectional study design is useful for highlighting an association 
between 2 or more factors, it cannot demonstrate causal relationships between them. 
Indeed, it is almost impossible to deduce which factor is the cause of the illness, and 
which is the consequence, even when the link between them is revealed to be statistically 
significant. This limitation is discussed in detail below with regard to the study about the 
relationship between the fear of negative evaluation from others and delusions. 
 
18.4.4 An issue relating to multiple comparisons 
A number of hypotheses were tested in the present study. That is to say, in a number of 
situations, one sample was used for not less than two comparisons in the analysis. 
Consequently, probability of finding a significant difference just by chance (a Type I 
error) would have become higher (Altman, 1991). Accordingly, the results, especially the 
statistically significant ones, from the comparisons made in this thesis should be 
interpreted cautiously.   
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18.5 Discussion of specific issues arising out of each study in this thesis: 
interpretation of the results and their clinical implications 
18.5.1 Relationship between the fear of negative evaluation from others and 
delusions 
As described in Chapter 12 (“Relationship between the Fear of Negative Evaluation from 
Others and Delusions”), the present study demonstrated the association between FNE and 
delusional ideation in a non-clinical population. Martin & Penn’s earlier research (2001), 
which similarly revealed the relationship between FNE and sub-clinical paranoid 
ideations in a non-clinical population, was therefore replicated herein with the non-
clinical sample in Japan.  
 
A similar link between FNE and delusional ideations was also demonstrated in this study, 
in patients with schizophrenia. In fact, the BFNE and PDI-21 scores were mildly 
associated with each other.  
Accordingly, although the influence of selection bias should be considered carefully, it 
can be concluded that the association between FNE and delusional thinking is a universal 
phenomenon, which is independent of where a person is from and whether or not he has 
schizophrenia. Indeed, a similar relationship was also found in the patients who were 
recruited in the UK for the study herein (Spearman’s r = 0.51, 95%CI = 0.24-0.71, p = 
0.001, n = 40).  
The linear regression analyses in both the non-clinical and clinical samples revealed that 
the relationships between FNE and delusional ideations were not confounded by 
depression, one of the key factors contributing to the development of psychotic symptoms 
(Drake et al., 2004; Freeman & Garety, 2003; Hafner et al., 2005; Iqbal et al., 2000; 
Krabbendam et al., 2005; Smith et al., 2006).  
 
Although the PDI-21 and BFNE scores seem to be higher in the student sample than in 
the patient sample (Table 12), these scores cannot be compared directly between the two 
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groups because of the reason described in Chapter 10 (see section 10.9.8, “Data 
collection and the assessment process”). 
 
These results lead us to conclude that FNE is clinically significant in terms of the 
development of delusions in patients with schizophrenia. However, these findings could 
be interpreted in one of two ways: 1. a high FNE is causal, and contributes to the 
development, maintenance or exaggeration of delusions; 2. a high FNE is a consequence, 
with delusions leading to an increase in this fear.  
 
A high FNE could be a causal factor in the development, maintenance or elevation of 
delusional ideations, and may, therefore, be a potential target for both the psychological 
and pharmacological treatment of patients with delusions. CBT is a psychological therapy 
which may be able to control FNE, and we are currently in the process of developing a 
version which targets it specifically. Similarly, in terms of the pharmacological treatment 
of FNE in patients with delusions, psychotropic drugs which can reduce this symptom 
might be used for patients with schizophrenia. Antidepressants, such as selective 
serotonin reuptake inhibitors (SSRIs) may be candidates, although the specific effect 
thereof on reducing FNE remains to be demonstrated. 
 
Even if high FNE is a consequence of delusions, it would still be a potential variable 
which could have an impact on the estimation of the severity thereof. In other words, 
even when a direct evaluation of delusions is difficult, FNE might still be assessed and 
used as a sensitive proxy indicator. Indeed, it is often the case that patients with 
schizophrenia demonstrate poor insight into, and decline to talk about, their delusions, 
thus making it difficult to directly evaluate the severity of this psychotic symptom. In 
such a circumstance, patients may feel more comfortable in talking about their FNE than 
their delusions. Moreover, a high FNE could be a maintaining factor, and may, thus, be a 
target for psychological or pharmacological intervention. 
 
There are 2 main limitations in the present study. 
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Firstly, the research employed a cross-sectional design, and it is therefore impossible to 
demonstrate a causal relationship between FNE and delusional ideations. In other words, 
we do not know from our results whether a high FNE leads to the development of 
delusions, or vice versa. Therefore, it is still unclear if either a reduction in FNE 
contributes to any improvement in the severity of delusions during a course of treatment, 
or if it is a suitable target for relevant psychotherapy. The implications for future research 
into the establishment of this causal relationship are discussed below (see section 18.7.1, 
“Assessment of the causal relationship between the fear of negative evaluation from 
others and delusions”). 
Secondly, the observed associations could be explained by content overlap between a 
number of the items in the BFNE and the PDI-21. For example, item 15 in the latter (“Do 
you ever feel that people look at you oddly because of your appearance?”) overlaps with 
what is asked in the BFNE. Moreover, individuals who answer ‘Yes’ to item 4 of the 
PDI-21 (“Do you ever feel as if you are being persecuted in some way?”) would naturally 
be concerned about negative evaluation from others. Yet, this overlap cannot explain 
away all of the associations between the BFNE and 5 of the 6 factors of the PDI-21 (see 
Table 17). For instance, factors 1: schizophrenia, 4: manic bipolar and 5: paranormal 
beliefs did not include any items whose content seemed to display a similarity, and yet 
they were still significantly associated with the BFNE in both the non-clinical and clinical 
samples. 
  
In conclusion, while also controlling for the effect of depression, the present study 
demonstrated the association between FNE and delusional thinking, both in the non-
clinical population and in patients with schizophrenia. It is possible that this link is a 
universal phenomenon, which is independent of where the person is from and whether or 
not he has the illness. Indeed, it was suggested in our research that FNE is clinically 
significant in terms of the psychopathology of delusions, and may well, therefore, be a 
potential target for both psychological and pharmacological treatments for patients with 
these symptoms. Finally, FNE might also be a good indicator of the severity of delusions, 
especially when their direct assessment is difficult. 
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18.5.2 Six month stability of the SCIPS diagnoses 
As described in Chapter 14 (“Six Month Stability of the SCIPS Diagnosis: A 
Longitudinal Study in Japan”), the study herein suggested that 2 of the sub-types of 
schizophrenia (drug related, anxiety and stress sensitivity) determined with the SCIPS 
were stable over a period of 6 months, though the stability of those for anxiety sub-type 
was not satisfactory.  
 
This instability of the sub-group was considered to be caused by inaccuracy of the 
information collected in the SCIPS interview. At least in theory, the factors assessed in 
the interview never change after the onset of psychosis, as discussed in Chapter 10 (see 
section 10.1, “Justification for the present study”). Therefore, main cause of the 
discrepancy between the 2 diagnoses with the interval could be the change of the ratings 
for any of these factors, which cannot occur theoretically. Accordingly, improvement of 
the stability could be achieved by collecting and using more accurate information for the 
SCIPS diagnosis. In other words, information from case notes or carers in addition to that 
from patients themselves can be used to improve the stability, as well as test-retest 
reliability, of the diagnosis. 
 
 This research was prospective in nature, and the categories were determined by 
interviewing the participants twice at 2 different times, with an interval of at least 6 
months between them. Unfortunately, there was only 1 patient in the traumatic sub-group 
in the sample, and this individual could not be followed up in the stability assessment.  
 
These results empirically support the theoretical expectation that our classification 
scheme would provide acceptably stable diagnoses of the sub-types of schizophrenia, as 
described in Chapter 10 (see section 10.1, “Justification for the present study”). Such 
stability may well be a major strength of the classification system because, as described 
in Chapter 3 (“Arguments on the Classification of Schizophrenia”), the instability of 
diagnoses has been suggested as a reason for reducing the usefulness of the sub-types of 
the illness that are defined by the DSM and ICD schemes. 
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Nevertheless, because its sample size is comparatively small, it is debatable whether the 
results of the current study can be generalised. In fact, our sample contained no patients 
in the traumatic category and only 2 in the drug related sub-group. In order to resolve this 
problem, a piece of work which adopts the same procedure as the research herein, but 
with a larger sample, including patients with the traumatic sub-type of schizophrenia, 
should be conducted. In addition, the follow up period in our study (6 months) is 
relatively brief, and stability in the longer term should also be explored in further work. 
The prevalence of the traumatic sub-type in the Japanese sample is similar to that 
expected from the results in earlier studies. No definite (0.0%), but 2 probable (3.2%), 
cases of borderline personality disorder among 63 patients with schizophrenia were 
reported in research conducted by Keshavan and his colleagues (Keshavan et al., 2005). 
In another piece of work, 1 (2.5%) of 40 individuals with the illness had a pre-morbid 
diagnosis of borderline personality disorder (Rodriguez Solano & Gonzβlez De Chβvez, 
2000). However, other studies have recruited significant numbers of such patients in the 
UK (Kingdon et al, submitted).  
 
There could be 3 explanations for this discrepancy. Firstly, some form of bias, including 
selection bias, may have caused the increase in the proportion of patients with the 
traumatic sub-type in other research. For instance, the prevalence of this category might 
be higher among patients from specific psychiatric units (e.g., forensic units). Secondly, 
issues about the reliability and validity of diagnostic procedures should also be 
considered. Even when the SCID is used to identify borderline personality disorder, the 
inter-rater reliability and concurrent validity of the diagnosis is not ideal. Indeed, it was 
reported that the former was comparatively low for diagnoses made by use of the 
Structured Interview for DSM-III-R Personality (SCID-II for DSM-III-R) (kappa 
coefficient = 0.58, to differentiate between patients with and without a personality 
disorder) (Pilkonis et al., 1995). In addition, in the same study, and in terms of the 
concurrent validity of the diagnosis, the kappa coefficient for the level of agreement 
between the SCID-II interview and the consensus diagnosis of whether there is a 
personality disorder or not was 0.37 (Pilkonis et al., 1995). 
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18.5.3 Construct validity of the distinction between the anxiety and stress sensitivity 
sub-types 
Despite our attempts to establish construct validity of the differentiation between the 
anxiety and stress sensitivity sub-types, no statistically significant differences were found 
between these 2 groups in terms of the scores of the selected psychometric scales. 
 
As discussed above (see section 18.4.2, “Selection of psychometric scales”), a possible 
reason for the absence of these distinctions is that the scores of the patients with 
schizophrenia sometimes changed over a period of a few months or longer, apparently in 
conjunction with alterations in their symptomatology. Indeed, the BFNE, BCSS and BDI-
II scores may not be constant over time, or even suitable for comparison between 
categories that are expected to be stable. 
 
It is, thus, important to identify psychometric scales which can both assess the properties 
that will not change over time, and differentiate between the anxiety and stress sensitivity 
sub-types. The construct validity of these sub-groups could, then, be established by using 
these psychometric scales. New criteria for the identification thereof are discussed below 
(see section 18.7.2, “Further evaluation of the construct validity of the distinction 
between the anxiety and stress sensitivity sub-types with the minimum influence of 
selection bias” and Table 37). 
 
With regard to the comparison of the SCIPS and the DSM sub-types, no association was 
suggested between these two classification schemes and the discriminant validity was 
indicated for the distinction between the anxiety and stress sensitivity sub-types (see 
section 16.6.4, “Comparison of the SCIPS and the DSM sub-types of schizophrenia”). 
Indeed, this result can be well explained by the premise that the approach employed in 
the SCIPS is different from that in the DSM, as described in Chapter 4 (see section 4.6, 
“A concept of clinical sub-groups integrating psychosocial factors”). However, there are 
2 major problems in this study. Firstly, both the SCIPS and DSM sub-types were 
determined for each participant by one interviewer and this might be a cause of bias.  
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Secondly, it is debatable if the diagnoses of the DSM sub-groups are valid enough. It 
seems difficult to collect sufficient information for a diagnosis of the DSM sub-types in 
only one interview with a participant, even when supplementing data are provided by 
psychiatric staff who is responsible for the patient (see section 10.8.5, “DSM sub-types”). 
Indeed, there is limited support for the concurrent validity of a diagnosis of the sub-types 
of schizophrenia according to the DSM-IV. Despite an extensive literature search, no 
article was found in which diagnoses of the sub-types according to the SCID, or the 
DSM-IV diagnostic criteria, were compared with the gold standard diagnoses thereof. 
 
18.5.4 Predictive value of the distinction between the anxiety and stress sensitivity 
sub-types 
Despite attempts to establish the predictive quality of the differentiation between the 
anxiety and stress sensitivity categories of schizophrenia, no statistically significant 
difference was found between these 2 sub-groups with regard to the variables selected for 
this study. 
 
Sampling bias in relation to the severity of patients’ conditions may have influenced the 
results. Most of the participants in Japan were recruited from day care units, and were 
experiencing a chronic clinical course. This meant that those who had a better clinical 
outcome and, therefore, did not need the continuous use of the mental health services, 
were not approached for this study. If patients in the anxiety sub-group had demonstrated 
better clinical results, and had, thus, required less regular access to treatment than those in 
the stress sensitivity category, this study may have included relatively severe cases of the 
former and mild cases of the latter. If this had happened, it might have been difficult to 
detect the differences which exist between these 2 sub-types in representative cases with 
schizophrenia. 
 
When participants with a diagnosis of schizoaffective disorder were included alongside 
those with schizophrenia, and a Chi square test was conducted, the patients with the 
anxiety sub-type not only had a higher risk of self harming than those in the stress 
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sensitivity sub-group, but this difference was statistically significant. This finding is 
consistent with the results of the work carried out by Pompili and his colleagues (2007), 
which revealed that schizophrenic patients with a good pre-morbid function are more 
likely to commit suicide. According to the diagnostic criteria, those with the anxiety form 
of the illness would have better pre-morbid functioning than those with the stress 
sensitivity sub-type.  
 
No statistically significant difference was found in terms of gender and status as 
outpatients between the 2 sub-types in our sample. These 2 variables did, therefore, not 
seem to be confounding factors causing an apparent difference in the risk of self-harm 
between the 2 categories. In terms of the age of the participants, the median age of those 
in the anxiety sub-group was higher than those with the stress sensitivity sub-type of the 
disease, and this difference was statistically significant. Consequently, this distinction 
may have caused the difference in the factor relating to the risk of self-harm. However, 
because there was no significant difference between these 2 groups in the number of 
years since the age of onset of the first psychotic episode, the increased risk of self-harm 
could not simply be explained by an increase in the length of time that a patient had 
suffered from schizophrenia or schizoaffective disorder.  
 
In any event, although the result obtained with the Chi square test was statistically 
significant, the RR indicated that the difference in the risk of self harming between the 2 
sub-types was not. Accordingly, the evidence is not strong enough to conclude that 
patients with the anxiety form of schizophrenia are more likely to harm themselves than 
those in the stress sensitivity sub-group. 
 
Moreover, the influence of selection bias in these circumstances should also be taken into 
consideration. If relatively severe cases of the anxiety sub-type had been selectively 
recruited for the study, as discussed above, the difference in the risk of self harming 
between these 2 sub-groups might have been exaggerated. In other words, we may have 
detected a difference which did not really exist in representative cases of schizophrenia 
and schizoaffective disorder. In addition, the reinclusion of the patients with 
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schizoaffective disorder into the analyses might be another cause of bias. Especially, this 
process could increase the risk of type I errors, or false positives, caused by multiple 
comparisons, as discussed above (see section 18.4.4, “An issue relating to multiple 
comparisons”). 
 
18.6 Implications for clinical practice of the SCIPS and the newly established sub-
grouping scheme 
18.6.1 General issues 
Antipsychotic medication and psychosocial interventions can be used together to 
substantially improve the likelihood of recovery from the symptoms of schizophrenia for 
many sufferers. However, there are 2 major problems, which have a negative impact on 
such treatment. Firstly, the term schizophrenia is itself associated with a major degree of 
stigma. Indeed, it has consistently proved difficult to use with many patients, who reject it 
either on the basis of the associations that it now has with aggressive behaviour and a 
deteriorating clinical course, or because they do not consider themselves to be unwell 
(British Psychological Society, 2000). 
 
Secondly, patients with a diagnosis of schizophrenia tend to be socially excluded 
(Kingdon et al., 2006) by the general population. Health promotion campaigns have had a 
marginal impact (Crisp et al., 2004), and concerns about the danger posed by those 
suffering from the disease have, if anything, become cemented in the public’s 
imagination (Department of Health, 2003). This is not simply due to a lack of knowledge, 
because campaigns to promote a biological model of schizophrenia have been successful 
in conveying this message. However, they may also have had the paradoxical effect of 
increasing social distancing (Angermeyer & Matschinger, 2005). 
 
In such a situation, our previous study (Kingdon et al., 2008a) suggested that using the 
terminology related to the 4 sub-groups of the illness significantly reduced the negative 
perceptions of medical students about those who suffer from the ‘group of 
schizophrenias’. Moreover, the terms for the sub-types, namely drug related, traumatic, 
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anxiety and stress sensitivity, might also be more acceptable to patients (Kingdon et al., 
2008b). The SCIPS would both provide strong empirical support for the classification 
scheme, and enable the dissemination of these terms, as well as the destigmatisation of 
people diagnosed with the disorder. 
 
Furthermore, in terms of its clinical application, the SCIPS might provide both clinicians 
and patients with a clear and broad understanding of the condition. In fact, consideration 
of the rating for each item in the SCIPS assessment would help all relevant parties to 
have a more comprehensive overview of an individual’s specific disorder. Moreover, sub-
grouping each patient according to the SCIPS would be helpful in the creation of an 
appropriate treatment plan. Indeed, it has been proposed that consideration of a patient’s 
sub-category of the illness, as well as all of the information gathered by the SCIPS, would 
be useful in enabling CBT to be targeted more effectively (Kingdon & Turkington, 2005).  
 
18.6.2 Application of the sub-types to patients with a diagnosis of psychotic 
disorders other than schizophrenia 
There is general agreement that patients who meet the criteria for schizophrenia, 
according to current versions of the DSM or ICD, are a very diverse group (Myin-
Germeys, Delespaul, & van Os, 2005; van Os, 2009), and there can be an overlap with 
bipolar disorder. A conference on ‘Deconstructing Psychosis’ held by the DSM-V 
prelude project (Allardyce et al., 2007; Kraemer, Shrout, & Rubio-Stipec, 2007; Regier, 
2007) recently included a recommendation that a broad psychosis spectrum should 
replace the current categories (First, 2007). This kind of approach is neither absolutely 
new nor unconventional, because patients with schizophrenia and other psychotic 
disorders (e.g., schizoaffective disorder and delusional disorder) have not been 
distinguished in a number of previously published articles (Barnes et al., 2008; Doering et 
al., 1998; Walshe et al., 2007). For instance, individuals with schizoaffective disorder and 
schizophrenia were recruited and assigned to the same group in a number of randomised 
controlled trials which evaluated the effectiveness of antipsychotics (Leucht et al., 2009; 
Meltzer et al., 2008; Robinson et al., 2006; Sikich et al., 2008). Furthermore, in most of 
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these studies (Robinson et al., 2006; Sikich et al., 2008), the differences in the different 
diagnostic categories were not considered. Thus, although further work is required to 
conclude that such an approach really is valuable, it may be clinically relevant to define a 
broad psychosis group in which patients with schizophrenia, schizoaffective disorder and 
delusional disorder are included, before then sub-grouping them into the 4 sub-categories. 
In these circumstances, the SCIPS may then be used to categorise patients belonging to 
this broad psychosis group.  
 
18.7 Implications for future research; building on the present study 
18.7.1 Assessment of the causal relationship between the fear of negative evaluation 
from others and delusions 
As discussed above (see section 18.5.1, “Relationship between the fear of negative 
evaluation from others and delusions”), it is important to demonstrate that there is a 
causal relationship between the FNE and delusional ideations. It is still questionable 
whether a reduction in the former symptom is either a suitable target for psychotherapy, 
or would contribute to any improvement over the course of treatment in the delusions that 
a patient is suffering from. A prospective experimental study which examines the 
effectiveness of CBT in the reduction of FNE in patients with delusions may, therefore, 
be valuable. Subsequently, if there is a reduction in FNE after CBT, which is then 
followed by an improvement in the extent of the delusions experienced by patients with 
psychotic disorders, a high FNE would have been proved to contribute to the 
development and/ or maintenance of this symptom. Accordingly, a randomised controlled 
study could be set up to compare the effects on the reduction in delusions of CBT and a 
control treatment. Although it is unclear if the FNE is a successful target for 
psychological intervention, it has been demonstrated that group cognitive behavioural 
therapy for social anxiety disorder has been effective in patients with schizophrenia, and 
did reduce their FNE (Kingsep, Nathan, & Castle, 2003). 
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18.7.2 Further evaluation of the construct validity of the distinction between the 
anxiety and stress sensitivity sub-types with the minimum influence of selection bias 
As discussed above (see sections 18.5.3, “Construct validity of the distinction between 
the anxiety and stress sensitivity sub-types” and 18.5.4, “Predictive value of the 
distinction between the anxiety and stress sensitivity sub-types”), the risk of selection 
bias and the use of psychometric variables which might change over time are 2 of the 
major problems in the present study. Accordingly, further research into the evaluation of 
construct validity in which these problems are dealt with could be planned. 
 
Firstly, with regard to the risk of selection bias, patients who are representative of both 
the anxiety and stress sensitivity sub-types of schizophrenia should be recruited. To do so, 
one possible procedure would be to approach such individuals at the time of either their 
first presentation at a psychiatric outpatient clinic, or at their first assessment by the 
community mental health service. This would enable us to contact all patients at about the 
time of the onset of their psychosis and to avoid selectively recruiting those with 
comparatively severe conditions. Early intervention teams, which are part of the mental 
health services available in the UK, are a promising resource. The difficulty of such an 
approach is that it would take a significant period of time to recruit a sufficient number of 
participants, because the annual incidence of schizophrenia is low, in the range of 0.5 to 
5.0 per 10000 people (American Psychiatric Association, 2000). For instance, a source of 
patients covering between 200, 000 and 2 million of the general population would be 
expected to provide approximately 100 individuals who have experienced a first episode 
of schizophrenia. Even if such a resource could be found, it would take at least a year to 
recruit this number of participants. 
 
Secondly, in relation to the psychometric variables which are stable over time, a further 
search for other such potential factors would be required. The new criteria, which consist 
of the 5 items listed in Table 37, could be used to identify candidates for these validators. 
Items 1 to 4 are the same as those listed in the criteria employed for the present study (see 
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section 8.2, “Criteria for the identification of the candidates to be validators”, and Table 
9). 
 
Table 37: The new criteria for the identification of potential validators. 
1. A variable which is not included in the SCIPS. 
2. A variable which is expected to differ among the sub-types. 
3. A variable which is suggested as being associated with the intensity of psychotic 
symptoms (e.g., delusions and hallucinations). 
4. A variable which is indicated as being a target for cognitive behavioural therapy 
(CBT). 
5. A variable which is stable over time. 
 
 
Pre and/or co-morbid diagnoses of schizoid personality disorder, which are revealed with 
the DSM diagnostic system (American Psychiatric Association, 2000), might be an 
option and able to differentiate between the anxiety and stress sensitivity sub-types. 
Patients in the latter sub-group, may be more likely to have a pre or/ and co-morbid 
diagnosis of schizoid personality disorder than those with the anxiety form thereof. 
However, the diagnostic criteria for both this personality disorder and the stress 
sensitivity category do overlap to some extent (i.e., both criteria include poor social 
relationships as an item). Thus, this variable would not fulfill item 1) of the criteria for 
the validators.    
 
Another possibility would be to use psychometric questionnaires for the assessment of 
temperament, which may differ between sub-types and is expected to be stable over a 
long period of time. This variable may also be a target for CBT. One study (Hori et al., 
2008) suggested that patients with schizophrenia had a unique personality profile when 
assessed with the Temperament and Character Inventory (TCI). This research also 
demonstrated that personality dimensions were moderately associated with the symptom 
dimensions assessed by the Positive and Negative Syndrome Scale (PANSS) (Hori et al., 
2008). However, in the same study, male patients were revealed to experience an even 
greater change in personality than females when both groups were compared to healthy 
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individuals, and instability of temperament is implicated in this finding. In addition, a 
further study, which also used the TCI (Fresan et al., 2007), suggested that novelty 
seeking and reduced cooperation, as character dimensions, were risk factors for violent 
behaviour in schizophrenic patients. 
 
Instruments for cognitive assessment might also be used to validate the classification. 
Although the level of cognitive functioning would not be stable over a long period of 
time, this variable might differ among the sub-types. Moreover, cognitive impairment 
might be a target for CBT. In fact, in one study (Brazo et al., 2002), it was suggested that 
schizophrenia could be characterised by heterogeneous cognitive dysfunctions. In this 
piece of work (Brazo et al., 2002), executive/attentional function and episodic memory 
were explored by conducting neuropsychological tests on individuals suffering from 
schizophrenia. These included the modified card sorting test (de Zubicaray et al., 1998; 
Nelson, 1976), the trail making test (Lezak, 1995), the Stroop colour-word test (Jensen & 
Rohwer, Jr., 1966; van der Elst et al., 2006) and the California verbal learning test 
(Hawkins & Wexler, 1999; Woods et al., 2006). Then, the differences in the 2 modals of 
cognitive functions, determined with the schedule for the deficit syndrome (Brazo et al., 
2002), was revealed among the sub-types. In order to test the cognition of patients with 
schizophrenia, brief assessment tools were also developed. For instance, the Brief 
Assessment of Cognition in Schizophrenia (BACS) and the Repeatable Battery for the 
Assessment of Neuropsychological Status (RBANS) were developed to analyse the 
cognitive levels of patients with the illness. Moreover, the psychometric properties and 
ease of use of these tests were demonstrated as being satisfactory (Chianetta et al., 2008). 
 
18.7.3 Evaluation of the construct validity of the classification system including the 
drug related and traumatic sub-types 
In this present study, the construct validity of the distinction between the anxiety and 
stress sensitivity sub-types were examined by exploring the potential differences between 
these categories. These 2 sub-groups were chosen for this assessment because there might 
be an overlap between the concepts behind them, and because the differentiation between 
  
 
169
them also seemed to be particularly important. However, the establishment of the 
construct validity of the other 2 categories – drug related and traumatic – is still important, 
and they have yet to be confirmed. 
 
Thus, in order to establish the construct validity of the classification system, including all 
of the 4 sub-types, another study should be conducted. The psychometric variables and 
procedure for recruiting subjects, which were discussed in the previous section, could be 
used therein, and if the early intervention teams can be a source of participants, as 
discussed above, the sample should be large enough to include a sufficient number of 
patients in the traumatic sub-group. This is because the prevalence of this sub-type 
among individuals with schizophrenia is comparatively low, and is not expected to 
exceed 5% (see section 18.5.2, “Six month stability of the SCIPS diagnosis”). 
  
18.8 Development of treatment interventions 
The overarching aim of this work was to explore whether clinically relevant sub-groups 
could be differentiated across the wide range of schizophrenia presentations seen in 
routine clinical practice. It is argued that this type of sub-grouping system should be 
simple and practical to use, and should highlight aspects of clinical presentation that, if 
addressed in treatment, may facilitate improved outcomes. Given this, future work could 
usefully focus on developing the links between the sub-types and treatment interventions. 
Initial work could involve defining the key components of treatment for patients 
presenting in each of the 4 sub-groups; a task that may involve conducting a number of 
case series. Treatments for those with the drug related sub-type could concentrate on 
controlling their drug misuse (e.g., as Haddock and colleagues (2003) have attempted). 
On the other hand, interventions for those with the traumatic sub-type may best focus 
more intensively on borderline personality issues and coping with early traumatic 
experiences. When clinicians plan treatment for patients with the anxiety sub-type, 
greater consideration may have to be given to the risk of self harming. In contrast, help 
for those in the stress sensitivity category could focus more heavily on therapeutic 
engagement and inter-personal functioning. In these circumstances, it would be valuable 
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to standardise these treatment approaches for each of the 4 sub-types, and then evaluate if 
they work better than the services currently offered to each group. 
 
18.9 Final conclusions 
Most of the studies which explore the classification of schizophrenia have focused on 
sub-grouping this mental disorder according to the symptom profiles of patients. The 
current research, however, made a novel attempt to sub-group a heterogeneous sample of 
individuals with the illness on the basis of psychosocial factors which would be relevant 
to treatment interventions and clinical outcome. A semi-structured interview, which we 
named SCIPS, was developed to sub-group patients into 4 categories, and its reliability 
and concurrent validity were established. The 6 month stability of SCIPS diagnoses of the 
drug related, anxiety and stress sensitivity sub-types was also indicated through a 
longitudinal study. A preliminary analysis provided little evidence of construct validity, 
though a comparison between the SCIPS and DSM sub-types indicated the discriminant 
validity of the differentiation between the anxiety and stress sensitivity sub-groups. The 
risk of self harming was, however, suggested as being associated with a distinction 
between these two categories – the anxiety and stress sensitivity – when the SCIPS was 
applied to a broader range of psychosis, including schizophrenia and schizoaffective 
disorder. Further investigations should be carried out into co-morbidity, clinical course 
and the outcomes for patients in each of the sub-groups. In the process of identifying 
candidate variables for the assessment of the construct validity of the sub-types, an 
association between FNE and delusional thinking was also demonstrated in both the non-
clinical population and patients with schizophrenia. 
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Appendix A: Semi-Structured Clinical Interview for Psychosis Sub-groups (SCIPS).  
 
 
 
 
 
 
    
Semi-Structured Clinical Interview for Psychosis Sub-
groups (SCIPS)  
 
Instructions: 
This interview is for use with patients with Schizophrenia, Persistent Delusional 
Disorders, Induced Delusional Disorder and Schizoaffective Disorders diagnosed with 
ICD-101, or Schizophrenia, Schizoaffective Disorder, Delusional Disorder, and Shared 
Psychotic Disorder diagnosed with DSM-IV2.  
 
This interview is semi-structured, and the interviewer may use additional questions and 
prompts to collect the required information. 
 
In order to sub-group a patient, the “SCIPS Interview” is completed first. Then, the 
“Rating Sheet for the SCIPS” is completed according to the results of the interview.  
Finally, the “Diagnostic Criteria for the SCIPS sub-groups” is used to sub-group the 
patient. Whenever an interviewer finds a difficulty in rating, Appendix 3, “The 
Diagnostic Guidelines for Psychosis Sub-types”, can be referred to clarify what should 
be rated for each item. 
 
 
                                                 
1 ICD-10: International Classification of Diseases 10th edition, World Health Organization. 
2 DSM-IV: Diagnostic and Statistical Manual for Mental Disorders 4th edition, American Psychiatric 
Association. 
 
  
 
172
  
SCIPS Interview 
1. Onset of psychosis 
Identify the initial psychotic symptom(s) experienced in the first psychotic episode and 
when they occurred3: 
………………………………………………………………………………………………
……………………………………………………………………………… 
 
1-1 Age at 1st episode 
Ask:  
How old were you when you first experienced psychotic symptoms (e.g., voices, 
paranoia)?    ……yrs  
RATE:   0  Under 30 / 1  30 or over 
 
1-2 Mode of onset 
Ask:  
How long did it take from when you first noticed that something was wrong with you to 
the peak of your first episode?  ………yrs……….mths 
(Prompt: Did your first psychotic episode develop quickly - within 1 month, or did it build 
up gradually, taking more than 1 month?)   
 
RATE:    0  Equal to or more than 1 mth / 1  less than 1 mth  
 
1-3 Triggers 
Show the Social Readjustment Rating Scale and Questionnaire (Appendix 1) to the 
patient.  
Ask:  
Was there any particular event that made you upset or stressed in the 3 months before the 
symptoms started?  Please identify the event(s) in the list, if any. 
  
• If no event was experienced, or the life change unit of the life event (which is 
shown in the list) is less than 40: 
RATE: 0  No, or minor, life event, and go to item 2-1. 
 
• If the life change unit of the life event is equal to or more than 40:  
 
Ask:  
Did it happen within 3 months of the onset of your psychotic symptoms? (Yes / No) 
Was there any change in your sleeping pattern just after the event? (Yes / No)  
If No to either or both of above, RATE: 0   No, or minor, life event 
If Yes to both of above,   RATE:  1   Stressful life event 
                                                 
3 Use information from clinical records or family interviews if available and necessary. 
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2. Social Functioning 
2-1 Change in work or school performance before the first episode 
Prompt: 
I would like to ask about your performance change during the period before you 
developed symptoms/problems.  
Ask:   
During this period did your work or school performance change?  
Did you find that you could do less work than before? (Yes / No) 
Did you find that you did your work slower than before? (Yes / No) 
If No to both of above, RATE: 2 No performance change and go to item 2-2 
If Yes to any of above, Ask: 
When did the change in your school/work performance start? Did it start within 6 months, 
or was it more than 6 months before you first experienced the [psychotic] symptoms you 
have described 
RATE:  0 change started within 6 mths of onset of first episode 
1. The change started at or more than 6 mths before onset of first episode 
 
2-2 Social relationships since early adolescence 
Prompt: 
 Now I would like to ask you about your early teens, meaning when you were aged 
between 12 and 15.  
Ask: 
i) Did you stay by yourself almost every day, or did you often get together with friends at, 
or after, school? Were you withdrawn or isolated, or did you get together with friends 
frequently? 
1. Withdrawn or isolated 
2. Getting together with friends frequently 
If rating is 2, RATE: 1 Moderate or good social relationships and go to item 2-3.  
 
Ask: 
ii) After that period in your later teens/early 20s, did you become more sociable? Were 
you still withdrawn or isolated, or did you start to get together with friends frequently? 
1. Still withdrawn or isolated 
2. Becoming sociable and getting together with friends frequently 
 
If rating is 1, RATE: 0 Poor social relationships 
If rating is 2, RATE: 1 Moderate or good social relationships 
 
2-3 Pre-morbid close relationships 
Ask: 
What was your marital status when you first became ill?4 
Single    
Married    
                                                 
4 Please note that all the questions in this item concern social relationships before the patient became ill. 
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Divorced    
Widowed   
If answer is other than single, RATE:  Pre-morbid close relationship: 1 Yes and go 
to item 3-1.  
 
Ask: 
Had you ever had someone you would describe as a boy or girlfriend? (Yes / No) 
If No, RATE: Pre-morbid close relationship: 0 No and go to item 3-1.  
  
Ask:  
Had you dated a girl/boyfriend constantly (more than once a week on average) for more 
than 6 months? (Yes / No) 
Had you ever lived with a partner for more than 1 month? (Yes / No) 
 
If Yes to either question, RATE:  Pre-morbid close relationship: 1 Yes  
If No to both, RATE:  Pre-morbid close relationship: 0 No    
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3.  Factors Related to Psychosis 
3-1 Usage of illicit drugs and their association with psychotic 
symptoms 
Ask: 
Have you ever used any kinds of illegal drugs? (Yes / No)  
If No (confirmed by other information sources, if possible),  
RATE:  Precipitating use of stimulants/hallucinogens: 0 No and go to item 3-2.  
 
Ask:  
What kind of drugs have you used? 
Stimulants/Hallucinogens: 
Amphetamine  (Yes / No)  
Cocaine  (Yes / No) 
LSD   (Yes / No)  
Ecstasy  (Yes / No) 
Cannabis  (Yes / No) 
Others5  (Yes: Name of the drug(s)?   /No) 
 
If a patient has not used any of the stimulants/hallucinogens listed above,  
RATE:  Precipitating use of hallucinogens: 1 No, and go to item 3-2. 
 
Ask: 
Were you taking them in the 2 weeks before the psychotic symptoms started? 
(Yes / No) 
 
If No, RATE:  Precipitating use of hallucinogens: 0 No  
If Yes, RATE:  Precipitating use of hallucinogens: 1 Yes 
 
3-2 Existence of early traumatic experience 
Prompt:  
Childhood traumatic experiences are often associated with mental health problems.  
Ask: 
Is it alright for me to ask you if you have had any such experiences?  (Yes / No) 
 
If No, RATE: Traumatic experience: 0 Not discussed.  
If Yes, proceed: 
 
Ask: 
Do you believe that you were emotionally or sexually abused in your childhood (under 
18)? (Yes/ No) 
If No, RATE: Traumatic experience: 1 No, and go to item 3-3. 
                                                 
5 If the patient has used any other kind of drugs which are proved to cause psychotic symptoms (e.g. 
diethylpropion), record their names here.  
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If Yes, RATE: Traumatic experience: 2 Yes 
 
Ask: 
Have you discussed it with your care manager/psychiatrist/therapist?   
If Yes, no action necessary. 
If No, ask: 
Would you like me to pass what you have said onto your care 
manager/psychiatrist/therapist? 
 
3-3 Borderline personality disorder 
Diagnose according to whether patient meets DSM-IV criteria (See Appendix 2)  
 
RATE: Diagnosis of borderline personality disorder: 0 No / 1 Yes 
 
YK/DK       1st November 2008 
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Rating Sheet for the SCIPS 
 
1-1. Age at 1st episode? 
0. Under 30 
1. 30 or over 
1-2. Mode of onset? 
0. Equal to or more than 1 month  
1. Less than 1 month  
1-3. Triggers? 
0. No, or minor, life event 
1. Stressful life event 
2-2. Social relationships since early adolescence? 
0. Poor   
1. Moderate or good 
2-3. Pre-morbid close relationships? 
0. No   
1. Yes   
 
Scores for differentiation between the 
anxiety and the stress sensitivity sub-groups 
(A) Number of items which are rated 
as ‘1’ (in items 1-1, 1-2, 1-3, 2-2 and 
2-3) (0-5)  
 
(B) Number of items which are rated 
as ‘0’ (in items 1-1, 1-2, 1-3, 2-2 and 
2-3) (0-5) 
 
 
3-1. Precipitating use of hallucinogens? 
0. No   
1. Yes    
3-2. Traumatic experience? 
0. Not discussed  
1. No    
2. Yes   
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3-3. Borderline personality disorder? (Diagnosed with DSM-IV) 
0. No   
1. Yes   
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Diagnostic Criteria for SCIPS Sub-groups 
 
• Diagnostic criteria for the drug related and traumatic sub-groups 
 
If Yes for 3-1: precipitating use of hallucinogens, 
SUB-GROUP: 1. Drug related; 
 
If Yes for both 3-2: traumatic experience and 3-3: borderline personality disorder,  
SUB-GROUP: 2. Traumatic; 
 
If the patient is sub-grouped as being drug related and/ or traumatic, stop here. 
 
If No for 3-1 and either of 3-2 or 3-3,  
go to “Diagnostic criteria for the anxiety and the stress sensitivity sub-groups”. 
  
• Diagnostic criteria for the anxiety and the stress sensitivity sub-groups 
 
If (A) Number of items which are rated as ‘1’ shown in the table: “Scores for the 
differentiation between the anxiety and the stress sensitivity sub-groups” is equal to or 
more than 3,  
SUB-GROUP: 3. Anxiety; 
 
If (B) Number of items which are rated as ‘0’ shown in the table: “Scores for 
differentiation between the anxiety sub-group and the stress sensitivity sub-group” is 
equal to or more than 3,  
SUB-GROUP: 4. Stress sensitivity. 
 
 
[Note: where items cannot be scored, or adequate information is not available, it may not 
be possible to determine sub-types.] 
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 Appendix 1: The Social Readjustment Rating Scale and Questionnaire (Life 
Change Unit >= 40). 
Life Experience Life Change 
Units 
Death of spouse 100 
Divorce 73 
Marital separation 65 
Jail term 63 
Death of close family member 63 
Personal injury or illness 53 
Marriage 50 
Fired at work 47 
Marital reconciliation 45 
Retirement 45 
Change in health of family member 44 
Pregnancy 40  
Sex difficulties 39 
Gain of new family member 39 
Business readjustment 39 
Change in financial state 38 
Death of close friend 37 
Change to different line of work 36 
Change in number of arguments with spouse 35 
Large mortgage 31 
Foreclosure of mortgage or loan 30 
Change in responsibilities at work 29 
Son or daughter leaving home 29 
Trouble with in-laws 29 
Outstanding personal achievement 28 
Wife begins or stops work 26 
Begin or end school 26 
Change in living conditions 25 
Revision of personal habits 24 
Trouble with boss 23 
Change in work hours or conditions 20 
Change in residence 20 
Change in schools 20 
Change in recreation 19 
Change in church activities 19 
Change in social activities 18 
Small loan 17 
Change in sleeping habit  16 
Change in number of family get-togethers 15 
Change in eating habits 15 
Vacation 13 
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Christmas 12 
Minor violation of the law 11 
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Appendix 2: Diagnostic Criteria for Borderline Personality Disorder in DSM-IV. 
 
A pervasive pattern of instability of interpersonal relationships, self-image, and affects, 
and marked impulsivity beginning by early adulthood and present in a variety of contexts, 
as indicated by 5 (or more) of the following: 
   
(1) Frantic efforts to avoid real or imagined abandonment. Note: do not include suicidal 
or self-mutilating behaviour covered in Criterion 5. 
(2) A pattern of unstable and intense interpersonal relationships characterized 
by alternating between extremes of idealization and devaluation.  
(3) Identity disturbance: markedly and persistently unstable self-image or sense of self. 
(4) Impulsivity in at least two areas that are potentially self-damaging (e.g., spending, 
sex, substance abuse, reckless driving, binge eating). Note: do not include suicidal or 
self-mutilating behaviour covered in Criterion 5. 
(5) Recurrent suicidal behaviour, gestures, or threats, or self-mutilating behaviour 
(6) Affective instability due to a marked reactivity of mood (e.g., intense episodic 
dysphoria, irritability, or anxiety usually lasting a few hours and only rarely more 
than a few days). 
(7) Chronic feelings of emptiness 
(8) Inappropriate, intense anger or difficulty controlling anger (e.g., frequent displays of 
temper, constant anger, recurrent physical fights) 
(9) Transient, stress-related paranoid ideation or severe dissociative symptoms 
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Appendix 3: Diagnostic Guidelines for Psychosis Sub-types 
Drug Related Psychosis 
Core characteristics 
The person has used at least 1 of the stimulants/ hallucinogens which are listed below in 
the 2 weeks before the onset of psychotic symptoms. 
 
List of hallucinogens: 
 
Amphetamine, cocaine, LSD, ecstasy, cannabis, others6 
 
Supporting characteristics 
Age of onset: 
• Usually in their teens or 20s. 
Mode of onset:7 
• Either acute or insidious. 
Lifetime pattern of social interaction: 
• Individuals with this sub-type are relatively sociable, having many friends at 
school and may have partners or spouses. 
Symptom pattern: 
• Symptom patterns tend to be diverse. 
• Negative symptoms tend to be less prominent with this sub-type. 
 
Traumatic Psychosis 
 
Core Characteristics 
The person meets the criteria for co-morbid borderline personality disorder and has 
experienced childhood sexual or emotional abuse. 
 
Supporting characteristics 
Age of onset: 
• Usually in their teens or 20s. 
Mode of onset: 
• Either acute or insidious. 
Lifetime pattern of social interaction: 
• Individuals with this sub-type have chaotic relationships with others (e.g., severe 
conflict with their families, unstable sexual relationships with many 
boy/girlfriends). 
                                                 
6 Any other kinds of drugs which are proved to cause psychotic symptoms (e.g., diethylpropion) can be 
included. 
7 Mode of onset is defined as the period between the first reported symptom or noticeable behavioural 
change and the patient’s subjective peak of the first episode. In this case, ‘acute’ onset means less than 1 
month, while ‘insidious’ onset means equal to or more than 1 month. 
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Symptom pattern: 
• Abusive hallucinations (auditory or visual) are frequent. 
 
Anxiety Psychosis 
 
Core characteristics 
The person has had good peer relationships in early adolescence and usually developed 
close relationships with a partner or spouse. 
 
Supporting characteristics 
Age of onset: 
• Usually in their 30s or older. 
Mode of onset: 
• Acute. 
• Individuals have experienced stressful life events which have immediately 
preceded psychotic symptoms within 3 months.  
• Lifetime pattern of social interaction: 
• Individuals with this sub-type are relatively sociable, having friends at school and 
partners or spouses in adulthood. 
Symptom pattern: 
• Delusions, especially systematized (well organized) delusions, are generally 
prominent. 
• Hallucinations (auditory, visual, or with other modals) can occur but are less 
prominent. 
• Negative symptoms tend to be less prominent with this sub-type. 
 
Stress Sensitivity Psychosis 
 
Core characteristics 
The person is more stress sensitive8 and less sociable. 
 
Supporting characteristics 
Age of onset: 
• Usually in their teens or early 20s. 
Mode of onset: 
• Insidious. 
Lifetime pattern of social interaction: 
• Individuals with this sub-type are less sociable, having few friends in their 
childhood and adolescence, and they do not have partners or spouses prior to 
developing symptoms. 
Symptom pattern: 
                                                 
8 ‘Stress sensitive’ means that emotional reactivity is high to daily life stress, or ‘daily hassles’ (Myin-
Germeys et al., 2001; Myin-Germeys & van Os, 2007). 
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• Negative symptoms are prominent, even in the first episode. 
• A diverse range of positive symptoms occur.
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Appendix C: The 21-item Peters Delusions Inventory (PDI-21). 
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The Brief Core Schema Scales: beliefs about self and others 
This questionnaire lists beliefs that people can hold about themselves and other people. 
Please indicate whether you hold each belief (NO or YES). If you hold the belief then 
please indicate how strongly you hold it by circling a number (1-4). Try to judge the 
beliefs on how you have generally, over time, viewed yourself and others. Do not 
spend too long on each belief. There are no right or wrong answers and the first 
response to each belief is often the most accurate. 
 
MYSELF                    
I am unloved   NO YES → 1    2      3        4 
I am worthless   NO YES → 1    2      3        4 
I am weak   NO YES → 1    2      3        4 
I am vulnerable  NO YES → 1    2      3        4 
I am bad   NO YES → 1    2      3        4 
I am a failure   NO YES → 1    2      3        4 
I am respected   NO YES → 1    2      3        4 
I am valuable   NO YES → 1    2      3        4 
I am talented   NO YES → 1    2      3        4 
I am successful  NO YES → 1    2      3        4 
I am good   NO YES → 1    2      3        4 
I am interesting  NO YES → 1    2      3        4 
 
OTHER PEOPLE 
Other people are hostile NO YES → 1    2      3        4 
Other people are harsh NO YES → 1    2      3        4 
Other people are unforgiving NO YES → 1    2      3        4 
Other people are bad  NO YES → 1    2      3        4 
Other people are devious NO YES → 1    2      3        4 
Other people are nasty NO YES → 1    2      3        4 
Other people are fair  NO YES → 1    2      3        4 
Other people are good  NO YES → 1    2      3        4 
Other people are trustworthy NO YES → 1    2      3        4 
Other people are accepting NO YES → 1    2      3        4 
Other people are supportive NO YES → 1    2      3        4 
Other people are truthful NO YES → 1    2      3        4 
Believe it 
slightly 
Believe it 
moderately 
Believe it 
very much 
Believe it 
totally 
Appendix D: The Brief Core Schema Scale (BCSS). 
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Appendix E: The Brief Fear of Negative Evaluation Scale (BFNE). 
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PATIENT INFORMATION SHEET                       14 September 2007
Study Title: Developing a Semi-structured Clinical Interview for Psychosis
Subgroups (SCIPS)
RESEARCHERS: Dr. Yoshihiro Kinoshita, Prof. David Kingdon
ETHICS NUMBER: 07/H0501/72
VERSION: 2
1. Invitation paragraph
You are being asked if you would agree to take part in a research study.  Before you decide about this, it
is important for you to understand why the research is being done and what it will involve.  Please take
time to read the following information carefully and discuss it with others if you wish.  Ask us if there is
anything that is not clear or if you would like more information.  Take time to decide whether or not you
wish to take part.
Thank you for reading this.
2. What is the purpose of the study?
The purpose of the study is to know whether a newly developed interview tool – SCIPS- is helpful for
understanding the situation of people who have been given a diagnosis of schizophrenia or a similar
diagnosis. Understanding this better may help you and mental health staff make choices about treatment
and could improve the treatments available.
3. What will I be asked about?
You will be asked about your symptoms and thoughts you get.  You will be helped to fill in some
questionnaires about these and also about past experiences. The questions you will be asked are similar
to those generally asked within mental health services. You do not have to answer any questions that you
don’t want to and can stop the interview at any time.
4. Why have I been chosen?
We have asked your consultant if we can approach you to ask you to take part and your consultant having
considered this, they have given consent. We are now asking you if you agree to participate in an
interview with the doctor doing this research.
5. Do I have to agree?
No, it is up to you to decide whether or not you take part.  If you do decide to, you will be given
this information sheet to keep and be asked to sign a consent form.  You are still free to
withdraw that consent at any time and without giving a reason. If you do so, you will be asked if
you consent to the information that you have already supplied being included in the study or
not. A decision to withdraw at any time, or a decision not to take part, will not affect the
standard of care you receive.
6. What will happen to me if I take part?
The researcher will meet with you and ask a number of questions and help you fill in some questionnaires.
It will probably take about 1 hour in one or two occasions but you will be free to stop at any time and, if you
agree, do the remainder of the interview later. If you agree, the interview will be audiotaped for the
purposes of this research study which require that it is listened to, by another research psychiatrist. The
audiotape will be destroyed at the end of the period specified by the Research Ethics Comittee.
University
of Southampton
School of Medicine
Community Clinical
Sciences Research Division
Department of Mental Health
University of Southampton
Royal South Hants Hospital
Brintons Terrace
Southampton SO14 0YG
United Kingdom
Tel  +44 023 80825054/80825191
Fax +44 02380234243
E-mail dgk@soton .ac.uk
Prof. David Kingdon, MD MRCPsych
Professor of Mental Health Care Delivery
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7. What do they have to do?
This just involves answering questions and filling in questionnaires.   If you don’t want to answer any
question, you do not have to do so.   Your care would not be affected in any way by this.
8. What are the possible disadvantages and risks of taking part?
This is an interview and questionnaire study so there are no significant risks or disadvantages of
participating.   If you should get distressed, tell the researcher who has instructions in how best to reduce
this and who will contact his supervisor and make sure that your care coordinator, consultant and GP are
made aware of this.
9. What are the possible benefits of taking part?
We hope that this study will help you.  However, this cannot be guaranteed.  The information we get from
this study may help us to treat future patients with schizophrenia better.
10. What if something goes wrong?
If you should have any complaints about this study, these will be documented by the researcher and
passed to the Complaints Officer, Hampshire Partnership Trust, Tatchbury Mount, Southampton or you
can write to them directly yourself.
11. Will my taking part in this study be kept confidential?
All information which is collected about you during the course of the research will be kept strictly
confidential.  Any information about you will have your name and address removed so that you cannot be
recognised from it.’
12. What will happen to the results of the research study?
The results of the research will be submitted for publication to scientific journals and may be presented at
conferences when the study is finished within the next two years.  A copy of the published results will be
available at that time from Professor Kingdon.  You will not be identified in any report/publication.
13. Who is organising and funding the research?
Hampshire Partnership Trust are sponsoring and funding the research.
14. Who has reviewed the study?
Isle of Wight, Portsmouth & South East Hampshire Research Ethics Committee has reviewed the study.
15. Contact for Further Information
If you would like more information now or in the future, please contact Professor Kingdon (023
80825045).
Thank you for your help.
You will be given a copy of the information sheet and a signed consent form to
keep.
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PATIENT CONSENT FORM                                        3 August 2007
Study: Developing a Semi-structured Clnical Interview for Psychosis Subgroups
RESEARCHERS:  Dr. Yoshihiro Kinoshita, Prof. David Kingdon
ETHICS NUMBER: 07/H0501/72
Version: 1
Please tick box:
________________________ ___________ ___________________
Name of Patient Date Signature
________________________ ___________ ___________________
Researcher Date Signature
P.I.N. for this trial: _____ 1 for patient, 1 for researcher, 1 to be kept with hospital notes
University
of Southampton
School of Medicine
Community Clinical
Sciences Research Division
Department of Mental Health
University of Southampton
Royal South Hants Hospital
Brintons Terrace
Southampton SO14 0YG
United Kingdom
Tel  +44 023 80825054/80825191
Fax +44 02380234243
E-mail dgk@soton .ac.uk
Prof. David Kingdon, MD MRCPsych
Professor of Mental Health Care Delivery
(1) I confirm that I have read and understand the information sheet
- dated 03/08/07 - for the above study and have had the
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Appendix I: Construct validity of the traumatic sub-type with broader 
conceptualization. 
 
1. Overview 
Though, according to the SCIPS diagnostic criteria, patients with traumatic sub-type 
should have childhood trauma and satisfy diagnostic criteria for borderline personality 
disorder, conceptualisation of this sub-type might be expanded by including those who 
have been traumatised in childhood but not diagnosed with borderline personality 
disorder. In order to examine the construct validity of the traumatic sub-group with this 
wider conceptualisation, those whose rating for item 3-2 “traumatic experience” was 
positive were put into the traumatic category and the data collected in the UK and Japan 
were re-analysed. In these analyses, negative and positive evaluative beliefs and FNE 
were employed as external validators. Furthermore, in order to establish the predictive 
value of the conceptualisation, clinical outcomes in relation to hospitalization and the 
history of self harming which were assessed in Chpater 17 (“Predictive Value of the 
Conceptualisation of the Anxiety and Stress Sensitivity Sub-types”) were compared 
between the traumatic and non-traumatic sub-types in the Japanese patients. 
 
1. Aims of this study 
The aims of this study are to examine 2 primary and 4 secondary hypotheses which are 
described below: 
Primary hypotheses: 
1. Patients with the traumatic sub-type of schizophrenia have higher levels of 
negative evaluative beliefs (negative-self and negative-others) than those without 
the sub-type. 
2. Patients with the traumatic sub-type have a higher risk of self harming than those 
without the sub-type. 
Secondary hypotheses: 
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1. Patients with the traumatic sub-type of schizophrenia have lower levels of positive 
evaluative beliefs (positive-self and positive-others) than those without the sub-
type. 
2. Individuals in the traumatic sub-group have a higher fear of negative evaluation 
from others than those in other sub-groups. 
3. Patients with the traumatic sub-type reveal higher levels of depression than those 
without the sub-type. 
4. Patients with the traumatic sub-type of schizophrenia stay in hospital shorter than 
those without the sub-type over a period of 3 years after the date of their first 
admission with the illness. 
5. The duration of the first hospitalization with schizophrenia is shorter in those with 
the traumatic sub-type than it is for those without the sub-type. 
 
3. Measures 
The Brief Core Schema Scale (BCSS) (Fowler et al., 2006)  
The Brief Fear of Negative Evaluation Scale (BFNE) (Collins et al., 2005)  
Beck Depression Inventory II (BDI-II) (Beck, Steer, & Brown, 1996)  
Details of the scales are provided in Chapter 10 (see section 10.8, “Measures”). 
 
4. Results 
Prevalence of the sub-types 
According to the ratings for item 3-2 in first SCIPS interview, the participants were 
categorized into the traumatic (i.e., patients who have been traumatised) and non-
traumatic (i.e., patients who have been traumatised) sub-types. Table A-1 presents the 
numbers of individuals in the traumatic and non-traumatic subtypes in the UK and 
Japanese samples. The sub-types could not be determined for 3 of the participants in the 
UK because 1 of them did not complete the interview and the other 2 could not give 
enough information about their childhood trauma. By including those who have been 
traumatised in childhood but not diagnosed with borderline personality disorder into the 
conceptualisation of the traumatic sub-type, the number of participants in this category 
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changed from 2 (4.8%) to 14 (33.3%) in the UK sample, while in the Japanese sample, it 
changed from 1 (0.9%) to 22 (20.6%). 
 
Table A-1: Numbers (%) of participants in the traumatic and non-traumatic sub-
types. 
Sub-type The UK (n = 42) Japan (n = 107) 
Traumatic 
Non-traumatic 
No information 
14 (33.3) 
25 (59.5) 
3 (7.1) 
22 (20.6) 
85 (79.4) 
0 (0) 
 
 
Differences in the BCSS, BFNE and BDI-II scores between the traumatic and non-
traumatic sub-types 
In the UK sample: 
The p values for the differences (Mann-Whitney U Test; This method was chosen 
because the scores showed non-normal distribution) between the scores for the negative-
self, positive-self, negative-others, and positive-others evaluative beliefs were 0.120 
(traumatic > non-traumatic), 0.463 (traumatic < non-traumatic), 0.076 (traumatic > non-
traumatic), and 0.917 (traumatic < non-traumatic) respectively. On the other hand, the p 
value for the discrepancy between the BFNE scores was 0.592 (traumatic > non-
traumatic). These differences were not statistically significant. 
 
In the Japanese sample: 
The p values for the differences (Mann-Whitney U Test; This method was chosen 
because the scores showed non-normal distribution) between the scores for the negative-
self, positive-self, negative-others, and positive-others evaluative beliefs were 0.554 
(traumatic > non-traumatic), 0.166 (traumatic > non-traumatic), 0.023 (traumatic > non-
traumatic), and 0.225 (traumatic < non-traumatic) respectively. On the other hand, the p 
value for the discrepancy between the BFNE scores was 0.994 (traumatic < non-
traumatic). In addition, the p value for the difference in the BDI-II score was 0.389 
(traumatic > non-traumatic). Only the difference in negative-others evaluative beliefs was 
statistically significant. 
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Differences in the 2 variables concerning hospitalization between the anxiety and 
stress sensitivity sub-types 
The p value for the discrepancies (Mann-Whitney U Test; This method was chosen 
because the scores showed non-normal distribution) in variable 1: “total time spent in the 
hospital over a period of 3 years after the date of 1st admission” and variable 2 “duration 
of 1st hospitalization” were 0.803 (traumatic < non-traumatic) and 0.280 (traumatic < 
non-traumatic) respectively. These differences were not statistically significant. 
Differences in the risk of self harming between the anxiety and stress sensitivity sub-
types 
A Chi square test was conducted, and revealed that the differences in the risk of self 
harming between the anxiety and stress sensitivity sub-types was not statistically 
significant (p = 0.938). RR for self harming was 1.02 (traumatic > non-traumatic, 95%CI 
= 0.58-1.80), which was also not statistically significant (Table A-2). 
 
Table A-2: 2x2 Table used for the evaluation of the differences in the risk of self 
harming between the traumatic and non-traumatic sub-types. 
 History of self harming 
Positive Negative Total 
Traumatic sub-type 9 13 22 
Non-traumatic sub-type 34 51 85 
Total 43 64 107 
 
5. Discussion 
A statistically significant difference was found in the negative-others evaluative beliefs 
between the traumatic and non-traumatic categories in the Japanese sample. Also in the 
UK sample, patients with the traumatic sub-type had higher negative-others evaluative 
beliefs than those without the sub-type, though the difference was not statistically 
significant. No difference was found between the traumatic and non-traumatic sub-types 
in other variables which were examined in the analyses. 
 
It is reasonable that those who have been traumatised or offended by others have higher 
negative evaluative beliefs for others. When clinicians plan treatment for patients with 
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childhood trauma, greater consideration may have to be given to this type of schema. 
Schema modification technique in CBT might be especially useful for this group of 
patients. 
 
There are 2 main limitations with the present study. Firstly, as discussed in Chapter 18 
(see section 18.3 “Strengths and weaknesses of the SCIPS”), childhood traumatic 
experiences were assessed with a single question, and no account was taken of duration, 
or the severity of the abuse, in item 3.2 of the SCIPS. This may decrease the validity, and 
even the reliability, of the diagnosis used in this analysis. Secondly, this analysis was a 
secondary one of the collected data and the risk of type I errors, or false positives, caused 
by multiple comparisons should be taken into consideration. 
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